Modulators for amyloid beta

ABSTRACT

The invention relates to compounds of formula 
     
       
         
         
             
             
         
       
     
     wherein the substituents are as described in claim  1 . Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer&#39;s disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

PRIORITY TO RELATED APPLICATION(S)

This application claims the benefit of European Patent Application No.08151825.0, filed Feb. 22, 2008, which is hereby incorporated byreference in its entirety.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) is the most common cause of dementia in laterlife. Pathologically, AD is characterized by the deposition of amyloidin extracellular plaques and intracellular neurofibrillary tangles inthe brain. The amyloid plaques are mainly composed of amyloid peptides(Aβ peptides) which originate from the β-Amyloid Precursor Protein (APP)by a series of proteolytic cleavage steps. Several forms of APP havebeen identified of which the most abundant are proteins of 695, 751 and770 amino acids length. They all arise from a single gene throughdifferential splicing. The Aβ peptides are derived from the same domainof the APP.

Aβ peptides are produced from APP through the sequential action of twoproteolytic enzymes termed β- and γ-secretase. β-Secretase cleaves firstin the extracellular domain of APP just outside of the trans-membranedomain (TM) to produce a C-terminal fragment of APP containing the TM-and cytoplasmatic domain (CTFβ). CTFβ is the substrate for γ-secretasewhich cleaves at several adjacent positions within the TM to produce theAβ peptides and the cytoplasmic fragment. Various proteolytic cleavagesmediated by γ-secretase result in Aβ peptides of different chain length,e.g. Aβ38, Aβ40 and Aβ42. The latter one is regarded to be the morepathogenic amyloid peptide because of its strong tendency to formneurotoxic aggregates.

The β-secretase is a typical aspartyl protease. The γ-secretase is aproteolytic activity consisting of several proteins, its exactcomposition is incompletely understood. However, the presenilins areessential components of this activity and may represent a new group ofatypical aspartyl proteases which cleave within the TM of theirsubstrates and which are themselves polytopic membrane proteins. Otheressential components of γ-secretase may be nicastrin and the products ofthe aph1 and pen-2 genes. Proven substrates for γ-secretase are the APPand the proteins of the Notch receptor family, however, γ-secretase hasloose substrate specificity and may cleave further membrane proteinsunrelated to APP and Notch.

The γ-secretase activity is absolutely required for the production of Aβpeptides. This has been shown both by genetic means, i.e., ablation ofthe presenilin genes and by low-molecular-weight inhibitory compounds.Since according to the amyloid hypothesis for AD the production anddeposition of Aβ is the ultimate cause for the disease, it is thoughtthat selective and potent inhibitors of γ-secretase will be useful forthe prevention and treatment of AD.

An alternative mode of treatment is the modulation of the γ-secretaseactivity which results in a selective reduction of the Aβ42 production.This will result in to an increase of shorter Aβ isoforms, such as Aβ38,Aβ37 or others, which have reduced capability for aggregation and plaqueformation, and hence less neurotoxic. Compounds which show this effecton modulating γ-secretase activity include certain non-steroidalanti-inflammatory drugs (NSAIDs) and related analogues (Weggen et al.Nature, 414 (2001) 212-16).

Numerous documents describe the current knowledge on γ-secretasemodulation, for example the following publications:

-   Morihara et al, J. Neurochem., 83 (2002) 1009-12-   Jantzen et al, J. Neuroscience, 22 (2002) 226-54-   Takahashi et al, J. Biol. Chem., 278 (2003) 18644-70-   Beher et al, J. Biol. Chem. 279 (2004) 43419-26-   Lleo et al, Nature Med. 10 (2004) 1065-6-   Kukar et al, Nature Med. 11 (2005) 545-50-   Perretto et al, J. Med. Chem. 48 (2005) 5705-20-   Clarke et al, J. Biol. Chem. 281 (2006) 31279-89-   Stock et al, Bioorg. Med. Chem. Lett. 16 (2006) 2219-2223-   Narlawar et al, J. Med. Chem. 49 (2006) 7588-91

SUMMARY OF THE INVENTION

The invention provides a compound of formula

wherein

-   R¹ is hydrogen, lower alkyl or lower alkyl substituted by hydroxy;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group    -   wherein the rings in the heteroaryl group are optionally        substituted by one or more R′ for any definition of L, or    -   when L is a bond, the rings in the heteroaryl are optionally        substituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,        OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings in the heteroaryl are optionally        substituted by one or more lower alkoxy, hydroxy, —C(O)O-lower        alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is NR⁸, the rings in the heteroaryl are optionally        substituted by one or more CH₂—C(O)O-lower alkyl, or    -   when L is C(O), the rings in the heteroaryl are optionally        substituted by one or more lower alkoxy, hydroxy or NR⁸ ₂;-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, or    is a five-membered heteroaryl group, which is optionally substituted    by lower alkyl;-   Ar is a five-membered heteroaryl group or is pyridinyl;-   Z is CH or N;-   X-Y is N—CR⁴═CR⁵, CH—CR⁴═N, CH—CR⁴═CR⁵ or N—NH; and wherein R⁴ and    R⁵ together with the corresponding carbon atoms to which they are    attached optionally form an additional ring with —(CH₂)_(n), with    the proviso that if X-Y is CH—CR⁴═CR⁵ or CH—CR⁴═N, then Z is N; or-   R⁴ and R⁵ are each independently hydrogen, halogen, lower alkyl,    lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or    more groups selected from fluoro, hydroxy, cyano and cycloalkyl,    -   or are cyano, phenyl, benzyl or a five- or six-membered        heteroaryl group wherein the rings in the heteroaryl group are        optionally substituted by one or more R′, or are cycloalkyl or        heterocycloalkyl, each of which is optionally substituted by        lower alkyl and hydroxy, with the proviso that R⁴ also is        optionally hydroxy or NR⁸ ₂;-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, cycloalkyl,    or phenyl or R⁶ and R⁷ together with the carbon atom to which they    are attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶    also is optionally hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl;-   m 0 or 1; and-   n is 3 or 4;    or a pharmaceutically active acid addition salt thereof.

The invention also provides all forms of optically pure enantiomers,racemates or diastereomeric mixtures for compounds of formula I.

The invention further provides pharmaceutical compositions containingcompounds of formula I and methods for the preparation of such compoundsand compositions.

The present compounds of formula I are modulators for amyloid beta and,thus, they may be useful for the treatment or prevention of a diseaseassociated with the deposition of β-amyloid in the brain, in particularAlzheimer's disease, and other diseases such as cerebral amyloidangiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type(HCHWA-D), multi-infarct dementia, dementia pugilistica and Downsyndrome.

DETAILED DESCRIPTION OF THE INVENTION

The following definitions of general terms used herein applyirrespective of whether the terms in question appear alone or incombination. It must be noted that, as used in the specification and theappended claims, the singular forms “a”, “an,” and “the” include pluralforms unless the context clearly dictates otherwise.

As used herein, the term “lower alkyl” denotes a saturated straight- orbranched-chain hydrocarbon group containing from 1 to 7 carbon atoms,for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl,2-butyl, t-butyl and the like. Preferred alkyl groups are groups with1-4 carbon atoms.

As used herein “halogen” denotes fluorine, chlorine, bromine, andiodine.

As used herein, the term “cycloalkyl” denotes a saturated carbon ringsystem, containing from 3 to 6 carbon atoms, for example cyclopropyl,cyclobutyl, cyclopentyl or cyclohexyl.

As used herein, the term “lower alkoxy” denotes a group containing analkyl group as defined above which is attached via an oxygen atom.

As used herein, the term “lower alkyl substituted by halogen” denotes analkyl group as defined above, wherein at least one hydrogen atom isreplaced by halogen. As used herein, the term “lower alkyl substitutedby fluoro” denotes an alkyl group as defined above, wherein at least onehydrogen atom is replaced by fluoro, for example CF₃, CHF₂, CH₂F,CH₂CF₃, CH₂CH₂CF₃, CH₂CF₂CF₃, CH₂CF₂CF₂CF₃, CH₂CH₂CF₂CF₃ and the like.

As used herein, the term “lower alkoxy substituted by fluoro” denotes analkoxy group as defined above, wherein at least one hydrogen atom isreplaced by fluoro, for example OCF₃, OCHF₂, OCH₂F, OCH₂CF₃, OCH₂CH₂CF₃,OCH₂CF₂CF₃, OCH₂CF₂CF₂CF₃, OCH₂CH₂CF₂CF₃ and the like.

The term “lower alkenyl” denotes a straight- or branched-chain carbongroup containing from 2-7, preferably from 2-4, carbon atoms, wherein atleast one bond is a double bond.

As used herein, the term “five-membered heteroaryl group” denotes anheterocyclic group, containing at least two heteroatoms, selected fromthe group consisting of N, O and S, wherein at least one of the rings inthe heterocyclic group is aromatic, for example oxazol-5-yl,[1,2,4]triazol-1-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-1-yl,imidazol-1-yl, thiazol-5-yl, thiazol-2-yl, furan-2-yl, thiophen-2-yl,pyrazol-4-yl, pyrazol-3-yl, pyrazol-1-yl, [1,2,4]-oxadiazol-5-yl,[1,3,4]-oxadiazol-2-yl or [1,2,4]thiadiazol-5-yl. Preferred are theimidazol-1-yl, pyrazol-4-yl, [1,2,4]triazol-1-yl or oxazol-5-yl groups.

The term “six-membered heteroaryl group” denotes a heterocyclic group,containing at least one heteroatom, selected from the group consistingof N, O and S, wherein at least one ring in the heterocyclic group isaromatic, for example pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl.

The term “aryl” denotes an aromatic mono or bicyclic carbon ring system,for example phenyl or naphthyl.

The term “heterocycloalkyl” denotes a non-aromatic ring system,containing at least one heteroatom, selected from the group consistingof N, O and S, for example tetrahydro-pyran-4-yl, piperidin-4-yl,pyrrolidin-1-yl, morpholinyl, 1,1-dioxo-6-thiomorpholin-4-yl,oxetan-3-yl or piperazin-1-yl.

“Pharmaceutically acceptable,” such as pharmaceutically acceptablecarrier, excipient, etc., means pharmacologically acceptable andsubstantially non-toxic to the subject to which the particular compoundis administered.

The term “pharmaceutically acceptable acid addition salts” embracessalts with inorganic and organic acids, such as hydrochloric acid,nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid,fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid,methane-sulfonic acid, p-toluenesulfonic acid and the like.

“Therapeutically effective amount” means an amount that is effective toprevent, alleviate or ameliorate symptoms of disease or prolong thesurvival of the subject being treated.

One embodiment of the invention provides compounds of formula

wherein

-   R¹ is hydrogen, lower alkyl, lower alkyl substituted by halogen or    by hydroxy, or is lower alkoxy or lower alkoxy substituted by    halogen;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkyl substituted by fluoro or is aryl or a    five- or six membered heteroaryl group    -   wherein the rings in the heteroaryl group are optionally        substituted by one or more R′ for any definition of L, or    -   when L is a bond, the rings in the heteroaryl group are        optionally substituted by one or more halogen, or    -   when L is a bond or —CR⁶R⁷—, the rings in the heteroaryl group        are optionally substituted by one or more hydroxy, C(O)O-lower        alkyl or C(O)NH₂;-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro or is a    five-membered heteroaryl group;-   Ar is a five-membered heteroaryl group;-   Z is CH or N;-   X-Y is N—CR⁴═CR⁵, N—CR⁴═N, CH—CR═N, CH—CR⁴═CR⁵ or N—NH; with the    proviso that if X-Y is CH—CR⁴═CR⁵ or CH—CR⁴═N, then Z is N;-   R⁴ and R⁵ are each independently hydrogen, halogen, hydroxy, lower    alkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by    fluoro, or are cyano, phenyl, benzyl or a five- or six-membered    heteroaryl group, wherein the rings in the five- or six-membered    heteroaryl group are optionally substituted by one or more R′;-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, lower    alkoxy, hydroxy, phenyl or R⁶ and R⁷ together with the carbon atom    to which they are attached form a C₃₋₆-cycloalkyl group; and-   R⁸ is hydrogen or lower alkyl;    or pharmaceutically active acid addition salts.

Preferred are compounds of formula I-A

wherein

-   R¹ is hydrogen, lower alkyl or lower alkyl substituted by hydroxy;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group    -   wherein the rings in the heteroaryl group is optionally        substituted by one or more R′ for any definition of L, or    -   when L is a bond, the rings in the heteroaryl group are        optionally substituted by one or more halogen, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings in the heteroaryl group are        optionally substituted by one or more lower alkoxy, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is NR⁸, the rings in the heteroaryl group are optionally        substituted by one or more CH₂—C(O)O-lower alkyl, or    -   when L is C(O), the rings in the heteroaryl group is lower        alkoxy, hydroxy or NR⁸ ₂;-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, or    is a five-membered heteroaryl group optionally substituted by lower    alkyl;-   Ar is a five-membered heteroaryl group or is pyridinyl;-   R⁴ and R⁵ are each independently hydrogen, halogen, lower alkyl,    lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or    more groups selected from fluoro, hydroxy, cyano and cycloalkyl, or    are cyano, phenyl, benzyl or a five- or six membered heteroaryl    group, wherein the rings in the heteroaryl group are optionally    substituted by one or more R′, or are cycloalkyl or    heterocycloalkyl, each of which is optionally substituted by lower    alkyl and hydroxy, with the proviso that R⁴ also is optionally    hydroxy or NR⁸ ₂, or wherein R⁴ and R⁵ together with the    corresponding carbon atoms to which they are attached optionally    form an additional ring with —(CH₂)_(n);-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, cycloalkyl,    or phenyl or R⁶ and R⁷ together with the carbon atom to which they    are attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶    also is optionally hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl;-   m is 0 or 1; and-   n is 3 or 4;    or pharmaceutically active acid addition salts thereof.

Preferred compounds from formula I-A are those of formula I-A-1

wherein

-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group, wherein the rings in the    heteroaryl group are optionally substituted by one or more R′ for    any definition of L, or    -   when L is a bond, the rings of the heteroaryl group are        optionally substituted by one or more halogen, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings of the heteroaryl group are        optionally substituted by one or more lower alkoxy, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is NR³, the rings of the heteroaryl group are optionally        substituted by one or more CH₂—C(O)O-lower alkyl, or    -   when L is C(O), the rings of the heteroaryl group are optionally        substituted by one or more lower alkoxy, hydroxy or NR⁸ ₂;-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, or    is a five-membered heteroaryl group, which is optionally substituted    by lower alkyl;-   R⁴ and R⁵ are each independently hydrogen, halogen, lower alkyl,    lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or    more groups selected from fluoro, hydroxy, cyano and cycloalkyl, or    are cyano, phenyl, benzyl or a five- or six-membered heteroaryl    group wherein the rings in the heteroaryl group are optionally    substituted by one or more R′, or are cycloalkyl or    heterocycloalkyl, each of which is optionally substituted by lower    alkyl and hydroxy, with the proviso that R⁴ also is optionally    hydroxy or NR⁸ ₂, or wherein R⁴ and R⁵ together with the    corresponding carbon atoms to which they are attached optionally    form an additional ring with —(CH₂)_(n);-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, cycloalkyl,    phenyl or R⁶ and R⁷ together with the carbon atom to which they are    attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶ also    is optionally hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl;-   m is 0 or 1; and-   n is 3 or 4;    or pharmaceutically active acid addition salts thereof.

Preferred compounds from this group are the following compounds:

-   (4-benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzyl)-pyrimidin-2-yl]-amine;-   [4-(3-chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl)-pyrimidin-2-yl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,4,5-trifluoro-phenoxy)-pyrimidin-2-yl]-amine;-   [4-(3,4-difluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(4-chloro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(2,6-dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(2-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromethoxy-phenoxy)-pyrimidin-2-yl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,3,4,4,4-pentafluoro-butoxy)-pyrimidin-2-yl]-amine;-   {4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   {4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   {4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   ethyl    4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-amine;-   (4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   (4-ethoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   N4-(2,2,3,3,4,4,4-heptafluoro-butyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;-   [4-(4-chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxy-6-methyl-pyrimidin-2-yl)-amine;-   (4-isopropoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(4-tert-butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   2-{6-ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   N4-(3-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;-   N4-(4-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;-   N4,N4-diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;-   1-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-piperidin-4-ol;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl-pyrimidin-2-yl)-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl-pyrimidin-2-yl)-amine;-   2-({2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-ethanol;-   2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl-pyrimidin-4-yl}-propan-2-ol;-   2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-pyrimidin-4-yl}-propan-2-ol;-   [4-butyl-6-(4-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-pyrimidin-2-yl)-amine;-   5-(4,6-dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile;-   5-[4-(4-chloro-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile;-   [5-ethyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-phenyl)-pyrimidin-2-yl]-amine;-   [4-(2,5-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(3,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(2,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(4-chloro-3-methyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(4-chloro-phenyl)-5-propyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(5-methoxy-4-phenyl-pyrimidin-2-yl)-amine;-   (4-cyclopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   ethyl    4-benzyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-methyl-pent-3-enyl)-5-phenyl-pyrimidin-2-yl]-amine;-   6-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4H-benzo[1,4]oxazin-3-one;-   [4-(2-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   (4-isobutyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   (4,6-diethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-phenyl-pyrimidin-2-yl)-amine;-   (4-furan-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-amine;-   (4,6-dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   (4,6-bis-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   (4-isopropyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   (4,6-diisopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   [4-(2-chloro-phenyl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;-   ethyl    2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyrimidine-4-carboxylate;-   ethyl    6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate;-   ethyl    6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate;-   ethyl    2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrimidine-4-carboxylate;-   ethyl    2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate;-   ethyl    6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate;-   2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-propan-2-ol;-   2-{6-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{6-isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{6-tert-butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyrimidin-4-yl}-propan-2-ol;-   2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrimidin-4-yl}-propan-2-ol;-   2-{6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;-   1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-ethanone;-   3-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-pentan-3-ol;-   2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluoro-phenyl)-pyrimidin-4-yl]-propan-2-ol;-   2-{6-(2,4-dichloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{6-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{6-(2-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5,6,7,8-tetrahydro-quinazolin-4-yl}-propan-2-ol;-   2-{2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimidin-4-yl}-propan-2-ol;-   2-[2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;-   2-{6-dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;-   1-{6-(1-hydroxy-1-methyl-ethyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4-methyl-piperidin-4-ol;-   1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-cyclopentanol;-   5-[4-(1-hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile;    and-   2-[2-[3-methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol.

Preferred compounds of formula I-A are further those, wherein R¹—Ar is2-methyl-imidazol-1-yl, 3-methyl-[1,2,4]triazol-1-yl, thiazol-5-yl,2-methyl-thiazol-5-yl, 2-methyl-oxazol-5-yl, 2-methyl-pyridin-4-yl,1-methyl-1H-pyrazol-4-yl, 3-methyl-[1,2,4]triazol-1-yl,[1,2,4]triazol-1-yl, 5-methyl-[1,2,4]triazol-1-yl, 1,3,4]oxadiazol-2-yl,4-pyridin-4-yl, 2-methyl-pyridin-4-yl, 3-methyl-[1,2,4]thiadiazol-5-yl,or oxazol-5-yl, for example the following compounds

-   (4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine;-   (4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenyl]-amine;-   (4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-oxazol-5-yl)-phenyl]-amine;-   2-[2-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;-   (4,6-dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine;    and-   (4-benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine.

Preferred are further compounds of formula

wherein

-   R¹ is hydrogen, lower alkyl or lower alkyl substituted by hydroxy;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group, hwerein the rings in the    heteroaryl group are optionally substituted by one or more R′ for    any definition of L, or    -   when L is a bond, the rings in the heteroaryl group are        optionally substituted by one or more halogen, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings in the heteroaryl group are        optionally substituted by one or more lower alkoxy, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is NR⁸, the rings in the heteroaryl group are optionally        substituted by one or more CH₂—C(O)O-lower alkyl, or    -   when L is C(O), the rings in the heteroaryl group are optionally        substituted by one or more lower alkoxy, hydroxy or NR⁸ ₂;    -   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl        substituted by fluoro, lower alkoxy substituted by fluoro, SF₅,        or is a five-membered heteroaryl group, which is optionally        substituted by lower alkyl;    -   Ar is a five-membered heteroaryl group or is pyridinyl;    -   R⁴ is hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower        alkyl, lower alkyl substituted by one or more groups selected        from fluoro, hydroxy, cyano or cycloalkyl, or is cyano, phenyl,        benzyl or a five- or six membered heteroaryl group in which the        rings of the heteroaryl group are optionally substituted by one        or more R′, or is cycloalkyl or heterocycloalkyl, each of which        is optionally substituted by lower alkyl and hydroxy, or is        hydroxy or NR⁸ ₂;-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, cycloalkyl,    phenyl or R⁶ and R⁷ together with the carbon atom to which they are    attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶ also    is optionally hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl;-   m is 0 or 1; and-   n is 3 or 4;    or pharmaceutically active acid addition salts.

Preferred compounds from formula I-B are for example the followingcompounds(6-benzyl-2-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amineand{6-[1-(4-chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.

Preferred are further compounds of formula

wherein

-   R¹ is hydrogen, lower alkyl or lower alkyl substituted by hydroxy;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group, wherein the rings of the    heteroaryl group are optionally substituted by one or more R′ for    any definition of L, or    -   when L is a bond, the rings of the heteroaryl group are        optionally substituted by one or more halogen, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings of the heteroaryl group are        optionally substituted by one or more lower alkoxy, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is NR⁸, the rings of the heteroaryl group are optionally        substituted by one or more CH₂—C(O)O-lower alkyl for L being        NR⁸, or    -   when L is C(O), the rings of the heteroaryl group are optionally        substituted by one or more lower alkoxy, hydroxy or NR⁸ ₂ for L        being C(O);-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, or    is a five-membered heteroaryl group, which is optionally substituted    by lower alkyl;-   Ar is a five-membered heteroaryl group or is pyridinyl;-   R⁴ is hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower    alkyl, lower alkyl substituted by one or more groups selected from    fluoro, hydroxy, cyano or cycloalkyl, or are cyano, phenyl, benzyl    or a five- or six-membered heteroaryl group, wherein the rings in    the heteroaryl group are optionally substituted by one or more R′,    or are cycloalkyl or heterocycloalkyl, each of which is optionally    substituted by lower alkyl and hydroxy or is hydroxy or NR⁸ ₂;-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, cycloalkyl,    phenyl or R⁶ and R⁷ form together with the carbon atom to which they    are attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶    also is hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl;-   m is 0 or 1; and-   n is 3 or 4;    or pharmaceutically active acid addition salts, for example the    compound    (2-benzyl-6-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.

Preferred are further compounds of formula

wherein

-   R¹ is hydrogen, lower alkyl or lower alkyl substituted by hydroxy;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group, wherein the rings of the    heteroaryl group are optionally substituted by one or more R′ for    any definition of L, or    -   when L is a bond, the rings of the heteroaryl group are        optionally substituted by one or more halogen, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings of the heteroaryl group are        optionally substituted by one or more lower alkoxy, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is NR⁸, is CH₂—C(O)O-lower alkyl, or    -   when L is C(O), is lower alkoxy, hydroxy or NR⁸ ₂;-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, or    is a five-membered heteroaryl group, which is optionally substituted    by lower alkyl;-   Ar is a five-membered heteroaryl group or is pyridinyl;-   R⁴ and R⁵ are each independently hydrogen, halogen, lower alkyl,    lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or    more groups selected from fluoro, hydroxy, cyano and cycloalkyl, or    are cyano, phenyl, benzyl or a five- or six-membered heteroaryl    group, wherein the rings of the heteroaryl group are optionally    substituted by one or more R′, or are cycloalkyl or    heterocycloalkyl, each of which is optionally substituted by lower    alkyl and hydroxy′, with the proviso that R⁴ also is optionally    hydroxy or NR⁸ ₂, or wherein R⁴ and R⁵ together with the    corresponding carbon atoms to which they are attached optionally    form an additional ring with —(CH₂)_(n);-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶ and R⁷ are each independently hydrogen, lower alkyl, cycloalkyl,    phenyl or R⁶ and R⁷ together with the carbon atom to which they are    attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶ also    optionally is hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl;-   m is 0 or 1; and-   n is 3 ro 4;    or pharmaceutically active acid addition salts thereof.

Preferred compounds from this group are for example the followingcompounds

-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-phenyl-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethoxy-phenyl)-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-pentafluorosulfanyl-phenyl)-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethyl-phenyl)-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine;-   N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N′-(4-trifluoromethyl-phenyl)-pyridine-2,6-diamine;    and-   [2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethoxy-phenylamino)-pyridin-4-yl]-methanol.

Preferred are further compounds of formula

wherein

-   R¹ is hydrogen, lower alkyl or lower alkyl substituted by hydroxy;-   R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;-   R³ is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,    (CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,    cycloalkyl optionally substituted by hydroxy, or is    heterocycloalkyl, which heterocycloalkyl is optionally substituted    by hydroxy or S(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five-    or six-membered heteroaryl group,    -   wherein the rings in the heteroaryl group are optionally        substituted by one or more R′ for any definition of L, or    -   when L is a bond, the rings in the heteroaryl group are        optionally substituted by one or more halogen, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or    -   when L is —CR⁶R⁷—, the rings in the heteroaryl group are        optionally substituted by one or more lower alkoxy, hydroxy,        —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂ or    -   when L is NR⁸, the rings in the heteroaryl group are optionally        substituted by one or more CH₂—C(O)O-lower alkyl, or    -   when L is C(O), the rings in the heteroaryl group are optionally        substituted by one or more lower alkoxy, hydroxy or NR⁸ ₂;-   R′ is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl    substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, or    is a five-membered heteroaryl group, which is optionally substituted    by lower alkyl;-   Ar is a five-membered heteroaryl group or is pyridinyl;-   L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—;-   R⁶R⁷ are each independently hydrogen, lower alkyl, cycloalkyl, or    phenyl or R⁶ and R⁷ together with the carbon atom to which they are    attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶ also    optionally is hydroxy or lower alkoxy;-   R⁸ is hydrogen or lower alkyl; and-   m is 0 or 1;    or pharmaceutically active acid addition salts thereof.

Preferred compounds from this group are the following compounds

-   [5-(4-chloro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine    and-   [5-(4-fluoro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.

The present compounds of formula I and their pharmaceutically acceptablesalts can be prepared by methods known in the art, for example, byprocesses described below, which processes comprise

a) reacting a compound of formula

-   -   with a compound of formula

-   -   or, alternatively, reacting a compound

-   -   with a compound of formula

-   -   to obtain a compound of formula

wherein the substituents have the meaning as described above, or,alternatively, reacting a compound of formula

with a compound of formula

wherein R is C₁₋₄-alkyl, to obtain a compound of formula

which may be further converted to a compound I-A, orb) reacting a compound of formula II

with a compound of formula

to obtain a compound of formula

wherein the substituents have the meaning as described above, orc) reacting a compound of formula

with a compound of formula

to obtain a compound of formula

wherein the substituents have the meaning as described above, ord) reacting a compound of formula

with a compound of formula

or, alternatively, a compound of formula

with a compound of formula

HL-R³  XII

to obtain a compound of formula

wherein the substituents have the meaning as described above, ore) reacting a compound of formula

with a compound of formula

to obtain a compound of formula

wherein the substituents have the meaning as described above, and ifdesired, converting the compounds obtained into pharmaceuticallyacceptable acid addition salts.

The detailed description can be found below and in Examples 1-238.

The preparation of compounds of formula I of the present invention canbe carried out in sequential or convergent synthetic routes. Synthesesof the compounds of the invention are shown in the following schemes 1to 7. The skills required for carrying out the reaction and purificationof the resulting products are known to those skilled in the art. Thesubstituents and indices used in the following description of theprocesses have the significance given herein before unless indicated tothe contrary.

In more detail, the compounds of formula I can be manufactured by themethods given below, by the methods given in the examples or byanalogous methods. Appropriate reaction conditions for the individualreaction steps are known to a person skilled in the art. The reactionsequence is not limited to the one displayed in the schemes, however,depending on the starting materials and their respective reactivity thesequence of reaction steps can be freely altered. Starting materials areeither commercially available or can be prepared by methods analogous tothe methods given below, by methods described in the examples, or bymethods known in the art.

An aniline II, a guanidine IV or a thiourea XIII can be prepared asdescribed in Scheme 1. Nucleophilic substitution at room temperature orelevated temperature (e.g reflux or under pressure using a microwaveoven) under neutral conditions or in the presence of a base (like e.g.potassium carbonate), neat or in a polar solvent (like e.g. THF or DMSOetc.) of a substituted 4-nitro-phenyl halide XVI (hal=F, Cl, Br, I) witha compound R¹ArH, (like 4-methyl-imidazole) yields a nitro derivativeXV. The nitro derivative XV can be also obtained by a Suzuki or Stillecoupling of a 4-nitro-phenyl halide XVI (hal=Cl, Br, I) and acorresponding aryl boronic acid or aryl tin derivative R¹ArM underpalladium(0) catalysis in the presence of a base in a polar or apolarsolvent and ambient or high temperature or by Suzuki coupling of a4-nitro-phenyl boronic acid XVIII with a halide R¹Arhal (hal=Cl, Br, I).Alternatively, a nitro derivative XV can be prepared from a suitableprecursor, such as e.g. a carbonyl derivative XVIII (R═H, NH₂, alkoxy orC₁₋₄-alkyl), by applying standard reaction sequences for the formationof the substituent ArR¹. A nitro compound XV can be reduced to ananiline II using generally known procedures, e.g. hydrogenation in thepresence of a catalyst (like e.g. 10% palladium on carbon) in a solvent(like e.g. ethanol or ethyl acetate) or, by using a metal (like e.g.iron) or a metal salt (like e.g. stannous chloride) in a polar solvent(like e.g. acetic acid or tetrahydrofuran). Alternatively, aniline IIcan be prepared by introducing a substituent ArR¹ into a N-protectedaniline derivative XIX (PG=protecting group) using generally knownprocedures, e.g. displacement reactions under catalytic conditions (likee.g. palladium(0) or copper(II) catalysis) or, by forming a group ArR¹in a N-protected carbonyl derivative XX, respectively, and subsequentlycleaving off the protecting group. The aniline derivative II can be alsoprepared directly in a Suzuki reaction of the boronic acid derivativeXXI with a corresponding aryl halide R¹Arhal (hal=Cl, Br, I) underpalladium(0) catalysis in the presence of a base in a polar or apolarsolvent and ambient or high temperature. A guanidine IV can be preparedfrom an aniline II by reaction with cyanamide under acidic conditions(e.g. hydrochloric acid or nitric acid) in a protic solvent (likeethanol) or, by treatment with a carboxamidine derivative, like3,5-dimethyl-pyrazole-1-carboxamidine, 2-methyl-isothiourea orsulfphoguanidine, in a polar or apolar solvent, optionally in thepresence of base. A thiourea XIII can be prepared by either reacting ananiline II with a thiophosgene derivative (like e.g.1,1′-thiocarbonyldi-2(1H)-pyridone) followed by aminolysis with ammoniaor, by treatment of II with an acyl isothiocyanate (like e.g. benzoylisothiocyanate) and subsequent hydrolysis of the intermediate formed.

Heterocyclic anilines II like an oxadiazole derivative IIa (Scheme 2)may be prepared from a corresponding ester XVIIIa by conversion to aacylated carboxylic acid hydrazide and subsequent cyclization to anoxadiazole XVa followed by reduction of the latter using generally knownmethods as described above. Treatment of an aldehyde XVIIIb with TosMIC(tosylmethyl isocyanide) yields an oxazole XVb. A ketone XIIIc can beconverted into a substituted oxazole XVc by treatment with iodobenzenediacetate, trifluoromethanesulfonic acid and a nitrile R¹CN. Athiadiazoles XVd can be prepared from a thioamide XXII in the presenceof N,N-dimethylacetamide dimethyl acetal and hydroxyl-amine-O-sulfonicacid. A thioamide XXII can be obtained by treatment of a correspondingamide XVIIId with Lawesson's reagent according to known procedures.Reduction of nitro derivatives XVa-d provides the respective anilinesIIa-d.

Heterocyclic anilines like the pyridine derivatives IIe (Scheme 3) maybe prepared by Suzuki coupling of a boronic acid XXI with a halideXXIII, or by Suzuki coupling of a halide XVI (hal=Cl, Br, I) to apyridine boronic acid or ester (like e.g. the pinacol ester) XXIV andsubsequent reduction of the nitro compound XVe. Aryl boronic acids andesters XXIV used as starting materials are either commercially availableor readily prepared by methods known to one skilled in the art oforganic synthesis, e.g. by treatment of the corresponding aryl bromidesR¹ArBr with bis(pinacolato)diboron in the presence of a palladiumcatalyst.

Heterocyclic anilines like the pyrazole derivative IIf can be preparedby Suzuki coupling of a 4-nitro-phenyl-boronic acid XVII, or an esterthereof (like e.g.2-(2-methoxy-4-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane),with a halide XXV (like e.g. 1-methyl-4-iodo-1H-pyrazole) underpalladium(II) catalysis in the presence of a base in a polar or apolarmedium under heating.

Heterocyclic anilines like the thiazole derivative IIg can be preparedfrom a halide XVI (hal=Cl, Br, I) by palladium(0) (like e.g. palladiumtetrakis-triphenylphosphine) catalyzed Heck reaction with an alkylsubstituted thiazole XXVI in the presence of a base (like e.g. potassiumacetate) in a polar solvent (like e.g. N,N-dimethylacetamide) underheating (e.g. to reflux or in a microwave oven) and subsequent reductionof the nitro group.

Compounds of formula I-A (Scheme 4) can be prepared by firstlyconverting a ketone XXIX to an enamine V or a diketone VI, respectively,followed by condensating these intermediates with a guanidine IV (Scheme2). A ketone XXVIII can be prepared by generally known methods, e.g. bytreating a nitrile XXVII in an inert solvent (like toluene) with asolution of a Grignard reagent (like methylmagnesium chloride intetrahydrofuran) at temperatures from 20 to 100° C.). Preparation of anenamine V can be achieved by reaction of XXVIII with an aminal of DMF(like N,N-diemethylformamide dimethyl acetal or Bredereck's reagent(tert.-butoxy-bis(dimethylamino)methane)). A diketone VI can be preparedfrom a ketone XXVIII by known methods, e.g. by reaction with acarboxylic acid ester in the presence of a strong base (like sodiumhydride, potassium tert.-butoxide, lithium diisopropylamide) in a polaror apolar solvent (like ethanol, tetrahydrofuran or toluene).Condensation of the guanidine IV with an enamine V or a ketone VI in apolar or unpolar solvent, optionally in the presence of base (liketriethylamine), at temperatures from 20 to 150° C., optionally using anmicrowave oven at 100 to 250° C., yields the pyrimidine I-A.Alternatively, compounds of structure I-A can be prepared by reacting aketo-ester VII with a guanidine IV and subsequently converting theresulting pyrimidine XXIX to a compound I-A by further reactions on thehydroxy substituent of the pyrimidine ring, e.g by preparing acorresponding chloro-pyrimidine which can be converted to a compound I-Acarrying a specific group R⁴. A keto-ester VII can be prepared from aketone XXVIII by known methods, e.g. by reaction with a dialkylcarbonate (like diethyl carbonate) in the presence of a strong base(like sodium hydride) in an aprotic solvent (like tetrahydrofuran orN,N-dimethylformamide).

Further route for the preparation of compounds of formula I-A consistsin reacting a 2-chloro-pyrimidine III with an aniline II (Scheme 5). Inan analogous manner, compounds of formula I-B and I-C can be prepared byreacting an aniline II with a chloro-pyridine VIII or IX, respectively.The intermediates III, VIII and IX can be prepared by generally knownmethods. A trichloro-pyrimidine XXX can first be reduced to adichloro-derivative XXXI, e.g. by treatment with zink in aquous ammoniaat 0° C., and subsequently, the 4-chloro substituent of XXXI is replacedby a group HL-R³ using a nucleophilic substitution reaction (likereaction with a Grignard reagent, e.g. benzylmagnesium chloride intetrahydrofuran at −80 to +20° C.) or, by a metal catalyst assisteddisplacement reaction (e.g. using palladium acetate,2-(dicyclohexylphosphino-biphenyl, tetrahydrofuran, microwave oven, 30min, 200° C.). Alternatively, one of the reactive chloro atoms of XXX isfirst replaced by a group Q-R³, followed by replacement of a secondchloro-substituent in the intermediate XXXII by a group R⁴, to affordIII. A chloro-pyrimidine VIII is prepared by replacement of one chloroatom by a group HL-R³, analogously as described for the preparation ofIII. In analogous manner, a chloro-pyrimidine IX is prepared byreplacement of one chloro atom of a compound XXXIV by a group R⁴. Thecoupling of intermediates III, VIII, and IX, respectively, with ananiline II is accomplished by applying a metal catalyst assisteddisplacement reaction (e.g. using palladium acetate,2-(dicyclohexylphosphino-biphenyl, potassium carbonate, dioxane,microwave oven, 30 min, 200° C.).

The preparation of a compound of formula I-D (Scheme 6) can be achievedby reacting a 1,6-dichloro-pyridine XXX with a compound HL-R³ (XII)followed by coupling of the resulting intermediate X with an aniline II.Alternatively, a compound XXX is at first coupled to an aniline II andthe resulting chloro-pyridine XI is then reacted with XII. The chlorodisplacement reactions used in these syntheses can be achieved bythermal nucleophilic displacement reactions, preferably in the presenceof a suitable catalyst (like an Pd(0) compound).

For the preparation of a compound I-E (Scheme 7), a thiourea XIII isconverted to a reactive derivative, such as a thio-amidino etherhydroiodide XXXVI which can be obtained by the treatment of XIII withmethyl iodide in acetone at 20° C. Condensation of XXXVI with acarboxylic acid hydrazide XIV, e.g. by heating the two components in apolar solvent (like ethanol), affords compounds I-E.

The compounds were investigated in accordance with the test givenhereinafter.

Cellular Assay

Human neuroglioma H4 cells overexpressing human APP were plated at30,000 cells/well/200 μl in 96-well plates in IMDM media containing 10%FCS, 0.2 mg/l Hygromycin B and incubated for 2 h at 37° C., 5% CO₂ priorto adding test compounds.

Compounds for testing were dissolved in 100% Me₂SO yielding in a 10 mMstock solution. Typically 12 μl of these solutions were further dilutedin 1000 μl of IMDM media (w/o FCS). Sub sequential 1:1 dilutions gave aten point dose response curve. 100 μl of each dilution was added to thecells in 96-well plates. Appropriate controls using vehicle only andreference compound were applied to this assay. The final concentrationof Me₂SO was 0.4%.

After incubation for 22 hrs at 37° C., 5% CO₂, 50 μl supernatant wastransferred into round-bottom 96-well polypropylene plates for detectionof Aβ42. 50 μl assay buffer (50 mM Tris/Cl, pH 7.4, 60 mM NaCl, 0.5%BSA, 1% TWEEN 20) was added to the wells followed by the addition of 100μl of detection antibody (ruthenylated Aβ42-specific antibody BAP150.0625 μg/mL in assay buffer). 50 μl of a premix of capture antibody(biotinylated 6E10 antibody, 1 μg/mL) and Steptavidin-coated magneticbeads (Dynal M-280, 0.125 mg/mL) were preincubated for 1 hr at roomtemperature before adding the assay plates. Assay plates were incubatedon a shaker for 3 hrs at room temperature and finally read in theBioveris M8 Analyser according to the manufacturer's instructions(Bioveris).

Toxicity of compounds was monitored by a cell viability test of thecompound-treated cells using a calorimetric assay (CellTiter 96™ AQassay, Promega) according to the manufacturer's instructions. Briefly,after removal of 50 μl cell culture supernatant for detection of Aβ42,20 μl of 1×MTS/PES solution was added to the cells and incubated for 30min at 37° C., 5% CO₂. Optical density was then recorded at 490 nm.

IC₅₀ values for inhibition of Aβ42 secretion were calculated bynonlinear regression fit analysis using XLfit 4.0 software (IDBS).

The preferred compounds show an IC₅₀<0.5 (nM). In the list below aredescribed some data to the γ-secretase inhibition:

Example No./ IC₅₀ in vitro Formula (nM)  1/I-A 0.22  2/I-A 0.21  3/I-A0.24  5/I-A 0.20  9/I-A 0.19  11/I-A 0.23  12/I-A 0.38  13/I-A 0.43 16/I-A 0.21  17/I-A 0.30  18/I-A 0.23  19/I-A 0.46  20/I-A 0.44  21/I-A0.47  22/I-A 0.49  28/IA 0.49  38/I-A 0.32  43/I-A 0.15  46/I-A 0.27 47/I-A 0.19  61/I-A 0.50  62/I-B 0.98  64/I-B 0.67  65/I-C 2.51  70/I-D0.26  72/I-E 0.10  73/I-E 0.22  75/I-A 0.31  76/I-A 0.49  81/I-A 0.34 82/I-A 0.48  88/I-A 0.39  90/I-A 0.17  91/I-A 0.07  92/I-A 0.45  94/I-A0.32  95/I-A 0.42  97/I-A 0.2 104/I-A 0.42 105/I-A 0.44 106/I-A 0.12108/I-A 0.28 109/I-A 0.32 112/I-A 0.32 113/I-A 0.22 115/I-A 0.4 116/I-A0.36 117/I-A 0.15 118/I-A 0.27 119/I-A 0.11 120/I-A 0.16 121/I-A 0.25122/I-A 0.46 131/I-A 0.32 134/I-A 0.38 136/I-A 0.29 137/I-A 0.43 140/I-A0.18 145/I-A 0.39 146/I-A 0.3 147/I-A 0.25 149/I-A 0.26 150/I-A 0.23152/I-A 0.22 153/I-A 0.21 154/I-A 0.43 155/I-A 0.13 156/I-A 0.41 157/I-A0.13 159/I-A 0.12 161/I-A 0.28 162/I-A 0.17 163/I-A 0.36 164/I-A 0.21165/I-A 0.23 166/I-A 0.28 167/I-A 0.07 168/I-A 0.06 169/I-A 0.17 170/I-A0.32 172/I-A 0.45 173/I-A 0.09 174/I-A 0.1 175/I-A 0.1 176/I-A 0.47179/I-A 0.08 180/I-A 0.14 181/I-A 0.09 182/I-A 0.26 183/I-A 0.43 187/I-D0.22 188/I-D 0.24 189/I-D 0.31 192/I-D 0.27 196/I-D 0.28 197/I-D 0.45198/I-D 0.31 202/I-D 0.33 205/I-A 0.49 209/I-A 0.43 218/I-A 0.36 220/I-A0.37 221/I-A 0.34 223/I-A 0.34 226/I-A 0.13 228/I-A 0.18 233/I-A 0.29234/I-A 0.22 235/I-A 0.28 236/I-A 0.45 237/I-A 0.5

The present invention also provides pharmaceutical compositionscontaining compounds of the invention, for example, compounds of formulaI or pharmaceutically acceptable salts thereof and a pharmaceuticallyacceptable carrier. Such pharmaceutical compositions can be in the formof tablets, coated tablets, dragées, hard and soft gelatin capsules,solutions, emulsions or suspensions. The pharmaceutical compositionsalso can be in the form of suppositories or injectable solutions.

The pharmaceutical compositions of the invention, in addition to one ormore compounds of the invention, contain a pharmaceutically acceptablecarrier. Suitable pharmaceutically acceptable carriers includepharmaceutically inert, inorganic or organic carriers. Lactose, cornstarch or derivatives thereof, talc, stearic acids or its salts and thelike can be used, for example, as such carriers for tablets, coatedtablets, dragées and hard gelatine capsules. Suitable carriers for softgelatine capsules are, for example, vegetable oils, waxes, fats,semi-solid and liquid polyols and the like. Depending on the nature ofthe active substance no carriers are, however, usually required in thecase of soft gelatine capsules. Suitable carriers for the production ofsolutions and syrups are, for example, water, polyols, glycerol,vegetable oil and the like. Suitable carriers for suppositories are, forexample, natural or hardened oils, waxes, fats, semi-liquid or liquidpolyols and the like.

The pharmaceutical composition can, moreover, contain preservatives,solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners,colorants, flavorants, salts for varying the osmotic pressure, buffers,masking agents or antioxidants. They can also contain still othertherapeutically valuable substances.

The present invention also provides a method for the manufacture ofpharmaceutical compositions. Such process comprises bringing one or morecompounds of formula I and/or pharmaceutically acceptable acid additionsalts thereof and, if desired, one or more other therapeuticallyvaluable substances into a galenical administration form together withone or more therapeutically inert carriers.

In accordance with the invention compounds of formula I as well as theirpharmaceutically acceptable salts are useful in the control orprevention of illnesses based on the inhibition of the γ-secretase, suchas of Alzheimer's disease.

The dosage at which compounds of the invention can be administered canvary within wide limits and will, of course, have to be adjusted to theindividual requirements in each particular case. In the case of oraladministration the dosage for adults can vary from about 0.01 mg toabout 1000 mg per day of a compound of general formula I or of thecorresponding amount of a pharmaceutically acceptable salt thereof. Thedaily dosage may be administered as single dose or in divided doses and,in addition, the upper limit can also be exceeded when this is found tobe indicated.

Tablet Formulation (Wet Granulation) mg/tablet Item Ingredients 5 mg 25mg 100 mg 500 mg 1. Compound of formula I 5 25 100 500 2. LactoseAnhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4. MicrocrystallineCellulose 30 30 30 150 5. Magnesium Stearate 1 1 1 1 Total 167 167 167831

Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.2. Dry the granules at 50° C.3. Pass the granules through suitable milling equipment.4. Add item 5 and mix for three minutes; compress on a suitable press.

Capsule Formulation mg/capsule Item Ingredients 5 mg 25 mg 100 mg 500mg 1. Compound of formula I 5 25 100 500 2. Hydrous Lactose 159 123 148— 3. Corn Starch 25 35 40 70 4. Talc 10 15 10 25 5. Magnesium Stearate 12 2 5 Total 200 200 300 600

Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.2. Add items 4 and 5 and mix for 3 minutes.3. Fill into a suitable capsule.

EXAMPLE 1(4-Benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-(2-Methoxy-4-nitro-phenyl)-4-methyl-1H-imidazole

A solution of 2-chloro-5-nitroanisole (187 mg, 1 mmol), of4-methyl-1H-imidazole (335 mg, 4 mmol) and of potassium hydroxide (99mg, 1.5 mmol) in DMSO (0.86 mL) was stirred for 5 h at 80° C. under anatmosphere of nitrogen. After cooling to 20° C. the reaction was pouredonto ice-water. A precipitation was formed and the suspension wasstirred for 15 min. The solid was filtered off, washed with water,dissolved in dichloromethane, dried over sodium sulfate, filtered andthe solvent was evaporated under reduced pressure to yield a yellowsolid. The crude product was purified on silica gel usingdichloromethane/methanol (19:1 v/v) as eluent to yield the titlecompound (106 mg, 45%) as a pale-yellow solid. Alternatively the productcan be also crystallized from the crude material from diethyl ether.

MS ISP (m/e): 234.3 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.97 (d, 1H), 7.96 (s, 1H), 7.83 (s,1H), 7.42 (d, 1H), 7.00 (s, 1H), 4.00 (s, 3H), 2.31 (s, 3H).

b) 3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine

1-(2-Methoxy-4-nitro-phenyl)-4-methyl-1H-imidazole (2.52 g, 10.8 mmol)dissolved in ethanol (110 mL) was stirred under an atmosphere ofhydrogen at 20° C. for 3.5 h in the presence of 10% palladium oncharcoal (0.25 g). The catalyst was filtered off and washed withethanol. The solvent of the filtrate was evaporated under reducedpressure. The crude product was purified on silica gel usingdichloromethane/methanol (19:1 v/v) as eluent. The fraction containingthe product was suspended in diethyl ether, stirred for 15 min, filteredand dried to yield the title compound (1.72 g, 78%) as a yellow solid.

MS ISP (m/e): 204.3 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.48 (s, 1H), 6.91 (d, 1H), 6.88 (s,1H), 6.35 (s, 1H), 6.17 (d, 1H), 3.68 (s, 3H), 2.11 (s, 3H).

c) 6-Benzyl-2,4-dichloro-pyrimidine

To a solution of 2,4,6-trichloropyrimidine (936 mg, 5.0 mmol) intetrahydrofuran (50 mL) was added at −78° C. under an atmosphere ofnitrogen and stirring drop wise 1 M benzylmagnesium chloride solution indiethyl ether (5 mL, 5.0 mmol). The reaction was let to warm up to 20°C. over 16 h. The solvent was removed under reduced pressure and theresidue was dissolved in water. The aqueous layer was extracted twicewith dichloromethane. The combined organic layers were washed once withbrine, dried over sodium sulfate, filtered and the solvent was removedunder reduced pressure. The residue was purified by columnchromatography on silica gel using heptane and then heptane/ethylacetate (9:1 v/v) as eluent to yield the title compound (778 mg, 65%) asa pale-yellow viscous oil.

MS ISP (m/e): 238.9/241.0 (100/70) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.73 (s, 1H), 7.26-7.34 (m, 5H), 4.12(s, 2H).

d) 4-Benzyl-2-chloro-pyrimidine

To an emulsion of 6-benzyl-2,4-dichloro-pyrimidine (239 mg, 1 mmol) in25% aqueous ammonia solution (1 mL) was added after stirring for 10 minat 0° C. zinc powder (82 mg, 1.25 mmol). The reaction was stirred at 20°C. for 16 h. The yellow suspension was diluted with ethyl acetate aninsoluble material was filtered off. The layers were separated and theaqueous layer was extracted with ethyl acetate. The combined organiclayers were washed with brine, dried over sodium sulfate and evaporatedunder reduced pressure to yield the crude title compound (210 mg, 92%)as a yellow oil.

MS EI (m/e): 203.1/204.2 (100/50) [M⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.66 (d, 1H), 7.73 (d, 1H), 7.25-7.45(m, 5H), 4.11 (s, 2H).

e)(4-Benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Palladium acetate (2.7 mg, 0.012 mmol) and2-(dicyclohexylphosphino)-biphenyl (8.7 mg, 0.024 mmol) were dissolvedunder an atmosphere of nitrogen in dioxane (1 mL) and stirred for 10 minat 20° C. This solution was added at 20° C. under an atmosphere ofnitrogen to a microwave flask containing3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol),4-benzyl-2-chloro-pyrimidine (68 mg, 0.3 mmol) and potassium carbonate(829 mg, 6.0 mmol). The mixture was diluted with dioxane (1.7 mL) andheated for 30 min to 200° C. in a microwave oven. The reaction waspoured onto water and extracted twice with ethyl acetate. The combinedorganic solutions were washed with brine, dried over sodium sulfate,filtered and the residue was purified by column chromatography on silicagel using dichloromethane/methanol (19:1 v/v) as eluent to yield thetitle compound (50 mg, 45%) as a yellow solid.

MS ISP (m/e): 372.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.77 (s, 1H), 8.41 (d, 1H), 7.83 (s,1H), 7.65 (s, 1H), 7.18-7.39 (m, 7H), 7.02 (s, 1H), 6.79 (d, 1H), 4.00(s, 2H), 3.73 (s, 3H), 2.14 (s, 3H).

EXAMPLE 2[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzyl)-pyrimidin-2-yl]-amine

a) 2,4-Dichloro-6-(3,4,5-trifluoro-benzyl)-pyrimidine

To a suspension of magnesium (0.24 g, 10.0 mmol) in diethyl ether (15mL) 3,4,5-trifluorobenzylbromide (1.69 g, 9.0 mmol) was added drop wise.The reaction was started with little iodine and heated to reflux for 2h. To a solution of 2,4,6-trichloropyrimidine (2.32 g, 10.0 mmol) intetrahydrofuran (90 mL) was added the above prepared Grignard solutionat −78° C. under an atmosphere of nitrogen. The reaction was continuedas described in example 1d) to yield the title compound (0.39 g, 15%) asa pale-yellow solid. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.74 (s, 1H),7.32 (m, 2H), 4.14 (s, 2H).

b) 2-Chloro-4-(3,4,5-trifluoro-benzyl)-pyrimidine

The title compound was prepared from2,4-dichloro-6-(3,4,5-trifluoro-benzyl)-pyrimidine in analogous manneras described in example 1d). It was obtained in 54% yield as a yellowoil.

MS ISN (m/e): 257.0/258.9 (100/30) [(M−H)⁻].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.69 (d, 1H), 7.47 (d, 1H), 7.31 (m,2H), 4.14 (s, 2H).

c)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzyl)-pyrimidin-2-yl]-amine

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and4-(3,4,5-trifluoro-benzyl)-2-chloro-pyrimidine. It was obtained as apale-brown solid in 54% yield.

MS ISP (m/e): 426.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.77 (s, 1H), 8.45 (d, 1H), 7.76 (s,1H), 7.65 (s, 1H), 7.40 (d, 1H), 7.32 (t, 2H), 7.19 (d, 1H), 7.02 (s,1H), 6.81 (d, 1H), 4.02 (s, 2H), 3.76 (s, 3H), 2.14 (s, 3H).

EXAMPLE 3[4-(3-Chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 2,4-Dichloro-6-(3-chloro-benzyl)-pyrimidine

The title compound was prepared in analogous manner as described inexample 2a) from 3-chloro-benzylbromide and 2,4,6-trichloropyrimidine.It was obtained as a pale-yellow oil in 26% yield.

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.77 (s, 1H), 7.27-7.43 (m, 4H), 4.14(s, 2H).

b) 2-Chloro-4-(3-chloro-benzyl)-pyrimidine

The title compound was prepared in analogous manner as described inexample 1d) from 2,4-dichloro-6-(3-chloro-benzyl)-pyrimidine. It wasobtained in 31% yield as a yellow oil. ¹H NMR (DMSO-D₆, 300 MHz): δ(ppm)=8.68 (d, 1H), 7.49 (d, 1H), 7.26-7.42 (m, 4H), 4.14 (s, 2H).

c)[4-(3-Chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-(3-chloro-benzyl)-pyrimidine. It was obtained as a yellowsolid in 55% yield.

MS ISP (m/e): 406.3/408.3 (100/29) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.78 (s, 1H), 8.43 (d, 1H), 7.79 (s,1H), 7.65 (s, 1H), 7.27-7.42 (m, 5H), 7.18 (d, 1H), 7.02 (s, 1H), 6.83(d, 1H), 4.02 (s, 2H), 3.74 (s, 3H), 2.14 (s, 3H).

EXAMPLE 4[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(1-phenyl-cyclohexyl)-pyrimidin-2-yl]-amine

a) 3-Dimethylamino-1-(1-phenyl-cyclohexyl)-propenone

Acetyl-1-phenylcyclohexane (101 mg, 0.5 mmol) was heated in dimethylformamide dimethyl acetale (0.8 mL) for 16 h to 110° C. under anatmosphere of nitrogen. The reaction was evaporated to dryness underreduced pressure and was twice evaporated with toluene to yield thecrude title compound (126 mg, 98%) as a yellow semi-solid which was usedwithout further purification in the next step.

MS ISP (m/e): 331.4 (79) [(M+H)⁺], 275.1 (100) [(M-isubutene+H)⁺].

b) N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate

To a solution of 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (5.08g, 25.0 mmol) in ethanol (25 mL) was added at 20° C. cyanamide (3.15 g,75 mmol) dissolved in water (3.2 mL) and then 37% aqueous hydrochloricacid solution (4.9 g, 50 mmol). The solution was heated for 3 h toreflux. Additional cyanamide (2.1 g) in water (2.1 mL) and 37% aqhydrochloric acid solution (2.8 mL) were added and the mixture washeated to reflux for another 2 h. At 20° C. 65% aqueous nitric acid (3.5mL, 50 mmol) was added. The reaction was stirred for 30 minute at 20° C.and the formed precipitate was filtered off, washed with ethanol anddiethyl ether. (Caution: the filtrate may contain the ethyl ester ofnitric acid). The solid was dried under reduced pressure at 20° C. toyield the title compound (5.42 g, 58%) as a white solid.

MS ISP (m/e): 246.1 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.17 (s, 1H), 9.34 (s, 1H), 8.40 (brs, 2H), 7.67 (br s, 4H), 7.63 (d, 1H), 7.21 (s, 1H), 6.99 (d, 1H), 3.88(s, 3H), 2.35 (s, 3H).

c)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(1-phenyl-cyclohexyl)-pyrimidin-2-yl]-amine

N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (74mg, 0.20 mmol), crude 3-dimethylamino-1-(1-phenyl-yclohexyl)-propenone(124 mg, 0.48 mmol) and triethylamine (41 mg, 0.40 mmol) in ethanol (2mL) were heated to reflux under an atmosphere of nitrogen for 16 h. Thereaction was transferred with 1-methyl-2-pyrrolidone (3 mL) into amicrowave tube and additional triethylamine (41 mg) was added. Thereaction was heated to 200° C. for 30 min, which yields only traces ofproduct. Therefore the reaction was heated to 250° C. in the microwaveoven, but decomposition of the starting material occurred. The reactionwas poured onto water, extracted twice with diethyl ether. The combinedorganic layers were washed with water and brine, dried over sodiumsulfate, filtered and the solvent was removed under reduced pressure.The residue was purified by column chromatography on silica gel usingdichloromethane/methanol (19:1 v/v) as eluent to yield the titlecompound (6 mg, 7%) as a pale-brown solid.

MS ISP (m/e): 440.3 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.27 (d, 1H), 7.79 (s, 1H), 7.64 (s,1H), 7.15-7.39 (m, 6H), 7.03 (d, 1H), 6.88 (s, 1H), 6.62 (d, 1H), 3.86(s, 3H), 2.55 (m, 2H), 2.30 (s, 3H), 2.40 (m, 2H), 1.20-1.70 (m, 6H).

EXAMPLE 5[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl)-pyrimidin-2-yl]-amine

a) 1-Dimethylamino-2-methyl-4-phenyl-pent-1-en-3-one

A mixture of 2-phenyl-3-pentanone (106 mg, 0.54 mmol) and oftert.-butoxy-bis(dimethylamino)methane (146 mg, 0.75 mmol, 90%) wasstirred at 110° C. for 16 h. The reaction was evaporated to dryness,treated twice with toluene and the solvent was evaporated under reducedpressure to give the crude title compound (138 mg, 97%) as a dark brownsolid which was used directly in the next step without furtherpurification.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.15-7.31 (m, 6H), 4.21 (q, 1H), 3.00(s, 6H), 1.94 (s, 3H), 1.41 (d, 3H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl)-pyrimidin-2-yl]-amine

The title compound was prepared in analogous manner described in example4c) from N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate, 1-dimethylamino-2-methyl-4-phenyl-pent-1-en-3-one andtriethylamine using 1-methyl-2-pyrrolidinone as the solvent. Thereaction was performed in a microwave at 200° C. for 30 min. The titlecompound was isolated as a pale-yellow solid in 39% yield.

MS ISP (m/e): 400.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.64 (s, 1H), 8.22 (s, 1H), 7.90 (s,1H), 7.66 (s, 1H), 7.42 (d, 1H), 7.15-7.32 (m, 6H), 7.03 (s, 1H), 4.38(q, 1H), 3.78 (s, 3H), 2.14 (s, 3H), 2.07 (s, 3H), 1.63 (d, 3H).

EXAMPLE 6[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(3-methoxy-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-amine

a) 1-Dimethylamino-4-(3-methoxy-phenyl)-4-methyl-pent-1-en-3-one

The title compound was prepared from3-(3-methoxy-phenyl)-3-methyl-butan-2-one in analogous manner asdescribed in example 5a) as a yellow viscous oil in 99% yield and wasused without further purification in the next step.

MS ISP (m/e): 248.2 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.54 (d, 1H), 7.21 (t, 1H), 6.91 (d,1H), 6.88 (s, 1H), 6.73 (d, 1H), 4.75 (d, 1H), 3.80 (s, 3H), 2.50-3.15(br s, 6H), 1.48 (s, 3H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(3-methoxy-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-amine

The title compound was prepared in analogous manner as described inexample 4c) fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate,1-dimethylamino-4-(3-methoxy-phenyl)-4-methyl-pent-1-en-3-one andtriethylamine using 1-methyl-pyrrolidinone as the solvent. The reactionwas performed in a microwave at 200° C. for 2.5 h. The title compoundwas isolated as a brown viscous oil in 44% yield.

MS ISP (m/e): 430.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.74 (s, 1H), 8.41 (d, 1H), 7.85 (s,1H), 7.64 (s, 1H), 7.29 (d, 1H), 7.23 (t, 1H), 7.19 (d, 1H), 7.02 (s,1H), 6.80-6.82 (m, 3H), 6.73 (d, 1H), 3.71 (s, 6H), 2.14 (s, 3H), 1.68(s, 6H).

EXAMPLE 7{4-[1-(4-Chloro-phenyl)-cyclopropyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-[1-(4-Chloro-phenyl)-cyclopropyl]-ethanone

To a solution of 1-(4-chlorophenyl)-1-cyclopropanecarbonitrile (181 mg,1.0 mmol) in toluene (5 mL) was added drop wise at 20° C. under anatmosphere of nitrogen a 3 M solution of methylmagnesium chloride intetrahydrofuran (0.5 mL, 1.5 mmol). The reaction was heated for 16 h to80° C. In an ice bath 6 N aqueous hydrochloric acid solution (1.08 mL)was added carefully and the reaction was heated to reflux for 2 h. Thereaction was diluted with toluene, extracted once with water, once withbrine, dried over sodium sulfate, filtered and the solvent wasevaporated under reduced pressure. The residue was purified by columnchromatography on silica gel using heptane/ethyl acetate (9:1 v/v) aseluent to yield the title compound (67 mg, 34%) as a yellow oil.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.31 (m, 4H), 2.00 (s, 3H), 1.61 (q,2H), 1.15 (q, 2H).

b) 1-[1-(4-Chloro-phenyl)-cyclopropyl]-3-dimethylamino-propenone

The title compound was prepared from1-[1-(4-chloro-phenyl)-cyclopropyl]-ethanone in analogous manner asdescribed in example 5a) as a pale-yellow viscous oil in 99% yield andwas used without further purification in the next step.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.52 (d, 1H), 7.26-7.33 (m, 4H), 6.73(d, 1H), 4.71 (d, 1H), 3.00 (br s, 3H), 2.65 (br s, 3H), 1.59 (m, 2H),1.00 (m, 2H).

c){4-[1-(4-Chloro-phenyl)-cyclopropyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 4c) fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate,1-[1-(4-chloro-phenyl)-cyclopropyl]-3-dimethylamino-propenone andtriethylamine using 1-methyl-2-pyrrolidine as the solvent. The reactionwas performed in a microwave at 200° C. for 2.5 h. The title compoundwas isolated as a brown viscous oil in 22% yield.

MS ISP (m/e): 432.3/434.3 (100/39) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.73 (s, 1H), 8.25 (d, 1H), 7.84 (s,1H), 7.66 (s, 1H), 7.47 (d, 2H), 7.43 (d, 2H), 7.26 (d, 1H), 7.20 (d,1H), 7.04 (s, 1H), 6.18 (d, 1H), 3.82 (s, 3H), 2.14 (s, 3H), 1.75 (m,2H), 1.38 (m, 1H).

EXAMPLE 8(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a)2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-ol

To a solution of sodium ethoxide (724 mg, 13 mmol) in methanol (60 mL)was added at 20° C. under an atmosphere of nitrogenN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate(2.10 g, 5.7 mmol) and ethyl acetoacetate (2.43 g, 18.7 mmol). Thereaction was heated to reflux for 40 h. After cooling it was poured ontowater and set to pH 7 with 1N aqueous hydrochloric acid solution. Theprecipitate was filtered off, washed with water and diethyl ether, anddried in high vacuum for 16 h at 45° C. to yield the title compound (146g, 83%) as a white solid.

MS ISP (m/e): 312.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.83 (br s, 1H), 7.67 (s, 1H), 7.25(s, 2H), 7.04 (s, 1H), 5.77 (s, 1H), 3.80 (s, 3H), 2.17 (s, 3H), 2.14(s, 3H).

b)(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A solution of2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-ol(1.45 g (46.6 mmol) in phosphorous oxychloride (4.7 mL) was heated toreflux for 2 h. The excess of phosphorous oxychloride was evaporatedunder reduce pressure and the residue was treated carefully with ice andthen, under ice cooling, with 25% aqueous ammonia. The precipitateformed was filtered off, washed with water and then with diethyl etherand dried to give the title compound (1.53 g, 100%) as a pale-brownsolid.

MS ISP (m/e): 330.1/332.2 (100/25) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.16 (s, 1H), 7.81 (s, 1H), 7.67 (s,1H), 7.36 (d, 1H), 7.27 (d, 1H), 7.05 (s, 1H), 6.95 (s, 1H), 3.80 (s,3H), 2.40 (s, 3H), 2.14 (s, 3H).

EXAMPLE 9[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,4,5-trifluoro-phenoxy)-pyrimidin-2-yl]-amine

To a solution of 3,4,5-trifluorophenol (33 mg, 0.22 mmol) in1-methyl-2-pyrrolidone (2 mL) was added at 20° C. under an atmosphere ofnitrogen a 55% dispersion of sodium hydride in oil (10 mg, 0.22 mmol).The reaction was stirred for 30 min and then,(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(66 mg, 0.2 mmol) was added. The mixture was heated in a microwave ovento 200° C. for 30 min and then poured onto 1 N aqueous sodium hydroxidesolution. The mixture was stirred for 15 min, and the precipitate formedwas filtered off, washed with water and dried to yield the titlecompound (72 mg, 8%) as a pale-brown solid.

MS ISP (m/e): 442.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.74 (s, 1H), 7.63 (s, 1H), 7.60 (s,1H), 7.46 (dd, 2H), 7.25 (d, 1H), 7.11 (d, 1H), 7.00 (s, 1H), 6.46 (s,1H), 3.64 (s, 3H), 2.38 (s, 3H), 2.14 (s, 3H).

EXAMPLE 10[4-(2,6-Dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-Chloro-6-(2,6-dichloro-phenoxy)-pyrimidine

4,6-Dichloropyrimidine (149 mg, 1.0 mmol), 2,6-dichlorophenol (179 mg,1.1 mmol), potassium carbonate (166 mg, 1.2 mmol), and sodium iodide(7.5 mg, 0.05 mmol) were stirred in acetonitrile (3 mL) at 20° C. underan atmosphere of nitrogen for 64 h. The reaction was poured onto 1Naqueous sodium hydroxide solution and extracted twice with diethylether. The combined organic layers were washed with brine, dried oversodium sulfate, filtered and the solvent was evaporated under reducedpressure to give the title compound (195 mg, 71%) as a white solid.

MS EI (m/e): 274.9/276.9/278.9 (100/95/50) [M⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.69 (s, 1H), 7.78 (s, 1H), 7.66 (d,2H), 7.42 (dd, 1H).

b)[4-(2,6-Dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and4-chloro-6-(2,6-dichloro-phenoxy)-pyrimidine. It was obtained as ayellow solid in 29% yield.

MS ISP (m/e): 442.1/444.1 (100/60) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.79 (s, 1H), 8.48 (d, 1H), 7.66 (d,2H), 7.61 (s, 1H), 7.42 (dd, 1H), 7.31 (s, 1H), 7.11 (d, 1H), 6.99 (s,1H), 6.96 (d, 1H), 6.71 (d, 1H), 3.64 (s, 3H), 2.13 (s, 3H).

EXAMPLE 11[4-(3,4-Difluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manners as described inexample 9) from 3,4-difluorophenol and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.It was obtained in 81% yield as a pale-brown solid.

MS ISP (m/e): 424.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.73 (s, 1H), 7.50-7.62 (m, 4H), 7.23(d, 1H), 7.14 (m, 1H), 7.08 (d, 1H), 6.99 (s, 1H), 6.43 (s, 1H), 3.60(s, 3H), 2.37 (s, 3H), 2.13 (s, 3H).

EXAMPLE 12[4-(4-Chloro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manners as described inexample 9) from 4-chlorophenol and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.It was obtained in 73% yield as a pale-brown solid.

MS ISP (m/e): 422.1/424.2 (100/35) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.72 (s, 1H), 7.61 (s, 1H), 7.58 (s,1H), 7.52 (d, 2H), 7.28 (d, 2H), 7.18 (d, 1H), 7.07 (d, 1H), 6.99 (s,1H), 6.43 (s, 1H), 3.54 (s, 3H), 2.37 (s, 3H), 2.13 (s, 3H).

EXAMPLE 13[4-(4-Dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-(4-chloro-phenoxy)-pyrimidine. It was obtained as a yellowsolid in 58% yield.

MS ISP (m/e): 408.3/410.2 (100/34) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.74 (s, 1H), 8.42 (d, 1H), 7.62 (s,1H), 7.53 (d, 2H), 7.48 (s, 1H), 7.31 (d, 2H), 7.23 (d, 1H), 7.07 (d,1H), 6.99 (s, 1H), 6.54 (d, 1H), 3.56 (s, 3H), 2.13 (s, 3H).

EXAMPLE 143-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yloxy}-benzonitrile

The title compound was prepared in analogous manners as described inexample 9) from 3-hydroxy-benzonitrile and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.It was obtained in 75% yield as a pale-brown solid. MS ISP (m/e): 413.4(100) [(M+H)⁺]

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.74 (s, 1H), 7.86 (s, 1H), 7.78 (d,1H), 7.61-7.71 (m, 3H), 7.51 (br s, 1H), 7.17 (br d, 1H), 7.05 (d, 1H),6.99 (s, 1H), 6.49 (s, 1H), 3.56 (s, 3H), 2.38 (s, 3H), 2.13 (s, 3H).

EXAMPLE 15[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(pyridin-3-yloxy)-pyrimidin-2-yl]-amine

The title compound was prepared in analogous manners as described inexample 9 from 3-hydroxy-pyridine and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.It was obtained in 53% yield as a pale-yellow solid after purificationby column chromatography on silica gel using dichloromethane/methanol(19:1 v/v) as eluent.

MS ISP (m/e): 389.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.72 (s, 1H), 8.54 (d, 1H), 8.48 (dd,1H), 7.73 (dd, 1H), 7.48 (s, 1H), 7.49-7.55 (m, 2H), 7.17 (br d, 1H),7.07 (d, 1H), 6.98 (s, 1H), 6.48 (s, 1H), 3.53 (s, 3H), 2.39 (s, 3H),2.13 (s, 3H).

EXAMPLE 16[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(2-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine

The title compound was prepared in analogous manners as described inexample 9 from 2-trifluoromethyl-phenol and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The reaction was heated for 3.5 h to 200° C. in a microwave oven.Several times the phenol (overall 4.4 equivalents) and additional sodiumhydride had to be added in order to obtain complete conversion. Thetitle compound was obtained, after purification by column chromatographyon silica gel using dichloromethane/methanol (19:1 v/v) as eluent, as awhite solid in 15% yield.

MS ISP (m/e): 456.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.75 (s, 1H), 8.82 (m, 2H), 7.60 (s,1H), 7.51 (m, 3H), 7.12 (br d, 1H), 7.01 (d, 1H), 6.96 (s, 1H), 6.53 (s,1H), 3.53 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H).

EXAMPLE 17[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromethoxy-phenoxy)-pyrimidin-2-yl]-amine

The title compound was prepared in analogous manners as described inexample 9 from 3-trifluoromethoxy-phenol and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.It was obtained in 95% yield as a pale-brown solid. MS ISP (m/e): 472.0(100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.77 (s, 1H), 751-7.63 (m, 3H),7.28-7.36 (m, 3H), 7.18 (br d, 1H), 7.3 (d, 1H), 6.96 (s, 1H), 6.48 (s,1H), 3.52 (s, 3H), 2.38 (s, 3H), 2.12 (s, 3H).

EXAMPLE 18[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine

The title compound was prepared in analogous manners as described inexample 9 from 3-trifluoromethyl-phenol and(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.It was obtained in 62% yield as a pale-yellow viscous oil.

MS ISP (m/e): 456.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.74 (s, 1H), 7.66-7.72 (m, 3H), 7.59(s, 1H), 7.58 (d, 1H), 7.51 (br s, 1H), 7.13 (br d, 1H), 7.01 (d, 1H),6.96 (s, 1H), 6.49 (s, 1H), 3.50 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H).

EXAMPLE 19[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,3,4,4,4-pentafluoro-butoxy)-pyrimidin-2-yl]-amine

Sodium (6.9 mg, 0.3 mmol) was dissolved under stirring and heating underan atmosphere of argon in 3,3,4,4,4-pentafluorobutan-1-ol (676 mg, 4.0mmol). To this solution(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(66 mg, 0.20 mmol) was added and the reaction mixture was stirred for 16h at 20° C. and then heated to 100° C. for 4 h. The reaction mixture waspoured onto water and was acidified with 1N aqueous hydrochloric acidsolution. It was extracted twice with diethyl ether. The aqueous layerwas set to basic pH with 1N aqueous sodium hydroxide solution andextracted three times with diethyl ether. The combined organic layerswere washed with brine, dried over sodium sulfate and evaporated underreduced pressure. The residue was purified by column chromatography onsilica gel using dichloromethane/methanol (19:1 v/v) as eluent to yieldthe title compound (59 mg, 64%) as a pale-yellow solid.

MS ISP (m/e): 458.1 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.71 (s, 1H), 7.89 (s, 1H), 7.65 (s,1H), 7.33 (d, 1H), 7.20 (d, 1H), 7.02 (s, 1H), 6.23 (s, 1H), 4.63 (t,2H), 3.79 (s, 3H), 2.80 (tt, 2H), 2.31 (s, 3H), 2.14 (s, 3H).

EXAMPLE 20{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 3-(4-Chlorophenyl)-3-methyl-2-pentanone

To a solution of 2-(4-chlorophenyl)-2-methylpropionitrile (243 mg, 1.4mmol) in benzene (1.4 mL) was added slowly at 50° C. under an atmosphereof nitrogen and with stirring to a 2.8 M solution of ethylmagnesiumchloride in tetrahydrofuran (1.45 ml, 4.1 mmol). The reaction mixturewas heated to reflux for 2 h, and thereafter, cooled and poured onto 10%aqueous ammonium chloride solution (4 mL). The organic layer wasseparated and treated with 2 N aqueous hydrochloric acid solution (1mL). The reaction was heated to reflux for 1 h. After cooling thereaction mixture was diluted with water and extracted twice withbenzene. The organic layer was washed with brine, dried over sodiumsulfate and evaporated under reduced pressure. The residue was purifiedby column chromatography on silica gel using heptane/ethyl acetate (9:1v/v) as eluent to give the title compound (64 mg, 20%) as a pale-yellowoil.

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.41 (d, 2H), 7.27 (d, 2H), 2.25 (q,2H), 1.41 (s, 6H), 0.83 (t, 3H).

b) 4-(4-Chloro-phenyl)-1-dimethylamino-2,4-dimethyl-pent-1-en-3-one

The title compound was prepared from3-(4-chlorophenyl)-3-methyl-2-pentanone in analogous manner as describedin example 5a) as a brown viscous oil in 97% yield and was used withoutfurther purification in the next step.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.27 (d, 2H), 7.17 (d, 2H), 6.81 (s,1H), 2.83 (s, 6H), 1.79 (s, 3H), 1.47 (s, 6H).

c){4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 4c) fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate,4-(4-chloro-phenyl)-1-dimethylamino-2,4-dimethyl-pent-1-en-3-one andtriethylamine using 1-methyl-2-pyrrolidone as the solvent. The reactionwas performed in a microwave oven at 200° C. for 2.5 h. The titlecompound was isolated as a yellow solid in 52% yield.

MS ISP (m/e): 448.1/450.1 (100/34) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.66 (s, 1H), 8.16 (s, 1H), 7.84 (s,1H), 7.65 (s, 1H), 7.44 (d, 1H), 7.38 (d, 2H), 7.23 (d, 1H), 7.20 (d,2H), 7.03 (s, 1H), 3.79 (s, 3H), 2.14 (s, 3H), 1.67 (s, 6H), 1.57 (s,3H).

EXAMPLE 21{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-(4-Chloro-phenyl)-1-dimethylamino-4-methyl-pent-1-en-3-one

The title compound was prepared from3-(4-chlorophenyl)-3-methyl-2-butanone in analogous manner as describedin example 5a) as a pale-yellow solid in 73% yield and was used withoutfurther purification in the next step.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.55 (d, 1H), 7.26 (m, 4H), 4.70 (d,1H), 3.00 (br s, 3H), 2.70 (br s, 3H), 1.47 (s, 6H).

b){4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 4c) fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate and4-(4-chloro-phenyl)-1-dimethylamino-4-methyl-pent-1-en-3-one, andtriethylamine using 1-methyl-2-pyrrolidone as solvent. The reaction wasperformed in a microwave oven at 200° C. for 2 h. The title compound wasisolated as a brown solid in 20% yield.

MS ISP (m/e): 434.3/436.1 (100/40) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.31 (d, 1H), 7.72 (s, 1H), 7.63 (s,1H), 7.27 (d, 2H), 7.21 (d, 1H), 7.15 (d, 1H), 7.01 (d, 1H), 6.87 (s,1H), 6.57 (d, 1H), 3.77 (s, 3H), 2.30 (s, 3H), 1.71 (s, 6H).

EXAMPLE 22{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-(2-Fluoro-4-nitro-phenyl)-4-methyl-1H-imidazole

3,4-Difluoro-4-nitro-benzene (7.97 g (50 mmol), 4-methyl-1H-imidazole(4.51 g (55 mmol) and N,N-diisopropylethylamine (16.16 g (125 mmol) weredissolved in acetonitrile (80 mL) and the reaction was heated to refluxfor 24 h under an atmosphere of nitrogen. The solvent was evaporatedunder reduced pressure and the residue was crystallized from a mixtureof ethyl acetate and heptane to yield the title compound (4.66 g, 42%)as a pale-yellow solid.

MS ISP (m/e): 222.1 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.42 (d, 1H), 8.21 (d, 1H), 8.11 (s,1H), 7.95 (t, 1H), 7.43 (s, 1H), 2.19 (s, 3H).

b) 3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine

1-(2-Fluoro-4-nitro-phenyl)-4-methyl-1H-imidazole (4.66 g, 21.1 mmol)was dissolved in a mixture of methanol (25 mL) and tetrahydrofuran (100mL). The solution was cooled to 0° C. under an atmosphere of nitrogen.Ammonium formate (6.64 g, 105 mmol) and 10% palladium on charcoal (0.24g) was added and the mixture was stirred at 20° C. for 18 h. The mixturewas filtered through celite and the celite was washed with methanol. Thefiltrate was evaporated under reduced pressure and the residue waspartitioned between ethyl acetate and 10% aqueous sodium bicarbonatesolution. The organic layer was separated, washed with brine, dried oversodium sulfate and evaporated under reduced pressure to yield the titlecompound (3.89 g, 97%) as a yellow solid.

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.62 (s, 1H), 7.12 (t, 1H), 7.01 (s,1H), 6.41-6.51 (m, 2H), 5.64 (br s, 2H), 2.13 (s, 3H).

c) N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine Nitrate

A suspension of 3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine (500 mg,2.62 mmol), of 50% aqueous cyanamide solution (249 mg, 2.96 mmol) and of65% aqueous nitric acid (253 mg, 2.62 mmol) in ethanol (2.6 mL) washeated for 5 days to reflux under an atmosphere of nitrogen. Twice thesame amounts of cyanamide and nitric acid were added to the reactionmixture after 2 and 4 days, respectively. The mixture was cooled and letstand at 20° C. for 1 d. The precipitated solid was filtered off(Caution: the filtrate may contain the ethyl ester of nitric acid) andwashed with ethanol to yield the title compound (280 mg, 36%) as anoff-white solid.

MS ISP (m/e): 234.1 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.82 (br s, 1H), 7.90 (s, 1H), 7.67(t, 1H), 7.56 (s, 4H), 7.43 (d, 1H), 7.25 (s, 1H), 7.21 (d, 1H), 2.18(s, 1H).

d){4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 4c) fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate,4-(4-chloro-phenyl)-1-dimethylamino-4-methyl-pent-1-en-3-one, andtriethylamine using 1-methyl-2-pyrrolidone as solvent. The reaction wasperformed in a microwave at 200° C. for 2.5 h. The title compound wasisolated as a yellow solid in 52% yield.

MS ISP (m/e): 448.1/450.1 (100/34) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.66 (s, 1H), 8.16 (s, 1H), 7.84 (s,1H), 7.65 (s, 1H), 7.44 (d, 1H), 7.38 (d, 2H), 7.23 (d, 1H), 7.20 (d,2H), 7.03 (s, 1H), 3.79 (s, 3H), 2.14 (s, 3H), 1.67 (s, 6H), 1.57 (s,3H).

EXAMPLE 23[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3,4,5-trifluoro-phenyl)-ethyl]-pyrimidin-2-yl}-amine

a) 2-Methyl-2-(3,4,5-trifluoro-phenyl)-propionitrile

Potassium tert.-butoxide (3.44 g, 30 mmol) was dissolved intetrahydrofuran (100 mL) and stirred under am atmosphere of nitrogen.(3,4,5-trifluorophenyl)-acetonitrile (2.12 g, 12 mmol) dissolved intetrahydrofuran (10 mL) was added drop wise at 0° C. The solution turnedorange and heat was evolved. Methyl iodide (1.88 mL, 30 mmol) dissolvedin tetrahydrofuran (10 mL) was added drop wise. The solution turned palebrown and was stirred for 4 h at 20° C. The reaction was poured ontowater and extracted twice with diethyl ether. The combined organiclayers were washed with brine, dried over sodium sulfate, filtered andthe solvent was evaporated und reduce pressure to yield the titlecompound (2.30 g, 96%) as a yellow solid.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.26 (m, 2H), 1.71 (s, 6H).

b) 3-Methyl-3-(3,4,5-trifluoro-phenyl)-butan-2-one

The title compound was prepared in analogous manner as described inexample 20a) from 2-methyl-2-(3,4,5-trifluoro-phenyl)-propionitrile and3 M methylmagnesium chloride solution in tetrahydrofuran in 42% yield asa pale-yellow oil.

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.24 (m, 2H), 1.97 (s, 3H), 1.42 (s,6H).

c) 1-Dimethylamino-4-methyl-4-(3,4,5-trifluoro-phenyl)-pent-1-en-3-one

The title compound was prepared crude in analogous manner as describedin example 5a) from 3-methyl-3-(3,4,5-trifluoro-phenyl)-butan-2-one as ayellow oil and was used as crude material in the next step.

MS ISP (m/e): 272.2 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.58 (d, 1H), 6.93 (m, 2H), 4.70 (d,1H), 3.04 (br s, 3H), 2.69 (br s, 3H), 1.44 (s, 6H).

d)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3,4,5-trifluoro-phenyl)-ethyl]-pyrimidin-2-yl}-amine

The title compound was prepared in analogous manner as described inexample 4c) fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate and1-dimethylamino-4-methyl-4-(3,4,5-trifluoro-phenyl)-pent-1-en-3-one as apale-brown solid in 21% yield.

MS ISP (m/e): 454.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.77 (s, 1H), 8.44 (d, 1H), 7.78 (s,1H), 7.65 (s, 1H), 7.32 (d, 1H), 7.17-7.28 (m, 4H), 7.02 (s, 1H), 6.75(d, 1H), 3.74 (s, 3H), 2.14 (s, 3H), 1.69 (s, 6H).

EXAMPLE 24{4-Chloro-6-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) Ethyl 4-(4-chloro-phenyl)-4-methyl-3-oxo-pentanoate

To a solution of 3-(4-chlorophenyl)-3-methyl-2-butanone (197 mg, 1 mmol)in diethyl carbonate (1.32 g, 11 mmol) was added at 20° C. under anatmosphere of nitrogen portion wise a dispersion of 55% sodium hydridein mineral oil (91 mg, 2.1 mmol). The reaction turned yellow and washeated to 50° C. After the gas evolution stopped the reaction wasstirred at 85° C. for 30 min. After cooling to 20° C. the reaction waspoured onto ice-water (2 mL) and then acetic acid (0.14 mL) was added.The reaction was extracted twice with diethyl ether. The combinedorganic layers were washed with water and with brine, dried over sodiumsulfate and evaporated under reduced pressure. The residue was purifiedby column chromatography on silica gel using heptene/ethyl acetate (9:1v/v) as eluent to yield the title compound as a pale-yellow oil (79 mg,29%).

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.43 (d, 2H), 7.30 (d, 2H), 3.99 (q,2H), 3.42 (s, 2H), 1.44 (s, 6H), 1.13 (t, 3H).

b)6-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ol

Sodium ethoxide (288 mg, 5.18 mmol) was dissolved in methanol (20 mL).At 20° C. under an atmosphere of nitrogenN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (835mg, 2.25 mmol) and ethyl 4-(4-chloro-phenyl)-4-methyl-3-oxo-pentanoate(700 mg, 2.48 mmol) dissolved in methanol (2.5 mL) were added. Thereaction was heated for 48 h to reflux. The solvent was evaporated underreduced pressure and the residue was taken up in water and acidified topH 6 with 1 N aqueous hydrochloric acid solution. The mixture wasextracted with dichloromethane and the organic layer was washed withbrine, dried over sodium sulfate and evaporated under reduced pressureto afford a solid residue. The concentrated aqueous layer was extractedfurther with boiling tetrahydrofuran. The organic layer was concentratedand combined with the first residue. The crude material was purified bycolumn chromatography on silica gel using dichloromethane/methanol (9:1v/v) as eluent. The product fraction was stirred with diethyl ether for15 min. The precipitate was collected by filtration to yield the titlecompound as an off-white solid (180 mg, 18%).

MS ISP (m/e): 450.1/452.0 (100/35) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.65-7.69 (m, 2H), 7.33 (dd, 4H),7.20 (m, 1H), 6.93-7.03 (m, 2H), 5.84 (s, 1H), 3.58 (s, 3H), 2.13 (s,3H), 1.58 (s, 6H).

c){4-Chloro-6-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 8b) starting with6-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ol.The crude product was purified by column chromatography on silica gelusing dichloromethane/methanol (19:1 v/v) as eluent to yield apale-yellow foam (92 mg, 49%).

MS ISP (m/e): 368.0/470.1 (100/59) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.16 (s, 1H), 7.75 (s, 1H), 7.65 (s,1H), 7.37 (dd, 4H), 7.26 (s, 2H), 7.03 (s, 1H), 6.86 (s, 1H), 3.69 (s,3H), 2.14 (s, 3H), 1.69 (s, 6H).

EXAMPLE 25[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-trifluoromethyl-pyrimidin-2-yl)-amine

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-trifluoromethyl-pyrimidine. The reaction was refluxed for 16h. The title compound was obtained as a pale-yellow solid in 43% yield.

MS ISP (m/e): 350.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.41 (s, 1H), 8.86 (d, 1H), 7.84 (s,1H), 7.69 (s, 1H), 7.37 (d, 1H), 7.32 (d, 1H), 7.29 (d, 1H), 7.06 (s,1H), 3.80 (s, 3H), 2.15 (s, 3H).

EXAMPLE 262-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-trifluoromethyl-pyrimidine-5-carboxylicAcid Methyl Ester

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine andmethyl 2-chloro-4-trifluoromethyl-pyrimidine-5-carboxylate. The reactionwas heated to reflux for 16 h. The title compound was obtained as apale-yellow solid in 20% yield.

MS ISP (m/e): 408.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.92 (s, 1H), 9.10 (d, 1H), 7.88 (brs, 1H), 7.72 (s, 1H), 7.35 (s, 2H), 7.08 (s, 1H), 3.87 (s, 3H), 3.81 (s,3H), 2.15 (s, 3H).

EXAMPLE 27 Methyl2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidine-4-carboxylate

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine andmethyl 2-chloro-6-methyl-pyrimidine-4-carboxylate. The reaction washeated to reflux for 16 h. The title compound was obtained as apale-brown solid in 18% yield.

MS ISP (m/e): 354.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.19 (s, 1H), 8.26 (br s, 1H), 7.67(s, 1H), 7.34 (s, 1H), 7.30 (d, 1H), 7.24 (d, 1H), 7.04 (s, 1H), 3.90(s, 3H), 3.84 (s, 3H), 2.14 (s, 3H).

EXAMPLE 28 Ethyl4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

a) Ethyl 3-dimethylamino-2-(4-chloromethyl-benzoyl)-acrylate

A mixture of ethyl 3-(4-chloro-phenyl)-3-oxo-propionate (227 mg, 1.0mmol) and of tert.-butoxy-bis(dimethylamino)methane (271 mg, 1.4 mmol,90%) was stirred at 110° C. for 2 h. The reaction was evaporated todryness, treated twice with toluene and the solvent was evaporated underreduced pressure to give the crude title compound (292 mg, 99%) as abrown oil which was used directly in the next step without furtherpurification.

MS ISP (m/e): 282.3 [(M+H)⁺].

b) Ethyl4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

A mixture of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (185 mg, 0.5 mmol), crude ethyl3-dimethylamino-2-(4-chloro-benzoyl)-acrylate (292 mg, 1.0 mmol), andtriethylamine (0.66 mL, 4.7 mmol) in ethanol (2 mL) was heated at refluxfor 15 h. The mixture was cooled and diluted with ethyl acetate (50 mL).The solution was washed with sat. sodium carbonate solution (5 mL) andwith brine (5 mL), dried over sodium sulfate and evaporated underreduced pressure. The residual material was purified by chromatographyon silica gel using dichloromethane/0-20% methanol as eluent to give thetitle compound (157 mg, 68%) as a pale-yellow solid. Mp 216-218° C.

MS ISP (m/e): 464.1 [(M+H)⁺].

EXAMPLE 29[4-(4-Chloro-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A mixture of 1-(4-chloro-phenyl)-4,4,4-trifluoro-butane-1,3-dione (50mg, 0.2 mmol), N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (74 mg, 0.2 mmol), and triethylamine (0.14 mL, 1.0 mmol) inethanol (0.5 mL) was heated to 78° C. for 18 h. The mixture was cooled,diluted with ethyl acetate (30 mL), and then washed with sat. sodiumcarbonate solution (5 mL) and with brine (5 mL). The organic layer wasdried over sodium sulfate and evaporated under reduced pressure. Theresidual material was purified by column chromatography on silica gel (5g) using ethyl acetate/0-10% ethanol as eluent to give the titlecompound (10 mg, 11%) as light-yellow solid. Mp 202-204° C.

MS ISP (m/e): 460.0 [(M+H)⁺].

EXAMPLE 30[4-(4-Imidazol-1-yl-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from4,4,4-trifluoro-1-(4-imidazol-1-yl-phenyl)-butane-1,3-dione (137 mg,0.49 mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (180 mg, 0.49 mmol) using in analogous manner the proceduredescribed in example 29). Obtained as a pale-yellow solid (19 mg, 8%).Mp 248-250° C.

MS ISP (m/e): 492.1 [(M+H)⁺].

EXAMPLE 31[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-pyrazol-1-yl-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-amine

a) 4,4,4-Trifluoro-1-(4-pyrazol-1-yl-phenyl)-butane-1,3-dione

A 5.4 N solution of sodium methoxide in methanol (3.0 mL, 16.2 mmol) wasadded drop wise over 10 min to a solution of ethyl trifluoro-acetate(1.81 mL, 15.2 mmol) in 2-ethoxy-2-methyl-propane (20 mL) at 20° C.followed by the addition of a suspension of1-(4-pyrazol-1-yl-phenyl)-ethanone (2.57 g, 13.8 mmol) in2-ethoxy-2-methyl-propane (10 mL). The reaction mixture was stirred for22 h at 20° C. and then poured onto ice-water (50 mL). The mixture wasextracted with ethyl acetate and the organic layer was washed withbrine, dried over sodium sulfate and evaporated under reduced pressure.The remaining solid was recrystallized from ethyl acetate/heptane togive the title compound (2.47 g, 63%) as off-white solid. Mp 96° C.

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-pyrazol-1-yl-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-amine

The title compound was prepared from4,4,4-trifluoro-1-(4-pyrazol-1-yl-phenyl)-butane-1,3-dione (137 mg,0.0.49 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (180mg, 0.49 mmol) using in analogous manner the procedure described inexample 29). Obtained as a pale-yellow solid (25 mg, 10%). Mp 252-254°C.

MS ISP (m/e): 492.0 [(M+H)⁺].

EXAMPLE 32 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylate

a) Ethyl 3-dimethylamino-2-(4-trifluoromethyl-benzoyl)-acrylate

Ethyl 3-oxo-3-(4-trifluoromethyl-phenyl)-propionate (130 mg, 0.5 mmol)was reacted with tert.-butoxy-bis-(dimethylamino)-methane using inanalogous manner the procedure described in example 28a) to give crudetitle compound (151 mg) as a red oil which was used directly in the nextstep.

MS ISP (m/e): 316.3 [(M+H)⁺].

b) Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylate

The title compound was prepared from ethyl3-dimethylamino-2-(4-trifluoromethyl-benzoyl)-acrylate (151 mg, 0.48mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (133 mg, 0.36 mmol) using in analogous manner the proceduredescribed in example 28b). Obtained as a pale-yellow solid (14 mg, 6%).

MS ISP (m/e): 498.0 [(M+H)⁺].

EXAMPLE 33 Ethyl4-(3-cyano-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

a) Ethyl 3-dimethylamino-2-(3-cyano-benzoyl)-acrylate

Ethyl 3-oxo-3-(3-cyano-phenyl)-propionate (109 mg, 0.5 mmol) was reactedwith tert.-butoxy-bis-(dimethylamino)-methane using in analogous mannerthe procedure described in example 28a) to give crude title compound (85mg) as a yellow oil which was used directly in the next step.

b) Ethyl4-(3-cyano-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

The title compound was prepared from ethyl3-dimethylamino-2-(3-cyano-benzoyl)-acrylate (85 mg, 0.31 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (116mg, 0.31 mmol) using in analogous manner the procedure described inexample 28b). Obtained as a pale-yellow solid (41 mg, 29%). Mp 195-197°C.

MS ISP (m/e): 455.1 [(M+H)⁺].

EXAMPLE 34 Ethyl{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-phenyl-pyrimidin-4-yl}-phenyl-acetate

a) Ethyl-5-dimethylamino-3-oxo-2,4-diphenyl-pent-4-enoate

Ethyl 3-oxo-2,4-diphenyl-butyrate (76 mg, 0.3 mmol) was reacted withtert.-butoxy-bis-(dimethylamino)-methane using in analogous manner theprocedure described in example 28a) to give crude title compound (102mg) as a red oil which was used directly in the next step.

MS ISP (m/e): 338.4 [(M+H)⁺].

b) Ethyl{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-phenyl-pyrimidin-4-yl}-phenyl-acetate

The title compound was prepared fromethyl-5-dimethylamino-3-oxo-2,4-diphenyl-pent-4-enoate (102 mg, 0.3mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (83 mg, 0.22 mmol) using in analogous manner the proceduredescribed in example 28b). Obtained as a light-brown solid (5 mg, 3%).Mp 84-86° C.

MS ISP (m/e): 520.0 [(M+H)⁺].

EXAMPLE 35 Ethyl4-(4-chloro-phenyl)-2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

The title compound was prepared from crude ethyl3-dimethylamino-2-(4-chloro-benzoyl)-acrylate (89 mg, 0.3 mmol) andN-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (80mg, 0.22 mmol) using in analogous manner the procedure described inexample 28b). Obtained as a pale-yellow solid (28 mg, 28%). Mp 232-234°C.

MS ISP (m/e): 452.1 [(M+H)⁺].

EXAMPLE 36 Ethyl4-(4-bromo-2-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

The title compound was prepared from crude ethyl2-(4-bromo-2-chloro-benzoyl)-3-dimethylamino-acrylate (50 mg, 0.14 mmol)and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate(43 mg, 0.12 mmol) using in analogous manner the procedure described inexample 28b). Obtained as a yellow solid (50 mg) in 28% yield.

MS ISP (m/e): 544.1/542.1/546.0/545.1/543.1 (100/85/39/30/26) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.74 (br s, 1H), 7.65 (s, 1H), 7.61 (d,1H), 7.51 (d, 2H), 7.24 (d, 1H), 7.19 (d, 1H), 7.08 (d, 1H), 6.88 (s,1H), 4.19 (q, 2H), 3.82 (s, 3H), 2.29 (s, 3H), 1.14 (t, 3H).

EXAMPLE 37[4-(4-Chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-(4-Chloro-phenyl)-3-dimethylamino-propenone

1-(4-Chloro-phenyl)-ethanone (49 mg, 0.3 mmol) was reacted withtert.-butoxy-bis-(dimethylamino)-methane using in analogous manner theprocedure described in example 28a) to give crude title compound (87 mg)as a yellow solid which was used directly in the next step.

MS ISP (m/e): 210.1 [(M+H)⁺].

b)[4-(4-Chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from crude1-(4-chloro-phenyl)-3-dimethylamino-propenone (87 mg, 0.3 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (83mg, 0.22 mmol) using in analogous manner the procedure described inexample 28b). Obtained as a pale-yellow solid (29 mg, 33%). Mp 202-204°C.

MS ISP (m/e): 392.1 [(M+H)⁺].

EXAMPLE 38[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-amine

a) 1-(4-Trifluoromethyl-phenyl)-3-dimethylamino-propenone

4-(Trifluoromethyl)-acetophenone (58 mg, 0.3 mmol) was reacted withtert.-butoxy-bis-(dimethylamino)-methane using in analogous manner theprocedure described in example 28a) to give crude title compound (81 mg)as a yellow solid which was used directly in the next step.

MS ISP (m/e): 244.4 [(M+H)⁺].

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-amine

The title compound was prepared from crude1-(4-trifluoromethyl-phenyl)-3-dimethylamino-propenone (81 mg, 0.3 mmol)and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate(83 mg, 0.22 mmol) using in analogous manner the procedure described inexample 28b). Obtained as a pale-yellow solid (25 mg, 27%).

MS ISP (m/e): 426.1 [(M+H)⁺].

EXAMPLE 39[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-2-yl)-amine

a) 3-Dimethylamino-1-pyridin-3-yl-propenone

Pyridin-3-yl-ethanone (62 mg, 0.5 mmol) was reacted withtert.-butoxy-bis-(dimethylamino)-methane using in analogous manner theprocedure described in example 28a) to give crude title compound (90 mg)as a yellow solid which was used directly in the next step.

MS ISP (m/e): 177.1 [(M+H)⁺].

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-2-yl)-amine

A mixture of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (185 mg, 0.37 mmol), crude3-dimethylamino-1-pyridin-3-yl-propenone (90 mg, 0.5 mmol) andtriethylamine (0.35 mL, 2.5 mmol) in ethanol (1 mL) was heated in asealed tube in a microwave oven to 160° C. for 0.5 h. The mixture wascooled, diluted with ethyl acetate (30 mL), and then washed with sat.sodium carbonate solution (5 mL) and with brine (5 mL). The organiclayer was dried over sodium sulfate and evaporated under reducedpressure. The residual material was purified by chromatography on silicagel using dichloromethane/0-20% methanol as eluent to give the titlecompound (62 mg, 47%) as a pale-yellow solid. Mp 204-206° C.

MS ISP (m/e): 359.4 [(M+H)⁺].

EXAMPLE 40[4-(4-Chloro-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from1-(4-chloro-phenyl)-4,4,4-trifluoro-butane-1,3-dione (125 mg, 0.5 mmol)and N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate(180 mg, 0.5 mmol) using in analogous manner the procedure described inexample 29). Obtained as a pale-yellow solid (18 mg, 8%). Mp 248-250° C.

MS ISP (m/e): 447.6 [(M+H)⁺].

EXAMPLE 41 Ethyl2-[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylate

The title compound was prepared from crude ethyl3-dimethylamino-2-(4-trifluoromethyl-benzoyl)-acrylate (142 mg, 0.45mmol) and N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (121 mg, 0.34 mmol) using in analogous manner the proceduredescribed in example 28b). Obtained as a pale-yellow solid (128 mg,78%). Mp 219-221° C.

MS ISP (m/e): 486.4 [(M+H)⁺].

EXAMPLE 42[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-amine

The title compound was prepared from crude1-(4-trifluoromethyl-phenyl)-3-dimethylamino-propenone (114 mg, 0.47mmol) and N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (126 mg, 0.35 mmol) using in analogous manner the proceduredescribed in example 39b). Obtained as a pale-yellow solid (99 mg, 68%).Mp 196-197° C.

MS ISP (m/e): 414.1 [(M+H)⁺].

EXAMPLE 43(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-Benzyl-2-chloro-6-methyl-pyrimidine

4-Benzyl-2,6-dichloro-pyrimidine (2.5 g, 10.5 mmol) was dissolved intetrahydrofuran (40 mL) under an atmosphere of nitrogen and subsequentlytreated with dimethylzinc (2M in toluene, 5.76 mL) andtetrakis(triphenylphosphine)palladium(0) (245 mg). After stirring for 18h at ambient temperature, ethyl acetate and water were added, the phasesseparated and the aqueous layer was extracted twice with ethyl acetate.The combined organic phases were dried over magnesium sulfate andevaporated under reduced pressure. Column chromatography on silica gelusing heptane/ethyl acetate 9:1 v/v) as eluent afforded the titlecompound (1.89 g, 83%) as colorless oil.

NMR (CDCl₃, 300 MHz): δ (ppm)=7.35-7.24 (m, 5H), 6.84 (s, 1H), 4.06 (s,2H), 2.44 (s, 3H).

MS ISP (m/e): 219.3 (100) [(M+H)⁺].

b)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Palladium(II) acetate (3.3 mg) and 2-(dicyclohexylphosphino)-biphenyl(11 mg) were stirred in dioxane (1.5 mL) while nitrogen was bubbledthrough the solution. In a second flask, a mixture of4-benzyl-2-chloro-6-methyl-pyrimidine (80 mg),3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (75 mg), and potassiumcarbonate (1.03 g) in dioxane (2 mL) was degassed with nitrogen, andsubsequently, the above described catalyst solution was added. Thereaction mixture was heated in a microwave oven at 200° C. for 30 min.The suspension was filtered, insoluble material was washed with ethylacetate, and the combined solutions are concentrated under reducedpressure. The residual material was purified by chromatography on silicagel using dichloromethane/methanol 19:1 v/v) as eluent to afford thetitle compound (93 mg, 66%) as a colorless wax.

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.84 (d, 1H), 7.62 (d, 1H), 7.33-7.26(m, 5H), 7.13 (m, 2H), 7.00 (m, 1H), 6.86 (s, 1H), 6.50 (s, 1H), 3.97(s, 2H), 3.78 (s, 3H), 2.37 (s, 3H), 2.30 (s, 3H);

MS ISP (m/e): 386.4 (100) [(M+H)⁺].

EXAMPLE 44[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3,4,5-trifluoro-phenyl)-ethyl]-pyrimidin-2-yl}-amine

The title compound was prepared in analogous manner as described inexample 5b) fromN-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (81mg, 0.30 mmol) and1-dimethylamino-4-methyl-4-(3,4,5-trifluoro-phenyl)-pent-1-en-3-one (98mg, 0.36 mmol) as a light yellow solid (74 mg) in 56% yield.

MS ISP (m/e): 442.2 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.0 (s, 1H), 8.48 (d, 1H), 7.78 (s,1H), 7.86 (d, 1H), 7.78 (s, 1H), 7.44 (m, 2H), 7.27 (dd, 2H), 7.15 (s,1H), 6.87 (d, 1H), 2.16 (s, 3H), 1.68 (s, 6H).

EXAMPLE 45[4-(4-Chloro-phenyl)-5-pyridin-4-yl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-(4-Chloro-phenyl)-3-dimethylamino-2-pyridin-4-yl-propenone

1-(4-Chloro-phenyl)-2-pyridin-4-yl-ethanone (116 mg, 0.5 mmol) wasreacted with tert.-butoxy-bis-(dimethylamino)-methane using in analogousmanner the procedure described in example 28a) to give crude titlecompound (165 mg) as a yellow oil which was used directly in the nextstep. MS ISP (m/e): 287.0 [(M+H)⁺].

b)[4-(4-Chloro-phenyl)-5-pyridin-4-yl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from crude1-(4-chloro-phenyl)-3-dimethylamino-2-pyridin-4-yl-propenone (165 mg,ca. 0.5 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (138mg, 0.37 mmol) using in analogous manner the procedure described inexample 39b). Obtained as yellow solid (9 mg, 5%).

MS ISP (m/e): 469.4 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.58 (d, 1H), 8.49 (s, 1H), 7.85 (s,1H), 7.65 (s, 1H), 7.42 (s, 1H), 7.41 and 7.30 (2 d, 4H), 7.18 (d, 1H),7.12 (s, 1H), 7.11 (d, 2H), 6.89 (s, 1H), 3.86 (s, 3H), 2.31 (s, 3H).

EXAMPLE 46(4-Ethoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A mixture of(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(165 mg, 0.5 mmol) and sodium ethoxide (54 mg, 0.75 mmol) in ethanol (3ml) was heated for 30 min to 160° C. in a microwave oven. The reactionmixture was concentrated under reduced pressure and the residue waspartitioned between ethyl acetate and water. The organic layer waswashed with brine, dried over sodium sulfate and evaporated underreduced pressure. The residue was stirred with diethyl ether for 30 minto yield the title compound as a brown solid (139 mg, 82%).

MS ISP (m/e): 340.1 [(M+H)⁺];

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.77 (s, 1H), 7.62 (s, 1H), 7.15 (d,1H), 7.06 (s, 1H), 7.01 (d, 2H), 6.87 (s, 1H), 6.10 (s, 1H), 4.41 (q,2H), 3.86 (s, 3H), 2.35 (s, 3H), 2.30 (s, 3H), 1.40 (t, 3H).

EXAMPLE 47N-4-(2,2,3,3,4,4,4-Heptafluoro-butyl)-N-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

A mixture of(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(66 mg, 0.20 mmol) and 1H,1H-heptafluorobutylamine (119 mg, 0.60 mmol)in 1-methyl-2-pyrrolidone (2 mL) was heated for 1 h to 200° C. in amicrowave oven. The reaction mixture was poured onto 1 N aqueous sodiumhydroxide solution and the mixture was extracted with diethyl ether. Theorganic layer was washed with water and with brine, dried over sodiumsulfate and evaporated under reduced pressure. The residue was purifiedby column chromatography on silica gel using dichloromethane/methanol(9:1 v/v) as eluent to yield the title compound as a brown solid (15 mg,13%).

MS ISP (m/e): 493.1 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.62 (s, 1H), 7.54 (s, 1H), 7.14 (s,2H), 6.96 (s, 1H), 6.87 (s, 1H), 5.90 (s, 1H), 4.79 (br t, 1H),4.32-4.16 (m, 2H), 3.84 (s, 3H), 2.30 (s, 6H).

EXAMPLE 48(4-Benzyl-pyrimidin-2-yl)-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine (94 mg, 0.49 mmol) and4-benzyl-2-chloro-pyrimidine (100 mg, 0.49 mmol) in analogous manner tothe procedure described in example 1e). Obtained as a pale-yellow solid(50 mg, 29 MS ISP (m/e): 360.3 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.33 (d, 1H), 7.94 (dd, 1H), 7.66 (s,1H), 7.28 (m, 8H), 6.92 (s, 1H), 6.65 (d, 1H), 4.025 (s, 2H), 2.30 (s,3H).

EXAMPLE 49(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(2-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from3-fluoro-4-(2-methyl-imidazol-1-yl)-phenylamine (87 mg, 0.46 mmol) and4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) in analogousmanner to the procedure described in example 1e). Obtained as a lightyellow oil (140 mg, 82%).

MS ISP (m/e): 374.4 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.00 (dd, 1H), 7.30 (m, 5H), 7.18 (m,3H), 7.05 (s, 1H), 6.94 (s, 1H), 3.99 (s, 2H), 2.39 (s, 3H), 2.30 (s,3H).

EXAMPLE 50(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-imidazol-1-yl-phenyl)-amine

The title compound was prepared from3-fluoro-4-imidazol-1-yl-phenylamine (81 mg, 0.46 mmol) and4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) in analogousmanner to the procedure described in example 1e). Obtained as a lightyellow wax (40 mg, 24%).

MS ISP (m/e): 360.4 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.01 (dd, 1H), 7.76 (s, 1H), 7.27 (m,10H), 6.54 (s, 1H), 3.99 (s, 2H), 2.39 (s, 3H).

EXAMPLE 51(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-[1,2,4]triazol-1-yl-phenyl)-amine

The title compound was prepared from3-fluoro-4-[1,2,4]triazol-1-yl-phenylamine (81.4 mg, 0.46 mmol) and4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) in analogousmanner to the procedure described in example 1e). Obtained as a lightyellow wax (98 mg, 60%).

MS ISP (m/e): 361.0 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.57 (d, 1H), 8.11 (s, 1H), 8.11 (dd,1H), 7.69 (dd, 1H), 7.31 (m, 5H), 7.20 (m, 2H), 6.55 (s, 1H), 3.99 (s,2H), 2.39 (s, 3H).

EXAMPLE 52(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-methoxy-4-thiazol-5-yl-phenyl)-amine

a) 5-(2-Methoxy-4-nitro-phenyl)-thiazole

In a microwave vial, a mixture of 2-bromo-5-nitroanisole (300 mg, 1.27mmol), potassium acetate (188 mg, 1.90 mmol) andtetrakis(triphenylphosphine)palladium(0) (74 mg, 0.634 mmol) in 4 mldimethyl acetamide was flushed with argon. Thiazole (459 uL, 6.34 mmol)was added, the tube was sealed, and the mixture was heated for 1 h to160° C. in a microwave oven. The mixture was diluted with ethyl acetateand water, the layers were separated and the aqueous layer wasextraceted with ethyl acetate. The organic phase was dried overmagnesium sulfate and evaporated under reduced pressure. The residualmaterial was subjected to column chromatography on silica gel usingheptane/ethyl acetate (7:3) as eluent to afford the title compound asyellow solid (177 mg, 59%). Mp 125-128° C.

MS ISP (m/e): 237.1 [(M+H)⁺].

¹H NMR (CDCl₃, 400 MHz): δ (ppm)=8.91 (s, 1H), 8.44 (s, 1H), 7.93 (d,1H), 7.87 (d, 1H), 7.81 (d, 1H), 4.08 (s, 3H),%). ¹³C NMR (CDCl₃, 100MHz): δ (ppm)=155.5, 154.7, 148.0, 143.1, 132.0, 128.7, 126.9, 116.42,106.7, 56.3.

b) 3-Methoxy-4-thiazol-5-yl-phenylamine

A suspension of 5-(2-methoxy-4-nitro-phenyl)-thiazole (160 mg, 0.68 mmoland stannous dichloride (655 mg, 3.39 mmol) in ethanol (10 mL) wasstirred at reflux temperature for 75 min. The yellow solution wasevaporated under reduced pressure and the residue was dissolved in ethylacetate. This solution is washed successively with 2N aqueous sodiumhydroxide and with brine, dried over magnesium sulfate and evaporatedunder reduced pressure. The residual material was triturated withdichloromethane, insoluble material was filtered off, and the filtratewas evaporated under reduced pressure to afford the title compound (128mg, 92%) as orange oil.

MS ISP (m/e): 206.9 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.68 (s, 1H), 8.11 (s, 1H), 7.40 (d,1H), 6.31-6.36 (m, 2H), 3.89 (s, b, 5H).

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-methoxy-4-thiazol-5-yl-phenyl)-amine

The title compound was prepared from3-methoxy-4-thiazol-5-yl-phenylamine (118 mg, 0.57 mmol) and4-benzyl-2-chloro-6-methyl-pyrimidine (125 mg, 0.57 mmol) in analogousmanner to the procedure described in example 1e). Obtained as acolorless wax (70 mg, 32%).

MS ISP (m/e): 389.4 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.72 (s, 1H), 8.20 (s, 1H), 7.86 (d,1H), 7.53 (d, 1H), 7.29-7.34 (m, 5H), 7.16 (s, 1H), 7.01 (dd, 1H), 6.49(s, 1H), 3.98 (s, 2H), 3.89 (s, 3H), 2.37 (s, 3H).

EXAMPLE 53(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-[1,3,4]oxadiazol-2-yl-phenyl)-amine

a) Methyl 4-(4-benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoate

The title compound was prepared from methyl 4-amino-2-fluoro-benzoate(480 mg, 2.84 mmol) and 4-benzyl-2-chloro-6-methyl-pyrimidine (620 mg,2.84 mmol) in the same manner as described for example 1e). Obtained aswhite solid (840 mg, 84%). Mp 148-151° C.

MS ISP (m/e): 352.4 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.90 (dd, 1H), 7.85 (d, 1H), 7.31 (m,6H), 7.12 (d, 1H), 6.55 (s, 1H), 3.99 (s, 2H), 3.91 (s, 3H), 2.39 (s,3H).

b) 4-(4-Benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoic AcidHydrazide

A mixture of methyl4-(4-benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoate (420 mg,1.20 mmol) and hydrazine monohydrate (1.4 mL, 28.8 mmol) in ethanol (9mL) was stirred at 90° C. for 6 h. After cooling to 20° C., a whiteprecipitate was formed which was isolated by filtration to afford thetitle compound (345 mg, 82%) as white solid. Mp 191-193° C.

MS ISP (m/e): 352.4 [(M+H)⁺].

¹H NMR (DMSO-d6, 300 MHz): δ (ppm)=10.0 (s, 1H), 9.25 (s broad, 1H),7.88 (d, 1H), 7.48 (d, 2H) 7.33 (m, 3H), 7.25 (m, 2H), 6.75 (s, 1H),4.47 (d, 2H), 3.97 (s, 2H), 2.35 (s, 3H).

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-[1,3,4]oxadiazol-2-yl-phenyl)-amine

A suspension of4-(4-benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoic acidhydrazide (98 mg, 0.28 mmol) in trimethyl orthoformate (2.0 ml, 17.9mmol) was heated in a microwave oven for 2 h to 200° C. followed by 5.5h at 230° C. The mixture was evaporated under reduced pressure and theresidue was purified by column chromatography on silica gel usingdichloromethane/methanol (95:5 v/v) as eluent to afford the titlecompound (60 mg, 60%) as a light yellow solid. Mp 153-15 6° C.

MS ISP (m/e): 362.3 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.48 (s, 1H), 8.06 (dd, 1H), 7.96 (dd,1H), 7.29 (m, 6H), 6.58 (s, 1H), 4.01 (s, 2H), 2.40 (s, 3H).

EXAMPLE 54 Ethyl4-(2-chloro-4-fluoro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

a) 1-(4-Chloro-phenyl)-3-dimethylamino-propenone

Ethyl 3-(2-chloro-4-fluoro-phenyl)-3-oxo-propionate (42 mg, 0.17 mmol)was reacted with tert.-butoxy-bis-(dimethylamino)-methane using inanalogous manner the procedure described in example 28a) to give crudetitle compound (51 mg) as a white solid which was used directly in thenext step. Mp 100-101° C.

b) Ethyl4-(2-chloro-4-fluoro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

The title compound was prepared from crude ethyl2-(2-chloro-4-fluoro-benzoyl)-3-dimethylamino-acrylate (50 mg, 0.17mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (51 mg, 0.14 mmol) using in analogous manner the proceduredescribed in example 28b). Obtained as a yellow solid (14 mg, 21%).

MS ISP (m/e): 482.2/484.2/483.1 (100/39/27)[(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.73 (s, 2H), 7.65 (s, 1H), 7.62 (d,1H), 7.52 (d, 2H), 7.24 (s, 1H), 7.20 (d, 1H), 7.08 (d, 1H), 6.88 (s,1H), 4.19 (q, 2H), 3.82 (s, 3H), 2.30 (s, 3H), 1.15 (s, 3H).

EXAMPLE 554-(4-Chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carbonitrile

The title compound was prepared from crude2-(4-chloro-benzoyl)-3-dimethylamino-acrylonitrile (50 mg, 0.21 mmol)and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate(66 mg, 0.18 mmol) using in analogous manner the procedure described inexample 28b). Obtained as a pale-yellow solid (10 mg, 14%).

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.75 (s, 2H), 8.05 (s, 1H), 7.97 (s,1H), 7.70 (d, 2H), 7.40 (d, 2H), 7.24 (d, 1H), 7.15 (d, 1H), 6.90 (s,1H), 3.86 (s, 3H), 2.31 (s, 3H);

EXAMPLE 56[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrimidin-2-yl]-amine

a) 4-Dimethylamino-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-but-3-en-2-one

1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-propan-2-one (224 mg, 1.6 mmol) wasreacted with tert.-butoxy-bis-(dimethylamino)-methane using in analogousmanner the procedure described in example 28a) to give crude titlecompound (313 mg) as a yellow oil which was used directly in the nextstep.

MS ISP (m/e): 196.1[(M+H)⁺].

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrimidin-2-yl]-amine

The title compound was prepared from crude4-dimethylamino-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-but-3-en-2-one (313mg, 1.6 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (297mg, 0.8 mmol) using in analogous manner the procedure described inexample 39b). Obtained as a pale-yellow solid (142 mg, 47%).

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=9.08 (s, 1H), 7.77 (s, 1H), 7.66 (s,1H), 7.48 (s, 1H), 7.22 (d, 1H), 7.13 (dd, 1H), 6.90 (s, 1H), 3.90 (s,3H), 2.86 (s, 3H), 2.49 (s, 3H), 2.31 (s, 3H); MS ISP (m/e): 378.5[(M+H)⁺].

EXAMPLE 57[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(5-methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-pyrimidin-2-yl}-amine

a) 1-[1-(5-Methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-ethanone

A mixture of 1-(5-methyl-[1,3,4]oxadiazol-2-yl)-propan-2-one (312 mg,2.2 mmol), 1,2-dibromo-ethane (0.25 mL, 2.85 mmol), and potassiumcarbonate (770 mg, 5.6 mmol) in acetone (5 mL) was stirred at 60° C. for16 h. Insoluble material was filtered off and the filtrate was dilutedwith ethyl acetate (30 mL). The solution was washed with water andbrine, dried over sodium sulfate, and evaporated under reduced pressure.The residual material was purified by chromatography on silica gel usingheptane/0-100% ethyl acetate as eluent to afford the title compound (75mg, 20%) as pale-yellow oil.

MS ISP (m/e): 167.3 [(M+H)⁺].

b)3-Dimethylamino-1-[1-(5-methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-propenone

1-[1-(5-Methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-ethanone (75 mg, 0.45mmol) was reacted with tert.-butoxy-bis-(dimethylamino)-methane using inanalogous manner the procedure described in example 28a) to give crudetitle compound (118 mg) as a yellow oil which was used directly in thenext step.

MS ISP (m/e): 222.3 [(M+H)⁺].

c)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(5-methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-pyrimidin-2-yl}-amine

The title compound was prepared from crude3-dimethylamino-1-[1-(5-methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-propenone(118 mg, ca. 0.45 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (149mg, 0.4 mmol) using in analogous manner the procedure described inexample 39b). Obtained as a pale-yellow solid (31 mg, 17%).

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.34 (d, 1H), 7.64 (s, 1H), 7.60 (d,1H), 7.21 (s, 1H), 7.17 (d, 1H), 7.02 (dd, 1H), 6.95 (d, 1H), 6.88 (s,1H), 3.87 (s, 3H), 2.56 (s, 3H), 2.30 (s, 3H), 1.94 (m, 2H), 1.76 (m,2H); MS ISP (m/e): 404.5 [(M+H)⁺].

EXAMPLE 58[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethyl]-pyrimidin-2-yl}-amine

a) 3-Methyl-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one

Methyl iodide (0.375 ml, 6 mmol) was added to a mixture of1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propan-2-one (0.84 g, 6 mmol) andpotassium carbonate (4.15 g, 30 mmol) in acetoniotrile (8 mL), and themixture was stirred at 20° C. for 12 h. Insoluble material was filteredoff and the filtrate was diluted with dichloromethane. The solution waswashed with 1 N hydrochloric acid and with brine, dried over sodiumsulfate, and evaporated under reduced pressure. The residual oil wassubjected to column chromatography on silica gel. Heptane/0-20% ethylacetate eluted successively the title compound3-methyl-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (181 mg, 18%),obtained as colorless oil, Rf 0.4 (SiO₂, ethyl acetate/heptane 1:1), MSISP (m/e): 169.1 [(M+H)⁺];3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (296 mg, 3 2%), obtainedas colorless oil, Rf 0.2 (SiO₂, ethyl acetate/heptane 1:1), MS ISP(m/e): 155.1 [(M+H)⁺]; and3-hydroxy-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (204 mg, 20%),obtained as colorless oil, Rf 0.1 (SiO₂, ethyl acetate/heptane 1:1),

MS ISP (m/e): 171.1 [(M+H)⁺].

b)1-Dimethylamino-4-methyl-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-one

3-Methyl-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (101 mg, 0.6mmol) was reacted with tert.-butoxy-bis-(dimethylamino)-methane using inanalogous manner the procedure described in example 28a) to give crudetitle compound (140 mg) as a yellow oil which was used directly in thenext step.

MS ISP (m/e): 224.4 [(M+H)⁺].

c)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethyl]-pyrimidin-2-yl}-amine

The title compound was prepared from crude1-dimethylamino-4-methyl-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-one(140 mg, 0.6 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (186mg, 0.5 mmol) using in analogous manner the procedure described inexample 39b). Obtained as a pale-yellow solid (31 mg, 13%).

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.42 (d, 1H), 7.64 (s, 1H), 7.48 (br s,1H), 7.15 (d, 1H), 7.02 (dd, 1H), 6.87 (s, 1H), 6.73 (d, 1H), 3.87 (s,3H), 2.41 (s, 3H), 2.30 (s, 3H), 1.85 (s, 6H);

MS ISP (m/e): 406.1 [(M+H)⁺].

As a by-product2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-isobutyramide(20 mg, 9%) was obtained (see example 60)

EXAMPLE 591-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethanol

a)1-Dimethylamino-4-hydroxy-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-one

3-Hydroxy-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (see example58a) (102 mg, 0.6 mmol) was reacted withtert.-butoxy-bis-(dimethylamino)-methane using in analogous manner theprocedure described in example 28a) to give crude title compound (138mg) as a yellow oil which was used directly in the next step.

MS ISP (m/e): 226.3[(M+H)⁺].

b)1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethanol

The title compound was prepared from crude1-dimethylamino-4-methyl-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-one(138 mg, 0.6 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (185mg, 0.5 mmol) using in analogous manner the procedure described inexample 39b). Obtained as a pale-yellow solid (32 mg, 16%);

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.51 (d, 1H), 7.59 (s, 1H), 7.66 (s,1H), 7.46 (s, 1H), 7.19 (d, 1H), 7.05 (d, 1H), 7.03 (dd, 1H), 6.88 (s,1H), 3.88 (s, 3H), 2.40 (s, 3H), 2.30 (s, 3H), 2.03 (s, 3H); MS ISP(m/e): 408.1 [(M+H)⁺].

EXAMPLE 602-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-isobutyramide

The title compound was isolated as a by-product in the preparation ofexample 58 (see example 58c)). Obtained as a pale-yellow solid.

MS ISP (m/e): 367.1 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (d, 1H), 7.70 (s, 1H), 7.64 (s,1H), 7.40 (s, 1H), 7.19 (d, 1H), 7.08 (dd, 1H), 6.89 (d, 1H), 6.88 (s,1H), 6.16 and 5.44 (2 br s, 2H), 3.88 (s, 3H), 2.30 (s, 3H), 1.65 (s,6H).

EXAMPLE 61[4-(4-Chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-(4-Chloro-phenyl)-3-dimethylamino-2-(4-methoxy-benzyl)-propenone

1-(4-Chloro-phenyl)-3-(4-methoxy-phenyl)-propan-1-one (137 mg, 0.5 mmol)was reacted with tert.-butoxy-bis-(dimethylamino)-methane using inanalogous manner the procedure described in example 28a) to give crudetitle compound (172 mg) as a yellow solid which was used directly in thenext step.

MS ISP (m/e): 330.4 [(M+H)⁺].

b)4-(4-Chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from crude1-(4-chloro-phenyl)-3-dimethylamino-2-(4-methoxy-benzyl)-propenone (172mg, 0.5 mmol) andN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (137mg, 0.37 mmol) using in analogous manner the procedure described inexample 39b). Obtained as an off-white solid (38 mg, 20%).

MS ISP (m/e): 512.3 [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.32 (s, 1H), 7.84 (s, 1H), 7.62 (s,1H), 7.49 and 7.41 (2d, 4H), 7.16 (d, 1H), 7.02 (dd, 1H), 6.95 (d, 2H),6.87 (s, 1H), 6.82 (d, 2H), 3.91 (s, 2H), 3.81 (s, 3H), 3.79 (s, 3H),2.29 (s, 3H).

EXAMPLE 62(6-Benzyl-2-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Palladium acetate (2.7 mg, 0.012 mmol) and2-(dicyclohexylphosphino)-biphenyl (8.5 mg, 0.024 mmol) were dissolvedunder an atmosphere of nitrogen under stirring in dioxane (1 mL). After10 min stirring this solution was added to a suspension of3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol),4-benzyl-2,6-dichloropyrimidine (71.7 mg, 0.3 mmol) and potassiumcarbonate (829 mg, 6 mmol) in dioxane (1.7 mL). The reaction was heatedto reflux for 16 h. After cooling to 20° C. the reaction was poured ontowater and the mixture was extracted with ethyl actate. The organic layerwas washed with brine, dried over sodium sulfate, and the solvent wasevaporated under reduced pressure. The residue was purified by columnchromatography on silica gel using dichloromethane/methanol (19:1 v/v)as eluent to yield the title compound (9.0 mg, 24%) as a yellow solid.

MS ISP (m/e): 406.3/408.3 (100/50) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.63 (s, 1H), 7.20-7.33 (m, 5H), 7.18(d, 1H), 7.00 (s, 1H), 6.87 (s, 1H), 6.82 (d, 1H), 6.30 (s, 1H), 3.99(s, 2H), 3.77 (s, 3H), 2.29 (s, 3H).

EXAMPLE 63[6-(4-Chloro-phenoxy)-pyrimidin-4-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-Chloro-6-(4-chloro-phenoxy)-pyrimidine

4,6-Dichloropyrimidine (149 mg, 1 mmol), 4-chlorophenol (135 mg, 1.05mmol), potassium carbonate (166 mg, 1.2 mmol) and sodium iodide (7.5 mg,0.05 mmol) were stirred in acetonitrile (3 mL) at 20° C. under anatmosphere of nitrogen for 16 h. The reaction was poured onto 1 Naqueous sodium hydroxide solution and the mixture was extracted withdiethyl ether. The organic layer was washed with brine, dried oversodium sulfate, and the solvent was evaporated under reduced pressure.The title compound (224 mg, 93%) was obtained as a pale-yellow solid.

MS EI (m/e): 240.1/242.0 (100/55) [M⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.06 (s, 1H), 7.53 (d, 2H), 7.45 (s,1H), 7.31 (d, 2H).

b)[6-(4-Chloro-phenoxy)-pyrimidin-4-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from4-chloro-6-(4-chloro-phenoxy)-pyrimidine and3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine in analogous manner asdescribed in example 62 by heating the reaction mixture in a microwaveoven at 200° C. for 2.5 h. Obtained as a yellow solid in 18% yield.

MS ISP (m/e): 408.3/410.2 (100/34) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.79 (s, 1H), 8.40 (s, 1H), 7.68 (s,1H), 7.51-7.54 (m, 3H), 7.25-7.32 (m, 3H), 7.05 (s, 1H), 6.19 (s, 1H),3.80 (s, 3H), 2.14 (s, 3H).

EXAMPLE 64{6-[1-(4-Chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) Methyl 3-[1-(4-chlorophenyl)cyclobutyl]-3-oxopropionate

Sodium hydride (1.86 g of a 60% dispersion in mineral oil, 46.5 mmol)was added to a solution of 1-[1-(4-chlorophenyl)cyclobutyl]ethanone(4.18 g, 20.0 mmol) and of dimethyl carbonate (8.4 mL, 99.6 mmol) in ofdioxane (20 mL). After the reaction mixture had been refluxed for 4 h,it was chilled in an ice-water bath and treated drop wise with 1 Maqueous sodium hydrogen sulfate solution (50 mL). The mixture containingnow a thick precipitate was then partitioned between diethyl ether andwater. The organic phase was washed with sat. sodium hydrogen carbonatesolution and with brine, dried over magnesium sulfate, and evaporatedunder reduced pressure. The residual material was purified bychromatography on silica gel using heptane/0-10% ethyl acetate as eluentto afford the title compound (4.45 g, 79%) as pale-yellow oil.

b) 6-[1-(4-Chlorophenyl)cyclobutyl]-2-methylpyrimidin-4-ol

To a solution of acetamidine hydrochloride (0.617 g, 6.53 mmol) inmethanol (10 mL) was added potassium tert.-butoxide (0.80 g, 6.54 mmol)followed by methyl 3-[1-(4-chlorophenyl)cyclobutyl]-3-oxopropionate(1.34 g, 5.02 mmol). The mixture was stirred at 20° C. for 16 h, thenrefluxed for 2 h. The reaction mixture was cooled, diluted with water,made alkaline by the addition of 10 mL of 10% aqueous sodium hydroxidesolution, and then washed with diethyl ether. The aqueous phase wasacidified with concentrated hydrochloric acid, and then extracted withdiethyl ether. This ether extract was washed with brine, dried overmagnesium sulfate, and concentrated under reduced pressure to give thetitle compound (1.04 g, 75%) as a solid foam. Mp 130-140° C.

MS ISP (m/e): 275 [(M+H)⁺].

c) 4-Chloro-6-[1-(4-chlorophenyl)cyclobutyl]-2-methylpyrimidine

To 6-[1-(4-chlorophenyl)cyclobutyl]-2-methylpyrimidin-4-ol (1.00 g, 3.65mmol) was added phosphorous oxychloride (10 mL) and the mixture wasrefluxed for 1.5 h. After cooling to 20° C., the reaction mixture waspoured into ice/water (55 mL). After the addition of dichloromethane,the mixture was neutralized with 32% aqueous sodium hydroxide solution.The layers were separated and the organic layer was washed with 0.1 Nsodium hydroxide solution and with water, dried over magnesium sulfate,and evaporated under reduced pressure. The residual material waspurified by chromatography on silica gel using dichloromethane/methanol(95:5 v/v) as eluent to afford the title compound (0.91 g, 85%) as anoff-white solid. Mp 96-98° C.

MS ISP (m/e): 293 [(M+H)⁺].

d){6-[1-(4-Chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 62 from4-chloro-6-[1-(4-chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidine and3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine. Obtained as apale-yellow solid in 81% yield after column chromatography of the crudeproduct on silica gel using dichloromethane/methanol (19:1 v/v) aseluent.

MS ISP (m/e): 460.3/462.2 (100/44) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.57 (s, 1H), 7.75 (s, 1H), 7.66 (s,1H), 7.40 (d, 2H), 7.35 (d, 2H), 7.24 (s, 2H), 6.36 (s, 1H), 3.79 (s,3H), 2.78-2.99 (m, 2H), 2.50-2.62 (m, 2H), 2.14 (s, 3H), 1.79-1.99 (m,2H).

EXAMPLE 65(2-Benzyl-6-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 62 from 2-benzyl-4,6-dichloro-pyrimidine and3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine. Obtained as yellowsolid in 48% yield after column chromatography of the crude product onsilica gel using dichloromethane/methanol (98:2 and then 95:5 v/v) aseluent.

MS ISP (m/e): 406.3/408.4 (100/26) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.01 (s, 1H), 7.68 (s, 1H), 7.64 (s,1H), 7.32 (d, 4H), 7.18-7.28 (m, 2H), 7.17 (d, 1H), 7.05 (s, 1H), 6.69(s, 1H), 4.06 (s, 2H), 3.72 (s, 3H), 2.14 (s, 3H).

EXAMPLE 66 Methyl2-Chloro-6-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-isonicotinate

The title compound was prepared in analogous manner as described inexample 1e) from methyl-2,6-dichloroisonicotinate (64 mg, 0.3 mmol) and3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol). Thereaction mixture was heated for 16 h to reflux. Obtained as a yellowsolid (40 mg, 36%) after column chromatography of the crude product onsilica gel using dichloromethane/methanol (19:1 v/v) as eluent.

MS ISP (m/e): 373.2/375.2 (100/42) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.94 (s, 1H), 7.69 (s, 1H), 7.64 (s,1H), 7.36 (s, 1H), 7.31 (d, 1H), 7.28 (d, 1H), 7.16 (s, 1H), 7.06 (s,1H), 3.90 (s, 3H), 3.82 (s, 3H), 2.15 (s, 3H).

EXAMPLE 67[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(6-methyl-4-trifluoromethyl-pyridin-2-yl)-amine

The title compound was prepared in analogous manner as described inexample 1e) from 2-chlor-6-methyl-4-(trifluormethyl)pyridine (59 mg, 0.3mmol) and 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3mmol). The reaction was heated for 16 h to reflux. Obtained as apale-yellow solid (75 mg 69%) after column chromatography of the crudereaction product on silica gel using dichloromethane/methanol (19:1 v/v)as eluent.

MS ISP (m/e): 363.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.63 (s, 1H), 7.88 (s, 1H), 7.66 (s,1H), 7.25 (s, 2H), 7.04 (s, 1H), 6.96 (s, 1H), 6.93 (s, 1H), 3.82 (s,3H), 2.14 (s, 3H).

EXAMPLE 68{2-Chloro-6-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyridin-4-yl}-methanol

The title compound was prepared in analogous manner as described inexample 1e) from 2,6-dichlorpyridin-4-methanol (53 mg, 0.3 mmol) and3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol). Thereaction was heated for 16 h to reflux. Obtained as a pale-yellow solid(25 mg, 24%) after column chromatography on silica gel usingdichloromethane/methanol (9:1 v/v) as eluent.

MS ISP (m/e): 345.2/347.1 (100/39) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.57 (s, 1H), 7.66 (s, 1H), 7.64 (s,1H), 7.25 (s, 2H), 7.03 (s, 1H), 6.83 (s, 1H), 6.76 (s, 1H), 5.48 (t,1H), 4.47 (d, 2H), 3.80 (s, 3H), 2.14 (s, 3H).

EXAMPLE 69[6-(4-Chloro-phenoxy)-pyridin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 2-Chloro-6-(4-chloro-phenoxy)-pyrimidine

The title compound was prepared in analogous manner as described inexample 10a) from 4,6-dichlorpyrimidin (149 mg, 1.0 mmol) and4-chlorphenol (129 mg, 1.05 mmol). Obtained as a pale-yellow solid (224mg, 93%).

MS EI (m/e): 240.1/242.0 (100/55) [M⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.66 (s, 1H), 7.53 (d, 2H), 7.45 (s,1H), 7.31 (d, 2H).

b)[6-(4-Chloro-phenoxy)-pyridin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogous manner as described inexample 1e) from 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61mg, 0.3 mmol) and 4-chloro-6-(4-chloro-phenoxy)-pyrimidine (90 mg, 0.3mmol). The reaction was heated in a microwave oven to 200° C. for 1 h.Obtained as a yellow solid (48 mg, 39%) after chromatography of thecrude reaction product on silica gel using dichloromethane/methanol (9:1v/v) as eluent.

MS ISP (m/e): 407.2/409.3 (100/31) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.37 (s, 1H), 7.67 (m, 2H), 7.58 (s,1H), 7.48 (d, 2H), 7.33 (s, 1H), 7.17 (d, 2H), 6.97 (s, 2H), 6.61 (d,1H), 6.44 (d, 1H), 3.42 (s, 3H), 2.13 (s, 3H).

EXAMPLE 70N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-phenyl-pyridine-2,6-diamine

a) (6-Chloro-pyridin-2-yl)-phenyl-amine

A mixture of palladium(II)acetate (303 mg; 1.35 mmol) andrac-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (842 mg; 1.35 mmol) intoluene (10 mL) was stirred under argon for 10 min at 20° C., and thenadded to a mixture of 2,6-dichloroaniline (2.0 g; 13.5 mmol), aniline(1.51 g; 16.2 mmol), and potassium carbonate (37.4 g; 270 mmol) in 140ml toluene. The reaction mixture was heated to reflux for 16 h. Theresulting suspension was cooled, filtered, and the filtrate wasconcentrated under reduced pressure. Column chromatography of theresidue on silica gel using heptane/ethyl acetate (4:1 v/v) as eluentgave the title compound (1.5 g, 54%) as an orange oil.

MS ISP (m/e): 205.1 (100)/207.1 (30) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.50-7.25 (m, 5H), 7.13 (t, 1H), 6.74(dd, 2H), 6.58 (s broad, 1H).

b)N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-phenyl-pyridine-2,6-diamine

A mixture of palladium(II)acetate (4 mg; 0.02 mmol) and(2-biphenyl)dicyclohexylphosphine (14 mg; 0.04 mmol) in dioxane (5 mL)was stirred under argon for 10 min at 20° C.(6-Chloro-pyridin-2-yl)-phenyl-amine (100 mg; 0.5 mmol),3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (99 mg; 0.5 mmol), andpotassium carbonate (1.35 g; 10 mmol) were added and the mixture wasrefluxed under argon for 3 h. After quenching the reaction by additionof water, the mixture was extracted with ethyl acetate. The organicphase was dried over sodium sulfate, concentrated under reducedpressure. The crude product was purified by column chromatography onsilica gel using dichloromethane/0-20% methanol as eluent to give thetitle compound (42 mg, 23%) as a light yellow solid.

MS ISP (m/e): 372.2 (100) [(M+H)⁺].

NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.06 (br s, 1H), 8.85 (br s, 1H), 7.65(d, 1H), 7.55 (d, 2H), 7.47 (d, 1H), 7.41 (t, 1H), 7.23 (t, 3H), 7.14(d, 1H), 7.02 (s, 1H), 6.87 (t, 1H), 6.27 (dd, 2H), 3.56 (s, 3H), 2.14(s, 3H).

EXAMPLE 71(5-Benzyl-4H-[1,2,4]triazol-3-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 1-(4-Isothiocyanato-2-methoxy-phenyl)-4-methyl-1H-imidazole

A solution of 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (203 mg,1 mmol) and of 1,1′-thiocarbonyldi-2(1H)-pyridone (263 mg, 1.1 mmol) indichloromethane (10 mL) was stirred at 20° C. for 16 h to yield anorange solution. The solution was concentrated under reduced pressure to¼ Of its volume and subjected to column chromatography on silica gelusing dichloromethane/methanol (95:5 v/v) as eluent to yield the titlecompound (230 mg, 94%) as a yellow oil which solidified on standing.

MS ISP (m/e): 246.3 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.67 (s, 1H), 7.21 (d, 1H), 6.91-6.86(m, 3H), 3.86 (s, 3H), 2.29 (s, 3H).

b) [3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea

1-(4-Isothiocyanato-2-methoxy-phenyl)-4-methyl-1H-imidazole (227 mg,0.93 mmol) was dissolved in tetrahydrofuran (2.3 mL). At 0° C. understirring ammonia gas was bubbled through the solution for 5 min. A solidprecipitated. The suspension was stirred at 20° C. for 16 h. The solventwas evaporated under reduced pressure and the residue was stirred withdiethyl ether for 30 min. The solid was filtered off and dried to yieldthe title compound (170 mg, 70%) as a pale-yellow solid.

MS ISP (m/e): 263.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.84 (s, 1H), 7.90-7.20 (br s, 2H),7.71 (s, 1H), 7.46 (s, 1H), 7.28 (d, 1H), 7.07 (s, 1H), 7.03 (d, 1H),3.79 (s, 3H), 2.15 (s, 3H).

c)(5-Benzyl-4H-[1,2,4]triazol-3-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A solution of [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea(400 mg, 1.52 mmol) in acetone (25 ml) was treated with iodomethane(0.14 ml, 2.29 mmol) and stirred at 20° C. for 16 h. The reactionmixture was concentrated and the crude S-methyl-isothiourea redissolvedin ethanol (25 ml). Phenylacetic acid hydrazide (252 mg, 1.52 mmol) wasadded and the mixture was refluxed for 16 h under argon. After coolingto 20° C., 2 N sodium hydroxide solution (5 ml) was added and themixture was refluxed for 2 h. After cooling to 20° C., the mixture wasbrought to pH 7 by careful addition of 1 N aqueous hydrochloric acid andthen extracted with ethyl acetate. The organic phase was dried oversodium sulfate and evaporation under reduced pressure to afford a stickysemisolid which was triturared in diethyl ether (3 mL). Filtrationyielded the title compound (146 mg, 27%) as greyish solid.

MS ISP (m/e): 361.5 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=13.5 (br s, 1H), 9.31 (br s, 1H),7.59 (s, 1H), 7.50 (s, 1H), 7.40-7.20 (m, 5H), 7.12 (qa, 2H), 6.97 (s,1H), 4.00 (s, 2H), 3.74 (s, 3H), 2.13 (s, 3H).

EXAMPLE 72[5-(4-Chloro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogy to example 71c) starting with[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (150 mg, 0.57mmol) and (4-chloro-phenyl)-acetic acid hydrazide (116 mg, 0.57 mmol).Obtained as a brownish solid (36 mg, 16%) after chromatography of thecrude reaction product on amino-modified silica gel (Merck HPTLC SilicaGel 60 NH2F254S) using ethyl acetate as eluent.

MS ISN (m/e): 393.3 (100) [(M−H)⁻].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=13.2 (very br s, 1H), 9.50 (br s,1H), 7.59 (s, 1H), 7.50 (s, 1H), 7.40-7.30 (qa, 4H), 7.20-7.10 (m, 2H),6.97 (s, 1H), 3.99 (s, 2H), 3.73 (s, 3H), 2.13 (s, 3H).

EXAMPLE 73[5-(4-Fluoro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogy to example 71c) starting with[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (200 mg, 0.76mmol) and (4-fluoro-phenyl)-acetic acid hydrazide (141 mg, 0.76 mmol).Obtained as a greyish solid (21 mg, 7%).

MS ISP (m/e): 379.3 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=13.1 (br s, 1H), 9.32 (br s, 1H),7.59 (s, 1H), 7.49 (s, 1H), 7.40-7.30 (m, 2H), 7.20-7.10 (m, 3H), 6.98(s, 1H), 4.00 (s, 2H), 3.74 (s, 3H), 2.13 (s, 3H).

EXAMPLE 74[5-(4-Fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared in analogy to example 71c) starting with[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (250 mg, 0.95mmol) and 4-fluoro-benzhydrazide (162 mg, 0.95 mmol). Obtained as abrownish solid (41 mg, 12%).

MS ISP (m/e): 365.1 (100) [(M+H)⁺].

¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=13.85 (br s, 1H), 9.56 (br s, 1H),8.01 (t, 2H), 7.63 (s, 2H), 7.50-7.25 (m, 2H), 7.19 (br s, 2H), 7.01 (s,1H), 3.81 (s, 3H), 2.14 (s, 3H).

EXAMPLE 75[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxy-6-methyl-pyrimidin-2-yl)-amine

A mixture of(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(99 mg, 0.3 mmol) and sodium methoxide (25 mg, 0.45 mmol) in methanol (3mL) was heated for 30 min to 160° C. in a microwave oven. The reactionmixture was concentrated under reduced pressure and the residue waspartitioned between ethyl acetate and water. The aqueous layer wasextracted twice with ethyl acetate. The combined organic layers werewashed with brine, dried over sodium sulfate and evaporated underreduced pressure. The residue was purified by reversed preparative HPLCusing acetonitril/water (0.1% formic acid) to yield the title compoundas a yellow solid (30 mg, 31%). MS ISP (m/e): 326.2 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.80 (s, 1H), 7.62 (s, 1H), 7.15 (d,1H), 7.11 (s, 1H), 7.02 (d, 1H), 6.87 (s, 1H), 6.12 (s, 1H), 3.97 (s,3H), 3.86 (s, 3H), 2.35 (s, 3H), 2.30 (s, 3H).

EXAMPLE 76(4-Isopropoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Sodium (10 mg, 0.45 mmol) was dissolved under heating and stirring underan atmosphere of nitrogen in isopropanol (1 mL).(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(99 mg, 0.3 mmol) was added and the suspension was heated to reflux overnight. The solvent was evaporated under reduced pressure and the residuewas taken up in water and extracted twice with diethyl ether. Thecombined organic layers were washed with brine, dried over sodiumsulfate, filtered and evaporated under reduced pressure to dryness. Theresidue was purified by column chromatography on silica gel usingdichloromethane/methanol (19:1 v/v) as eluent. The fraction containingthe product was purified by reversed preparative HPLC usingacetonitril/water (0.1% formic acid) to yield the title compound as anoff-white solid (25 mg, 24%). MS ISP (m/e): 354.2 (100) [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=7.73 (s, 1H), 7.63 (s, 1H), 7.18 (d, 1H), 7.04(s, 1H), 7.03 (d, 1H), 6.87 (s, 1H), 6.06 (s, 1H), 5.36 (sept, 1H), 3.86(s, 3H), 2.33 (s, 3H), 2.30 (s, 3H), 1.38 (s, 3H), 1.36 (s, 3H).

EXAMPLE 77[4-(2-Methoxy-ethoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Sodium (10 mg, 0.45 mmol) was dissolved under an atmosphere of nitrogenin 2-methoxyethanol (0.95 mL).(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(99 mg, 0.3 mmol) was added and the suspension was heated to 100° C. for2 hours. The solvent was evaporated under reduced pressure and theresidue was taken up in water and extracted twice with diethyl ether.The combined organic layers were washed with brine, dried over sodiumsulfate, filtered and evaporated under reduced pressure to dryness. Theresidue was purified by column chromatography on silica gel usingdichloromethane/methanol (19:1 v/v) as eluent to yield the titlecompound as a yellow solid (41 mg, 37%). MS ISP (m/e): 370.2 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.74 (s, 1H), 7.63 (s, 1H),7.18 (d, 1H), 7.05 (s, 1H), 7.03 (d, 1H), 6.87 (s, 1H), 6.18 (s, 1H),4.51 (dd, 2H), 3.86 (s, 3H), 3.73 (dd, 2H), 3.45 (s, 3H), 2.35 (s, 3H),2.30 (s, 3H).

EXAMPLE 78[4-(2-Dimethylamino-ethoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Sodium (10 mg, 0.45 mmol) was dissolved under an atmosphere of nitrogenin 2-dimethylaminoethanol (0.92 mL).(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(99 mg, 0.3 mmol) was added and the suspension was heated to 100° C. for2 hours. The solvent was evaporated under reduced pressure and theresidue was taken up in water and extracted twice with diethyl ether.The combined organic layers were washed with brine, dried over sodiumsulfate, filtered and evaporated under reduced pressure to dryness. Theresidue was purified by column chromatography on silica gel usingdichloromethane/methanol/saturated aqueous ammonia solution (19:1:0.2v/v/v) as eluent to yield the title compound as a brown viscous oil (37mg, 33%). MS ISP (m/e): 383.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.74 (s, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.07 (s, 1H), 7.05 (d,1H), 6.87 (s, 1H), 6.16 (s, 1H), 4.45 (t, 2H), 3.86 (s, 3H), 2.71 (t,2H), 2.36 (s, 3H), 2.34 (s, 6H), 2.30 (s, 3H).

EXAMPLE 79[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(tetrahydro-pyran-4-yloxy)-pyrimidin-2-yl]-amine

Sodium (10 mg, 0.45 mmol) was dissolved under stirring and heating (100°C. for 3 hours) under an atmosphere of nitrogen intetrahydro-4H-pyran-4-ol (0.99 mL).(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(99 mg, 0.3 mmol) was added and the suspension was heated to 100° C. for2 hours. The solvent was evaporated under reduced pressure and theresidue was taken up in water and extracted twice with diethyl ether.The combined organic layers were washed with brine, dried over sodiumsulfate, filtered and evaporated under reduced pressure to dryness. Theresidue was purified by reversed preparative HPLC usingacetonitril/water (0.1% formic acid) to yield the title compound as awhite solid (13 mg, 11%). MS ISP (m/e): 396.2 (100) [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=7.65 (s, 1H), 7.62 (s, 1H), 7.17 (d, 1H), 7.15(s, 1H), 7.13 (d, 1H), 6.87 (s, 1H), 6.12 (s, 1H), 5.30 (m, 1H), 3.98(m, 2H), 3.86 (s, 3H), 3.62 (m, 2H), 2.36 (s, 3H), 2.31 (s, 3H), 2.04(m, 2H), 1.84 (m, 2H).

EXAMPLE 80(4-Cyclopentyloxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 2-Chloro-4-cyclopentyloxy-6-methyl-pyrimidine and4-chloro-2-cyclopentyloxy-6-methyl-pyrimidine

To a solution of cycpopentanol (86 mg, 1.0 mmol) in tetrahydrofurane (6mL) was added at under an atmosphere of nitrogen potassiumtert.-butylate (126 mg, 1.1 mmol). 2,4-Dichloro-6-methylpyrimidine (166mg, 1.0 mmol) was added to this solution and the reaction was stirred atfor 3 hours. The solvent was evaporated under reduced pressure and theresidue was taken up in water and extracted twice with diethyl ether.The combined organic layers were washed with brine, dried over sodiumsulfate, filtered and evaporated under reduced pressure to dryness. Theresidue was purified by column chromatography on silica gel usingheptane/ethyl acetate (9:1 v/v) as eluent to yield the title compound asa colorless oil as a 1:1 mixture of regioisomers (116 mg, 55%). MS ISP(m/e): 213.1/215.5 (14/3) [(M+H)⁺], 145.0/147.0 (100/41)[(M-cyclopentene+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=6.81 (s, 1H),6.42 (s, 1H), 5.45 (m, 2H), 2.42 (s, 3H), 2.40 (s, 3H), 1.58-2.04 (m,16H).

b)(4-Cyclopentyloxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Palladium acetate (7.1 mg, 0.03 mmol) and2-(dicyclohexylphosphino)biphenyl (23.1 mg, 0.64 mmol) were dissolved indioxane (3.6 mL) and stirred for 10 minutes at. Sodium tert.-butylate(59 mg, 0.6 mmol), 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (81mg, 0.4 mmol) and 1:1 mixture of2-chloro-4-cyclopentyloxy-6-methyl-pyrimidine and4-chloro-2-cyclopentyloxy-6-methyl-pyrimidine (94 mg, 0.44 mmol) wereadded and the reaction was heated to 200° C. for 30 minutes in amicrowave oven. The solvent was evaporated under reduced pressure andthe residue was taken up in water and extracted twice with ethylacetate. The combined organic layers were washed with brine, dried oversodium sulfate, filtered and evaporated under reduced pressure todryness. The residue was purified by column chromatography on silica gelusing methylenechloride/methanol (19:1 v/v) as eluent to yield the titlecompound as a white solid (56 mg, 37%). MS ISP (m/e): 380.1 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.70 (s, 1H), 7.62 (s, 1H),7.15 (d, 1H), 7.07 (d, 1H), 7.05 (s, 1H), 6.87 (s, 1H), 6.06 (s, 1H),5.30 (m, 1H), 3.85 (s, 3H), 2.33 (s, 3H), 2.30 (s, 3H), 1.75-2.00 (m,6H), 1.60-1.68 (m, 2H).

EXAMPLE 81[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

2-Chloro-4-(4-fluoro-phenoxy)-6-methyl-pyrimidine

4-Fluorophenol (103 mg, 0.92 mmol) and potassium-tert-butylate (113 mg,1.0 mmol) were dissolved in 7 mL of tetrahydrofurane.2,4-dichloro-6-methylpyrimidine (150 mg, 0.92 mmol) was added and themixture stirred at 20° C. overnight. Water was added and the mixtureextracted with diethyl ether. Chromatography of the crude reactionproduct on silica gel using a heptane/ethyl acetate as an eluent gavethe title compound (150 mg, 68%) as a slightly yellow solid. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=7.50-7.40 (m, 2H), 7.28 (t, 1H), 7.14 (d, 2H),6.57 (s, 1H), 2.47 (s, 3H).

b)[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Palladium acetate (7 mg, 0.03 mmol) and2-(dicyclohexylphosphino)biphenyl (22 mg, 0.06 mmol) were dissolved in2.5 mL of dioxane and stirred at 20° C. under argon for 10 minutes.Sodium tert-butylate (57 mg, 0.59 mmol) was added, followed by3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (80 mg, 0.39 mmol) and2-chloro-4-(4-fluoro-phenoxy)-6-methyl-pyrimidine (115 mg, 0.48 mmol).The resulting mixture was heated in the microwave oven for 20 minutes at200° C. Dichloromethane was added, insoluble material filtered off andthe resulting solution purified by chromatography on silica gel usingethyl acetate as a solvent. The title compound was isolated as a yellowsolid (50 mg, 31%). MS ISP (m/e): 406.3 (100) [(M+H)⁺]. ¹H NMR (CDCl₃,300 MHz): δ (ppm)=7.58 (d, 1H), 7.46 (d, 1H), 7.17 (s, 1H), 7.15-7.05(m, 4H), 7.04 (d, 1H), 6.91 (dxd, 1H), 6.80 (s, 1H), 6.23 (s, 1H), 3.62(s, 1H), 2.40 (s, 3H), 2.28 (s, 3H).

EXAMPLE 82[4-(4-tert-Butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-(4-tert-Butyl-phenoxy)-2-chloro-6-methyl-pyrimidine

Prepared in analogy to example 81a) from 4-t-butylphenol and2,4-dichloro-6-methylpyrimidine in a yield of 51%. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=7.44 (d, 2H), 7.07 (d, 2H), 6.54 (s, 1H), 2.45 (s, 3H),1.35 (s, 9H).

b)[4-(4-tert-Butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and4-(4-tert-butyl-phenoxy)-2-chloro-6-methyl-pyrimidine in a yield of 39%.MS ISP (m/e): 444.3 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.58 d, 1H), 7.55 (d, 1H, 7.42 (d, 2H), 7.18 (s, 1H), 7.08 (d,2H), 7.03 (d, 1H), 6.91 (dxd, 1H), 6.82 (s, 1H), 6.21 (s, 1H), 3.59 (s,3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.35 (s, 9H).

EXAMPLE 83[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine

a) 2-Chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine

Prepared in analogy to example 81a) from 4-trifluoromethylphenol and2,4-dichloro-6-methylpyrimidine in a yield of 56%. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=7.70 (d, 2H), 7.28 (d, 2H), 6.70 (s, 1H), 2.52 (s, 3H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine in a yieldof 29%. MS ISP (m/e): 456.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.70 (d, 2H), 7.58 (d, 1H), 7.46 (s broad, 1H), 7.30 (d, 2H), 7.05(s broad, 1H), 7.03 (d, 1H), 7.37 (dxd, 1H), 6.82 (s, 1H), 6.32 (s, 1H),3.55 (s, 3H), 2.43 (s, 3H), 2.28 (s, 3H).

EXAMPLE 84[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidin-2-yl]-amine

a) 2-Chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine

Prepared in analogy to example 81a) from 4-trifluoromethoxyphenol and2,4-dichloro-6-methylpyrimidine in a yield of 60%. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=7.28 (d, 2H), 7.18 (d, 2H), 6.65 (s, 1H), 2.50 (s, 3H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidin-2-yl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine in a yieldof 13%. MS ISP (m/e): 472.1 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.44 (s, 1H), 7.35-7.15 (m, 5H), 7.01 (s, 2H), 6.86 (s, 1H), 6.30(s, 1H), 3.63 (s, 3H), 2.43 (s, 3H), 2.39 (s, 3H).

EXAMPLE 85(4,6-Dimethoxy-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4,6-dimethoxypyrimidine, using potassium carbonate as a base.The title compound was isolated in a yield of 52%. MS ISP (m/e): 342.1(100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.70-7.55 (m broad,2H), 7.35-7.20 (m broad, 3H), 7.04 (s broad, 1H), 3.92 (s broad, 6H),3.81 (s broad, 3H), 2.14 (s broad, 3H).

EXAMPLE 86[4-(4-Pentafluorothio-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 2-Chloro-4-methyl-6-(4-pentafluorothio-phenoxy)-pyrimidine

Prepared in analogy to example 81a) from 4-pentafluorothiophenol and2,4-dichloro-6-methylpyrimidine in a yield of 55%. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=7.83 (d, 2H), 7.26 (d, 2H), 6.73 (s, 1H), 2.53 (s, 3H).

b)[4-(4-Pentafluorothio-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-methyl-6-(4-pentafluorothio-phenoxy)-pyrimidine in a yield of23%. MS ISP (m/e): 514.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.82 (d, 2H), 7.58 (d, 1H), 7.40 (s, 1H), 7.30-7.20 (m, 2H), 7.06(s, 1H), 7.03 (s, 1H), 6.87 (dxd, 1H), 6.83 (s, 1H), 6.33 (s, 1H), 3.57(s, 3H), 2.44 (s, 3H), 2.29 (s, 3H).

EXAMPLE 87[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(oxetan-3-yloxy)-pyrimidin-2-yl]-amine

a) 2-Chloro-4-methyl-6-(oxetan-3-yloxy)-pyrimidine

A solution of oxetan-3-ol (173 mg, 2.34 mmol) in 5 mL oftetrahydrofurane was treated with potassium tert-butylate (288 mg, 2.57mmol) and stirred for 10 minutes at 20° C.2,4-Dichloro-6-methylpyrimidine (381 mg, 2.34 mmol) was added and theresulting mixture stirred for 2 hours at 20° C. Addition of water andextraction with ethyl acetate, followed by chromatography on silica gelusing heptane/ethyl acetate 7:3 v/v as a solvent gave the title compoundas a yellowish foam (206 mg, 44%). MS ISP (m/e): 201.2 (33) [(M+H)⁺].

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(oxetan-3-yloxy)-pyrimidin-2-yl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-chloro-4-methyl-6-(oxetan-3-yloxy)-pyrimidine, using potassiumcarbonate as a base. The title compound was isolated in a yield of 27%.MS ISP (m/e): 368.1 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=9.62 (s broad, 1H), 7.67 (d, 2H), 7.41 (dxd, 1H), 7.26 (d, 1H),7.04 (s, 1H), 6.28 (s, 1H), 5.65 (m, 1H), 4.90 (t, 2H), 4.58 (m, 2H),3.81 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H).

EXAMPLE 882-{6-Ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

a) Ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate

A mixture of methyl 2,4-dichloropyrimidine-6-carboxylate (2.07 g, 10.0mmol) and potassium tert.-butoxide (1.12 g, 10.0 mmol) in ethanol (50mL) was stirred for 4 h at 60° C. The mixture was cooled to, insolublematerial was removed by filtration, and the filtrate was evaporatedunder reduced pressure. The oily residue was partitioned between ethylacetate and brine, and the organic layer was dried over sodium sulfateand evaporated under reduced pressure to give crude title compound (0.98g, 43%) as colorless oil. MS ISP (m/e): 231.1 [(M+H)⁺]

b) 2-(2-Chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol

To a solution of ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate (460mg, 2.0 mmol) in tetrahydrofurane (5 mL) was added at 0° C. over 2 min a3 M solution of methyl-magnesiumchloride in tetrahydrofurane (1.67 mL,5.0 mmol). The reaction mixture was stirred at 0° C. for 15 min followedby 1.5 h at. The mixture was poured on saturated sodium carbonatesolution (10 mL) and the product was extracted with ethyl acetate (40mL). The organic layer was washed with brine (20 mL), dried over sodiumsulfate and evaporated under reduced pressure. The residual material waspurified by chromatography on silica gel using heptane/0-15% ethylacetate as eluent to afford the title compound (223 mg, 53%) ascolorless oil. MS ISP (m/e): 217.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=6.72 (s, 1H), 4.52 (q, 2H), 3.35 (s, 1H), 1.57 (s, 6H), 1.43 (t,3H).

c)2-{6-Ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

A solution of 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (102 mg,0.5 mmol), 2-(2-chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol (108 mg, 0.5mmol) and 1 N aqueous hydrochloric acid (0.025 mL) in ethanol (0.8 mL)was heated in a sealed tube in a microwave oven to 170° C. for 45 min.The mixture was cooled, diluted with ethyl acetate (50 mL), and thenwashed with water (20 mL) and brine (20 mL). The organic layer was driedover sodium sulfate and evaporated under reduced pressure. The residualmaterial was purified by chromatography on silica gel usingdichloromethane/0-10% ethanol as eluent to give the title compound (20mg, 10%) as yellow foam. MS ISP (m/e): 384.3 [(M+H)⁺].)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=8.20, 7.78, 7.75 and 7.63 (4 d, 4×2H), 7.31(s, 2H), 7.16 (s, 1H), 3.93 (s, 1H), 2.53 (s, 3H), 1.61 (s, 6H).

EXAMPLE 89N4-Cyclohexyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

A solution of(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(66 mg, 0.2 mmol) and cyclohexylamine (60 mg, 0.6 mmol) inN-methylpyrroldione (2 mL) was heated for 30 min to 200° C. in amicrowave oven. Additional cyclohexylamine (60 mg, 0.6 mmol) was addedand the reaction was heated for 30 min to 200° C. in a microwave oven.The reaction mixture was poured onto water and the precipitate wasfiltered off, washed with water, dissolved in 1N aqueous sodiumhydroxide solution and extracted twice with diethyl ether. The combinedorganic layers were washed with water, once with brine, dried oversodium sulfate, filtered and the solvent was evaporated under reducedpressure to yield the title compound as a light brown solid (64 mg,82%). MS ISP (m/e): 393.4 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.60 (br s, 2H), 7.13 (s, 2H), 6.92 (br s, 1H), 6.86 (s, 1H), 5.75(s, 1H), 4.61 (m, 1H), 3.85 (s, 3H), 3.69 (m, 1H), 2.30 (s, 3H), 2.26(s, 3H), 2.05 (br d, 2H), 1.60-1.82 (m, 4H), 1.18-1.45 (m, 4H).

EXAMPLE 90N4-(3-Chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

Palladium acetate (5.4 mg, 0.024 mmol) and2-(dicyclohexylphosphino)biphenyl (17.0 mg, 0.048 mmol) were dissolvedin dioxane (2.7 mL) and stirred for 10 minutes at 20° C. Sodiumtert.-butylate (44 mg, 0.45 mmol),3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (99 mg, 0.3 mmol) and3-chloroaniline (43 mg, 0.33 mmol) were added and the reaction washeated to 200° C. for 30 minutes in a microwave oven. The solvent wasevaporated under reduced pressure and the residue was taken up in waterand extracted twice with ethyl acetate. The combined organic layers werewashed with brine, dried over sodium sulfate, filtered and evaporatedunder reduced pressure to dryness. The residue was purified by columnchromatography on silica gel using methylenechloride/methanol (19:1 v/v)as eluent to yield the title compound as a yellow solid (34 mg, 27%). MSISP (m/e): 421.2 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.47(s, 1H), 9.41 (s, 1H), 7.88 (s, 1H), 7.18-7.68 (m, 10H), 7.02 (m, 2H),3.70 (s, 3H), 2.26 (s, 3H), 2.14 (s, 3H).

EXAMPLE 91N4-(4-Chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (99 mg, 0.3 mmol) and4-chloroaniline (43 mg, 0.33 mmol) in analogous manner as described inexample 90. It was obtained in 30% yield as a light yellow solid. MS ISP(m/e): 421.1/423.2 (100/30) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ(ppm)=9.43 (s, 1H), 9.36 (s, 1H), 7.74 (m, 3H), 7.66 (s, 1H), 7.43 (d,1H), 7.34 (d, 2H), 7.04 (s, 1H), 6.14 (s, 1H), 3.70 (s, 3H), 2.25 (s,3H), 2.15 (s, 3H).

EXAMPLE 92N4,N4-Diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

a) (2-Chloro-6-methyl-pyrimidin-4-yl)-diethyl-amine

To a solution of 2,4-dichloro-6-methylpyrimidine (166 mg, 1.0 mmol) intetrahydrofurane (5 mL) was added at 20° C. under stirring diethyl amine(88 mg, 1.2 mmol) and the reaction was stirred for 3 hours at 20° C.Additional diethylyamine (44 mg, 0.6 mmol) were added and the reactionwas stirred at 20° C. over night. The solvent was evaporated underreduced pressure and the residue was taken up in water and extractedtwice with diethyl ether. The combined organic layers were washed withbrine, dried over sodium sulfate, filtered and evaporated under reducedpressure to dryness. The residue was purified by column chromatographyon silica gel using heptane/ethyl acetate (9:1 to 7:3 v/v) as eluent toyield the title compound (90 mg, 45%) as a yellow viscous. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=6.11 (s, 1H), 3.49 (br s, 4H), 2.33 (s, 3H),1.19 (t, 6H).

b)N4,N4-Diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (67 mg, 0.33 mmol) and(2-chloro-6-methyl-pyrimidin-4-yl)-diethyl-amine (67 mg, 0.33 mmol) inanalogous manner as described in example 90. It was obtained in 65%yield as a light yellow viscous oil. MS ISP (m/e): 367.2 (100) [(M+H)⁺].¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.15 (s, 1H), 7.88 (s, 1H), 7.63 (s,1H), 7.32 (d, 1H), 7.16 (d, 1H), 7.01 (s, 1H), 6.00 (s, 1H), 3.78 (s,3H), 3.51 (br q, 4H), 2.20 (s, 3H), 2.14 (s, 3H), 1.13 (t, 6H).

EXAMPLE 93N4-Isobutyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

a) (2-Chloro-6-methyl-pyrimidin-4-yl)-isobutyl-amine

To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg, 6.0 mmol) intetrahydrofurane (30 mL) was added at 0° C. under stirring isobutylamine(895 mg, 12.0 mmol) and the reaction was stirred for 6 hours at 0° C.and for 2 hours at 20° C. The solvent was evaporated under reducedpressure and the residue was taken up in 1N aqueous sodium hydroxidesolution and extracted twice with diethyl ether. The combined organiclayers were washed with brine, dried over sodium sulfate, filtered andevaporated under reduced pressure to dryness. The residue was purifiedby column chromatography on silica gel using heptane/ethyl acetate (9:1to 7:3 v/v) as eluent to yield the title compound (655 mg, 55%) as whitecrystals. MS ISP (m/e): 200.2/202.2 (100/32) [(M+H)⁺]. ¹H NMR (DMSO-D₆,300 MHz, rotamers): δ (ppm)=7.75 (br s, 1H), 6.25 (br s, 1H), 2.90-3.12(br m, 2H), 2.12-2.22 (br s, 3H), 1.79 (sept, 1H), 0.88 (d, 6H).

b)N4-Isobutyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol) and(2-chloro-6-methyl-pyrimidin-4-yl)-isobutyl-amine (66 mg, 0.33 mmol) inanalogous manner as described in example 90. It was obtained in 89%yield as a yellow solid. MS ISP (m/e): 367.2 (100) [(M+H)⁺]. ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.12 (s, 1H), 7.97 (s, 1H), 7.63 (s, 1H),7.34 (d, 1H), 7.13 (d, 1H), 7.10 (br s, 1H), 7.01 (s, 1H), 5.87 (s, 1H),3.78 (s, 3H), 3.16 (br s, 2H), 2.13 (s, 3H), 1.74 (sept, 1H), 0.91 (d,6H).

EXAMPLE 941-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-piperidin-4-ol

a) 1-(2-Chloro-6-methyl-pyrimidin-4-yl)-piperidin-4-ol

To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg, 6.0 mmol) intetrahydrofurane (30 mL) was added under stirring N,N-diisopropyl ethylamine (853 mg, 6.6 mmol) and 4-hydroxypiperidine (681 mg, 6.6 mmol) andthe reaction was stirred over night at 20° C. The solvent was evaporatedunder reduced pressure and the residue was taken up in water andextracted twice with diethyl ether. The combined organic layers werewashed with brine, dried over sodium sulfate, filtered and evaporatedunder reduced pressure to dryness. The residue was purified by columnchromatography on silica gel using heptane/ethyl acetate (1:1 v/v) aseluent to yield the title compound (779 mg, 57%) as white crystals. MSISP (m/e): 228.2/230.2 (100/35) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ(ppm)=6.73 (s, 1H), 4.78 (d, 1H), 3.95 (br m, 2H), 3.75 (m, 1H), 3.25(m, 2H), 2.22 (s, 3H), 1.75 (m, 2H), 1.33 (m, 2H).

b)1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-piperidin-4-ol

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (41 mg, 0.20 mmol) and1-(2-chloro-6-methyl-pyrimidin-4-yl)-piperidin-4-ol (50 mg, 0.22 mmol)in analogous manner as described in example 90. It was obtained in 82%yield as a light brown solid. MS ISP (m/e): 395.2 (100) [(M+H)⁺]; ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.23 (s, 1H), 7.96 (s, 1H), 7.63 (s, 1H),7.18 (m, 2H), 7.01 (s, 1H), 6.22 (s, 1H), 4.75 (d, 1H), 4.03 (br m, 2H),3.78 (s, 3H), 3.75 (m, 1H), 3.23 (m, 2H), 2.20 (s, 3H), 2.14 (s, 3H),1.76 (m, 2H), 1.32 (m, 2H).

EXAMPLE 95[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl-pyrimidin-2-yl)-amine

a) 2-Chloro-4-methyl-6-pyrrolidin-1-yl-pyrimidine

To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg, 6.0 mmol) intetrahydrofurane (30 mL) was added under stirring N,N-diisopropyl ethylamine (853 mg, 6.6 mmol) and pyrrolidine (469 mg, 6.6 mmol) and thereaction was stirred over night at 20° C. The solvent was evaporatedunder reduced pressure and the residue was taken up in water andextracted twice with ethyl acetate. The combined organic layers werewashed with brine, dried over sodium sulfate, filtered and evaporatedunder reduced pressure to dryness. The residue was purified by columnchromatography on silica gel using heptane/ethyl acetate (9:1 to 7:3v/v) as eluent to yield the title compound (694 mg, 58%) as whitecrystals. MS ISP (m/e): 198.1/200.1 (100/40) [(M+H)⁺]. ¹H NMR (DMSO-D₆,300 MHz): δ (ppm)=6.35 (s, 1H), 3.44 (m, 2H), 3.30 (m, 2H), 2.29 (s,3H), 1.94 (m, 4H).

In addition 4-chloro-2-methyl-6-pyrrolidin-1-yl-pyrimidine (89 mg, 8%)was obtained as colorless oil. MS ISP (m/e): 198.1/200.1 (100/39)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=6.58 (s, 1H), 3.45 (m, 4H),2.26 (s, 3H), 1.90 (m, 4H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl-pyrimidin-2-yl)-amine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol) and2-chloro-4-methyl-6-pyrrolidin-1-yl-pyrimidine (65 mg, 0.33 mmol) inanalogous manner as described in example 90. It was obtained in 91%yield as a light brown solid. MS ISP (m/e): 365.2 (100) [(M+H)⁺]. ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.21 (s, 1H), 8.10 (s, 1H), 7.62 (s, 1H),7.27 (d, 1H), 7.15 (d, 1H), 7.00 (s, 1H), 5.86 (s, 1H), 3.79 (s, 3H),3.45 (br m, 4H), 2.19 (s, 3H), 2.14 (s, 3H), 1.94 (br m, 4H).

EXAMPLE 96[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-amine

a) 4-(2-Chloro-6-methyl-pyrimidin-4-yl)-morpholine

To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg, 6.0 mmol) intetrahydrofurane (30 mL) was added at 0° C. under stirringN,N-diisopropyl ethyl amine (853 mg, 6.6 mmol) and morpholine (627 mg,6.6 mmol) and the reaction was stirred over night at 20° C. The solventwas evaporated under reduced pressure and the residue was taken up inwater and extracted twice with ethyl acetate. The combined organiclayers were washed with brine, dried over sodium sulfate, filtered andevaporated under reduced pressure to dryness. The residue was purifiedby column chromatography on silica gel using heptane/ethyl acetate (7:3v/v) as eluent to yield the title compound (893 mg, 70%) as whitecrystals. MS ISP (m/e): 214.1/216.2 (100/34) [(M+H)⁺]. ¹H NMR (DMSO-D₆,300 MHz): δ (ppm)=6.73 (s, 1H), 3.65 (m, 4H), 3.58 (m, 2H), 2.25 (s,3H).

In addition 4-(2-chloro-6-methyl-pyrimidin-4-yl)-morpholine (304 mg,24%) was obtained as white crystals. MS ISP (m/e): 214.2/216.2 (100/39)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=6.68 (s, 1H), 3.65 (m, 8H),2.28 (s, 3H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-amine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol) and4-(2-chloro-6-methyl-pyrimidin-4-yl)-morpholine (71 mg, 0.33 mmol) inanalogous manner as described in example 90. The crude product waspurified by stirring with diethyl ether. It was obtained in 87% yield asa light brown solid. MS ISP (m/e): 381.3 (100) [(M+H)⁺]. ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.27 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H),7.23 (d, 1H), 7.16 (d, 1H), 7.01 (s, 1H), 6.21 (s, 1H), 3.77 (s, 3H),3.68 (m, 4H), 3.57 (m, 4H), 2.22 (s, 3H), 2.14 (s, 3H).

EXAMPLE 97[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl-pyrimidin-2-yl)-amine

a) 2-Chloro-4-methyl-6-piperidin-1-yl-pyrimidine

To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg, 6.0 mmol) intetrahydrofurane (30 mL) was added under stirring N,N-diisopropyl ethylamine (853 mg, 6.6 mmol) and piperidine (613 mg, 6.6 mmol) and thereaction was stirred over night at 20° C. The solvent was evaporatedunder reduced pressure and the residue was taken up in water andextracted twice with ethyl acetate. The combined organic layers werewashed with brine, dried over sodium sulfate, filtered and evaporatedunder reduced pressure to dryness. The residue was purified by columnchromatography on silica gel using heptane/ethyl acetate (9:1 to 7:3v/v) as eluent to yield the title compound (678 mg, 53%) as light yellowcrystals. MS ISP (m/e): 212.1/214.3 (100/40) [(M+H)⁺]. ¹H NMR (DMSO-D₆,300 MHz): δ (ppm)=6.70 (s, 1H), 3.58 (m, 4H), 2.22 (s, 3H), 1.61 (m,2H), 1.51 (m, 4H).

In addition 4-chloro-2-methyl-6-piperidin-1-yl-pyrimidine (220 mg, 17%)was obtained as colorless oil. MS ISP (m/e): 212.1/214.1 (100/73)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=6.57 (s, 1H), 3.70 (m, 4H),2.23 (s, 3H), 1.61 (m, 2H), 1.50 (m, 4H).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl-pyrimidin-2-yl)-amine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol) and2-chloro-4-methyl-6-piperidin-1-yl-pyrimidine (70 mg, 0.33 mmol) inanalogous manner as described in example 90. The crude product waspurified by stirring with diethyl ether. It was obtained in 78% yield asa light brown solid. MS ISP (m/e): 379.3 (100) [(M+H)⁺]. ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.21 (s, 1H), 7.97 (s, 1H), 7.63 (s, 1H),7.19 (d, 1H), 7.15 (d, 1H), 7.01 (s, 1H), 6.19 (s, 1H), 3.77 (s, 3H),3.62 (m, 4H), 2.20 (s, 3H), 2.14 (s, 3H), 1.63 (m, 2H), 1.53 (m, 4H).

EXAMPLE 98[4-(1,1-Dioxo-6-thiomorpholin-4-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-(2-Chloro-6-methyl-pyrimidin-4-yl)-thiomorpholine 1,1-dioxide

A mixture of 2,4-dichloro-6-methylpyrimidine (579 mg, 3.55 mmol),thiomorpholine-1,1-dioxide (480 mg, 3.55 mmol) and triethylamine (0.99mL, 7.10 mmol) in 7 mL isopropanol was refluxed overnight. Water wasadded and the mixture of the regioisomers were extracted with ethylacetate. Chromatography on on S1—NH2 gel (Isolute) usingcyclo-hexane/ethyl acetate (gradient 30 to 60% ethyl acetate) gave thetitle compound as a colourless solid (364 mg, 39%). MS ISP (m/e): 201.2(33) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=6.39 (s, 1H), 4.20 (tbroad, 4H), 3.08 (t broad, 4H), 2.41 (s, 3H).

b)[4-(1,1-Dioxo-6-thiomorpholin-4-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and4-(2-chloro-6-methyl-pyrimidin-4-yl)-thiomorpholine 1,1-dioxide, usingpotassium carbonate as a base. The title compound was isolated as aslightly yellow solid in a yield of 82%. MS ISP (m/e): 429.3 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.62 (s, 1H), 7.58 (d, 1H),7.16 (d, 1H), 7.04 (dxd, 1H), 6.99 (s, 1H), 6.87 (s, 1H), 6.07 (s, 1H),4.18 (t broad, 4H), 3.84 (s, 3H), 3.09 (t broad, 4H), 2.35 (s, 3H), 2.26(s, 3H).

EXAMPLE 99({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-aceticAcid tert-butyl Ester

a) [(2-Chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic acidtert-butyl ester

Prepared in analogy to example 98a), using2,4-dichloro-6-methylpyrimidine and sarcosine tert-butyl esterhydrochloride. The title compound was isolated as a slightly yellow oilin a yield of 52%. MS ISP (m/e): 272.2 & 274.0 (25 & 10) [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm)=6.23 (s broad, 1H), 4.21 (s broad, 2H),3.10 (s broad, 3H), 2.36 (s, 3H), 1.46 (s, 9H).

b)({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-aceticAcid tert-butyl Ester

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and[(2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic acid tert-butylester, using potassium carbonate as a base. The title compound wasisolated as a slightly yellow foam in a yield of 79%. MS ISP (m/e):439.3 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.65 (s broad,1H), 7.60 (d, 1H), 7.12 (d, 1H), 7.05-6.95 (m, 2H), 6.85 (s, 1H), 5.94(s, 1H), 3.87 (s, 3H), 3.12 (s broad, 3H), 2.30 (s, 3H), 2.29 (s, 3H),1.39 (s, 9H).

EXAMPLE 1001-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-2-methyl-propan-2-ol

a) [(2-Chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic Acid BenzylEster

Prepared in analogy to example 98a), using2,4-dichloro-6-methylpyrimidine and sarcosine-benzylester hydrochloride.The title compound was isolated as a slightly yellow oil in a yield of62%. MS ISP (m/e): 306.1 & 308.2 (100 & 38) [(M+H)⁺]. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=7.40-7.35 (m, 5H), 6.23 (s broad, 1H), 5.19 (s, 2H), 4.39(s broad, 2H), 3.11 (s broad, 3H), 2.36 (s, 3H).

b)({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-aceticAcid Benzyl Ester

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and[(2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic acid benzylester, using potassium carbonate as a base. The title compound wasisolated as a colorless solid in a yield of 56%. MS ISP (m/e): 473.3(100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.58 (s, 1H), 7.54 (sbroad, 1H), 7.35-7.20 (m, 4H), 7.10-6.95 (m, 2H), 6.89 (s broad, 1H),6.82 (s, 1H), 5.95 (s, 1H), 5.16 (s, 2H), 4.39 (s broad, 2H), 3.80 (s,3H), 3.14 (s, 3H), 2.31 (s, 3H), 2.30 (s, 3H).

c)1-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-2-methyl-propan-2-ol

A solution of({2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-aceticacid benzyl ester (32 mg, 0.07 mmol) in 2 mL of tetrahydrofurane wascooled in an ice-bath and treated with a 3 molar solution of methylmagnesium chloride in tetrahydrofurane (0.15 mL, 1.5 mmol). The mixturewas stirred for 10 minutes in the ice-bath and for additional 2 hours at20° C. Hydrolysis and extraction with ethyl acetate gave the titlecompound as a yellowish sticky gum (27 mg, 100%). MS ISP (m/e): 397.3(100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.62 (s, 1H), 7.52 (s,1H), 7.37 (d, 1H), 7.30-7.10 (m, 2H), 6.86 (s, 1H), 5.98 (s, 1H), 3.834(s, 3H), 3.62 (s, 2H), 3.19 (s, 3H), 2.33 (s, 3H), 2.29 (s, 3H), 1.25(s, 6H).

EXAMPLE 1012-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylamino}-ethanol

a) 2-(2-Chloro-pyrimidin-4-ylamino)-ethanol

Prepared in analogy to example 98a), using 2,4-dichloro-pyrimidine andethanolamine.

The title compound was isolated as a colorless solid in a yield of 16%.MS ISP (m/e): 174.3 & 172.1 (100 & 40) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300MHz): δ (ppm)=7.90 (s broad, 1H), 7.84 (d, 1H), 6.48 (d, 1H), 4.77 (t,1H), 3.52 (qa, 2H), 3.26 (qa broad, 2H).

b)2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylamino}-ethanol

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-(2-chloro-pyrimidin-4-ylamino)-ethanol, using potassium carbonate as abase.

The title compound was isolated as a slightly orange solid in a yield of23%. MS ISP (m/e): 341.2 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ(ppm)=9.14 (s, 1H), 7.91 (s broad, 1H), 7.82 (d broad, 1H), 7.63 (s,1H), 7.33 (d broad, 1H), 7.25 (s broad, 1H), 7.15 (d, 1H), 7.01 (s, 1H),6.00 (d, 1H), 4.74 (t, 1H), 3.78 (s, 3H), 3.55 (qa, 2H), 3.50-3.35 (m,2H), 2.14 (s, 3H).

EXAMPLE 1022-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylamino}-2-methyl-propan-1-ol

a) 2-(2-Chloro-pyrimidin-4-ylamino)-2-methyl-propan-1-ol

Prepared in analogy to example 98a), using 2,4-dichloro-pyrimidine and2-amino-2-methylpropan-1-ol. The title compound was isolated as ayellowish solid in a yield of 19%. MS ISP (m/e): 200.3 (100) [(M+H)⁺].¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.84 (d, 1H), 7.49 (s, 1H), 6.50 (d,1H), 4.85 (s, 1H), 3.53 (d, 2H), 1.29 (s, 6H).

b)2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylamino}-2-methyl-propan-1-ol

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-(2-chloro-pyrimidin-4-ylamino)-2-methyl-propan-1-ol, using potassiumcarbonate as a base. The title compound was isolated as a slightlyorange solid in a yield of 62%. MS ISP (m/e): 369.2 (100) [(M+H)⁺]. ¹HNMR (DMSO-D₆, 300 MHz): δ (ppm)=7.91 (d, 1H), 7.62 (d, 1H), 7.43 (d,1H), 7.20-7.10 (m, 2H), 6.87 (s, 1H), 6.79 (s, 1H), 5.88 (d, 1H), 4.74(s, 1H), 3.84 (s, 3H), 3.69 (s, 2H), 2.29 (s, 3H), 1.42 (s, 6H).

EXAMPLE 103[4-(4-Methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) 4-Chloro-2-(4-methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidine

Prepared in analogy to example 98a), using2,4-dichloro-6-methylpyrimidine and 1-methanesulfonyl-piperazine. Thetitle compound was isolated as a yellow solid in a yield of 41%. MS ISP(m/e): 291.1 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=6.81 (s,1H), 3.80-3.70 (m, 4H), 3.20-3.15 (m, 4H), 2.90 (s, 3H), 2.26 (s, 3H).

b)[4-(4-Methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and4-chloro-2-(4-methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidine. Thetitle compound was isolated as a yellowish solid in a yield of 4%. MSISP (m/e): 458.3 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.32(s, 1H), 7.90 (s, 1H), 7.63 (d, 1H), 7.24 (d, 1H), 7.18 (d, 1H), 7.01(s, 1H), 6.28 (s, 1H), 3.78 (s, 3H), 3.80-3.70 (m, 4H), 3.19 (t, 4H),2.91 (s, 3H), 2.23 (s, 3H), 2.14 (s, 3H).

EXAMPLE 1042-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-ethanol

a) 2-[(2-Chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-ethanol

Prepared in analogy to example 98a), using2,4-dichloro-6-methylpyrimidine and 2-(methylamino)ethanol. The titlecompound was isolated as a yellowish oil in a yield of 61%. MS ISP(m/e): 202.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=6.22 (s,1H), 3.86 (t, 2H), 3.70-3.60 (m, 2H), 3.11 (s, 3H), 2.70 (s very broad,1H), 2.34 (s, 3H).

b)2-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenalamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-ethanol

Prepared in analogy to example 81b) from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2-[(2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-ethanol. The titlecompound was isolated as a colorless solid in a yield of 57%. MS ISP(m/e): 369.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.70 (d,1H), 7.60 (s, 1H), 7.11 (d, 1H), 7.05-6.90 (m, 2H), 6.85 (s, 1H), 5.92(s, 1H), 3.95-3.80 (m, 2H), 3.84 (s, 3H), 3.80-3.70 (m, 2H), 3.12 (s,3H), 2.31 (s, 3H), 2.29 (s, 3H).

EXAMPLE 1052-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl-pyrimidin-4-yl}-propan-2-ol

a) 2-(2-Chloro-6-piperidin-1-yl-pyrimidin-4-yl)-propan-2-ol

Using in analogous manner the procedure described in example 88b), butreplacing ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl2-chloro-6-piperidin-1-yl-pyrimidine-4-carboxylate (511 mg, 2.0 mmol),the title compound was obtained as light yellow solid (144 mg, 26%). MSISP (m/e): 256.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=6.47 (s,1H), 3.64 (m, 4H), 3.44 (s, 1H), 1.63 (m, 6H), 1.50 (s, 6H).

b)2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 88c), butreplacing 2-(2-chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol by2-(2-chloro-6-piperidin-1-yl-pyrimidin-4-yl)-propan-2-ol (26 mg, 0.1mmol), the title compound was obtained as light yellow foam (5 mg, 12%).MS ISP (m/e): 423.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.67 (d,1H), 7.64 (s, 1H), 7.18 (d, 1H), 7.11 (s, 1H), 7.02 (dd, 1H), 6.88 (s,1H), 6.27 (s, 1H), 4.43 (q, 2H), 4.10 (br s, 1H), 2.30 (s, 3H), 1.51 (s,6H), 1.42 (t, 3H).

EXAMPLE 1062-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-pyrimidin-4-yl}-propan-2-ol

a) Methyl 2-chloro-6-pyrrolidin-1-yl-pyrimidine-4-carboxylate

A mixture of methyl 2,4-dichloropyrimidine-6-carboxylate (1.66 g, 8.0mmol), pyrrolidine (0.66 mL, 8 mmol) and sodium carbonate (1.54 g, 14.0mmol) in methanol (8 mL) was stirred for 1 h at. The mixture waspartitioned between ethyl acetate and water, and the organic layer wassubsequently washed with brine, dried over sodium sulfate and evaporatedunder reduced pressure to give crude title compound (0.78 g, 40%) aslight yellow solid. MS ISP (m/e): 242.2 [(M+H)⁺].

b) 2-(2-Chloro-6-pyrrolidin-1-yl-pyrimidin-4-yl)-propan-2-ol

Using in analogous manner the procedure described in example 88b), butreplacing ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl2-chloro-6-pyrrolidin-1-yl-pyrimidine-4-carboxylate (773 mg, 3.2 mmol),the title compound was obtained as light yellow solid (584 mg, 76%). MSISP (m/e): 242.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=6.24 (s,1H), 3.64 (m, 2H), 3.56 (s, 1H), 3.37 (m, 2H), 2.04 (m, 4H), 1.50 (s,6H).

c)2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 88c), butreplacing 2-(2-chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol by2-(2-chloro-6-pyrrolidin-1-yl-pyrimidin-4-yl)-propan-2-ol (120 mg, 0.5mmol), the title compound was obtained as light yellow foam (16 mg, 8%).MS ISP (m/e): 409.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.82 (d,1H), 7.62 (s, 1H), 7.14 (d, 1H), 7.02 (dd, 1H), 6.98 (s, 1H), 6.87 (s,1H), 5.86 (s, 1H), 4.46 (br s, 1H), 3.86 (s, 3H), 3.3-3.8 (m, 4H), 2.30(s, 3H), 2.05 (m, 4H), 1.57 (s, 6H).

EXAMPLE 1071-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-piperidin-4-ol

The title compound was prepared from1-(2-chloropyrimidin-4-yl)-4-piperidinol (120 mg, 0.534 mmol) and3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (109 mg, 0534 mmol)using in analogous manner the procedure described in example 43b).Obtained after trituration in dichloromethane/methanol (19:1 v/v) as awhite solid (117 mg, 57%). MS ISP (m/e): 381.1 [(M+H)⁺]. ¹HNMR (DMSO-D₆,300 MHz): δ (ppm)=9.24 (s, 1H), 7.97 (d, 1H), 7.84 (d, 1H), 7.63 (s,1H), 7.26 (dd, 1H), 7.18 (d, 1H), 7.03 (s, 1H), 6.31 (d, 1H), 4.77 (d,1H), 4.07 (mbroad, 2H), 3.78 (s, 3H), 3.77 (m, 1H), 3.25 (m broad, 2H),2.14 (s, 3H), 1.78 (m broad, 2H), 1.36 (m broad, 2H). Mp 197-200° C.

EXAMPLE 108[4-Butyl-6-(4-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A suspension ofN-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (153mg, 0.41 mmol), 1-(4-chloro-phenyl)-hept-2-yn-1-one (100 mg, 0.45 mmol,CAS 105363-17-5) and sodium methanolat (120 mg, 1.24 mmol) inacetonitrile (2.0 mL) was heated two times to 120° C. for 30 minutes ina microwave oven. Water was added and the reaction was extracted twicewith ethyl acetate. The combined organic layers were dried over sodiumsulfate, filtered and the solvent was evaporated. The residue waspurified by column chromatography on silica gel usingdichloromethane/methanol (9:1 v/v) as eluent to yield the title compoundas a yellow solid (30 mg, 16%). MS ISP (m/e): 448.3/450.1 (100/37)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.04 (d, 2H), 7.98 (s, 1H),7.64 (s, 1H), 7.46 (d, 2H), 7.29 (s, 1H), 7.18 (d, 1H), 7.04 (d, 1H),6.89 (s, 1H), 3.89 (s, 3H), 2.74 (t, 2H), 2.31 (, 3H), 1.79 (m, 2H),1.43 (m, 2H), 0.98 (t, 3H).

EXAMPLE 109[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-pyrimidin-2-yl)-amine

A solution of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (249 mg, 0.67 mmol), 3-(dimethylamino)-1-phenyl-2-propen-1-one(141 mg, 0.80 mmol, CAS 1131-80-2) and triethyl amine (187 uL. 1.34mmol) in ethanol (4 mL) was heated to 160° C. for 1 hour in a microwaveoven. The solvent was evaporated under reduced pressure and the residuepurified by column chromatography on silica using methylenechloride anddichloromethane/methanol (19:1 v/v) as eluent to yield the titlecompound a a yellow solid (67 mg, 28%). MS ISP (m/e): 358.2 (100)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.90 (s, 1H), 8.60 (s, 1H),8.20 (br s, 2H), 7.99 (s, 1H), 7.68 (s, 1H), 7.43-7.56 (m, 5H), 7.26 (t,1H), 7.06 (s, 1H), 3.84 (s, 3H), 2.15 (s, 3H).

EXAMPLE 110[5-(3,4-Dichloro-phenyl)-4-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

a) (E/Z)-3-(3,4-Dichloro-phenyl)-4-dimethylamino-but-3-en-2-one

A mixture of 1-(3,4-dichlorophenyl)propan-2-one (1.0 g, 4.93 mmol) andN,N-dimethylformamide dimethyl acetal (1.64 mL, 12.3 mmol) was heatedovernight at 130° C. The resulting solution was concentrated, treatedwith diethyl ether and filtered to yield the crude title product as abrownish solid. MS ISP (m/e): 258.0 & 260.1 (100 & 68) [(M+H)⁺].

b)[5-(3,4-Dichloro-phenyl)-4-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A solution of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (100 mg, 0.27 mmol; see Example 4b),(E/Z)-3-(3,4-dichloro-phenyl)-4-dimethylamino-but-3-en-2-one (156 mg,0.60 mmol) and triethylamine (0.19 mL, 1.34 mmol) in 5 mL of ethanol wasrefluxed for 28 hours. The mixture was diluted with water, extractedwith ethyl acetate and the product purified by chromatography on silicagel using ethyl acetate as a solvent. The product was isolated as ayellow solid (3 mg, 3%). MS ISP (m/e): 440.1 (100) [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=9.65 (s very broad, 1H), 8.38 (s, 1H), 8.20(s, 1H), 7.50-6.90 (m, 5H), 6.92 (s, 1H), 3.85 (s, 3H), 2.40 (s, 3H),2.38 (s, 3H).

EXAMPLE 111[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

a) (E/Z)-3-Dimethylamino-1-thiazol-2-yl-propenone

A mixture of 2-acetylthiazole (145 mg, 1.14 mmol) and tert-butoxy-bis(dimethylamino)methane (0.33 mL, 1.59 mmol) was heated for 2 hours at130° C. The mixture was concentrated in vacuo to give the crude titlecompound (160 mg; 93%) as a brownish gum.

MS ISP (m/e): 183.0 (100).

b)[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

A solution of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (75 mg, 0.22 mmol; see Example 4b),(E/Z)-3-dimethylamino-1-thiazol-2-yl-propenone (160 mg, 0.88 mmol) andtriethylamine (0.12 mL, 0.87 mmol) in 5 mL of ethanol was heated in themicrowave oven for 1.5 hours at 100° C. The mixture was diluted withwater, extracted with ethyl acetate and the product purified bychromatography on silica gel using a mixture of heptane/ethyl acetate2:8 v/v as a solvent. The product was isolated as a yellow solid (10 mg,12%). MS ISP (m/e): 365.1 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.59 (d; 1H), 8.02 (d, 1H), 7.84 (d, 1H), 7.77 (s, 1H), 7.62 (d,1H), 7.57 (d, 1H), 7.35 (s, 1H), 7.22 (d, 1H), 7.10 (dxd; 1H), 6.91 (s,1H), 3.97 (s, 3H), 2.34 (s, 3H).

EXAMPLE 1125-(4,6-Dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile

a) 5-Bromo-2-(4-methyl-imidazol-1-yl)-benzonitrile

This compound was prepared from 5-bromo-2-fluorobenzonitrile and4-methylimidazole, as described in US2006/0004013.

b)5-(4,6-Dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile

A mixture of 5-bromo-2-(4-methyl-imidazol-1-yl)-benzonitrile (200 mg,0.76 mmol), 2-amino-4,6-dimethyl-pyrimidine (141 mg, 1.14 mmol), sodiumphenoxide (266 mg, 2.29 mmol), tris(dibenzylideneacetone)dipalladiumchloroform complex (21 mg, 0.02 mmol) and4,5-bis(diphenylphosphino)-9,9-dimethylxanthene=xanthphos (26 mg, 0.04mmol) in 5 mL of dioxane was heated to 80° C. under argon for 2 hours.The mixture was diluted with water, extracted with ethyl acetate and theproduct purified by chromatography on silica gel usingdichloromethane/methanol 9:1 v/v as an eluent. The title compound wasobtained as a colorless solid (144 mg, 62%). MS ISP (m/e): 305.1 (100)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=10.08 (s, 1H), 8.44 (s,1H), 8.15 (d, 1H), 7.89 (s, 1H), 7.55 (d, 1H), 7.25 (s, 1H), 6.76 (s,1H), 2.36 (s, 6H), 2.18 (s, 3H).

EXAMPLE 1135-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile

Prepared in analogy to example 112b) from5-bromo-2-(4-methyl-imidazol-1-yl)-benzonitrile and4-(4-chloro-phenyl)-pyrimidin-2-ylamine. The title compound was obtainedas a colorless solid (Yield=35%). MS ISP (m/e): 387.2 (100) [(M+H)⁺]. ¹HNMR (DMSO-D₆, 300 MHz): δ (ppm)=10.31 (s, 1H), 8.69 (d, 1H), 8.47 (s,1H), 8.25-8.15 (m, 3H), 7.97 (s, 1H), 7.55-7.50 (m, 3H), 7.57 (d, 1H),7.29 (s, 1H), 2.20 (s, 3H).

EXAMPLES 114-138

Using in analogous manner the procedure described in example 28a),1-(4-trifluoromethyl-phenyl)-propan,1-(4-trifluoromethyl-phenyl)-butan-1-one,1-(3,4,5-trifluoro-phenyl)-ethanone, 1-(2,5-dichloro-phenyl)-ethanone,1-(3,4-dichloro-phenyl)-ethanone, 1-(2,4-dichloro-phenyl)-ethanone,1-(4-chloro-3-methyl-phenyl)-ethanone, 1-(4-chloro-phenyl)-pentan-1-one,1-(4-chloro-phenyl)-2-methoxy-ethanone,1-(3,5-dimethyl-pyrazin-2-yl)-ethanone, 3-methyl-butan-2-one,3,3-dimethyl-butan-2-one, 1-methoxy-propan-2-one, acetic acid2-oxo-propyl ester, 3-hydroxy-butan-2-one,3-hydroxy-3-methyl-butan-2-one, 1-cyclopentyl-propan-2-one,1-cyclopropyl-ethanone, 1-cyclopentyl-ethanone,1-cyclohexyl-propan-1-one, ethyl 3-oxo-4-phenyl-butyrate, ethyl7-methyl-3-oxo-oct-6-enoate, 6-methyl-1-phenyl-hept-5-en-2-one, ethyl2-oxo-propionate, and 6-acetyl-4H-benzo[1,4]oxazin-3-one, were reactedwith tert.-butoxy-bis-(dimethylamino)-methane, respectively, and theresulting products were subsequently reacted withN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrateoperating in analogous manner as described in example 39b) to afford thefollowing compounds:

EXAMPLE 114[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-amine

Obtained in 42% yield as light yellow solid. MS ISP (m/e): 440.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.40 (s, 1H), 7.74-7.80 (m,5H), 7.62 (s, 1H), 7.23 (s, 1H), 7.17 (d, 1H), 7.06 (dd, 1H), 6.87 (s,1H), 3.82 (s, 3H), 2.30 (s, 3H), 2.29 (s, 3H).

EXAMPLE 115[5-Ethyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 53% yield as light yellow solid. MS ISP (m/e): 454.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (s, 1H), 7.77 (d, 1H),7.75 and 7.70 (2 d, 2×2H), 7.62 (s, 1H), 7.22 (s, 1H), 7.16 (d, 1H),7.05 (dd, 1H), 6.86 (s, 1H), 3.81 (s, 3H), 2.64 (q, 2H), 2.30 (s, 3H),1.65 (t, 3H).

EXAMPLE 116[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-phenyl)-pyrimidin-2-yl]-amine

Obtained in 7% yield as yellow solid. MS ISP (m/e): 412.2 [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm)=8.55 (d, 1H), 7.78 (d, 1H), 7.73-7.78 (m,2H), 7.66 (s, 1H), 7.32 (s, 1H), 7.22 (d, 1H), 7.12 (d, 1H), 7.09 (dd,1H), 6.90 (s, 1H), 3.91 (s, 3H), 2.31 (s, 3H).

EXAMPLE 117[4-(2,5-Dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 36% yield as light yellow solid. MS ISP (m/e): 426.1[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.55 (d, 1H), 7.92 (d, 1H),7.73 (d, 1H), 7.63 (s, 1H), 7.45 (d, 1H), 7.37 (dd, 1H), 7.35 (s, 1H),7.21 (d, 1H), 7.19 (d, 1H), 7.00 (dd, 1H), 6.88 (s, 1H), 3.81 (s, 3H),2.30 (s, 3H).

EXAMPLE 118[4-(3,4-Dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 18% yield as light yellow solid. MS ISP (m/e): 426.1[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.53 (d, 1H), 8.27 (d, 1H),7.90 (d, 1H), 7.87 (dd, 1H), 7.66 (s, 1H), 7.58 (d, 1H), 7.33 (s, 1H),7.21 (d, 1H), 7.18 (d, 1H), 7.03 (dd, 1H), 6.90 (s, 1H), 3.93 (s, 3H),2.31 (s, 3H).

EXAMPLE 119[4-(2,4-Dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 24% yield as light yellow solid. MS ISP (m/e): 426.0[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.53 (d, 1H), 7.79 (d, 1H),7.64 (s, 1H), 7.63 (d, 1H), 7.54 (s, 1H), 7.38 (dd, 1H), 7.31 (s, 1H),7.18 (d, 1H), 7.16 (d, 1H), 7.08 (dd, 1H), 6.88 (s, 1H), 3.84 (s, 3H),2.30 (s, 3H).

EXAMPLE 120[4-(4-Chloro-3-methyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 15% yield as light yellow solid. MS ISP (m/e): 406.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.50 (d, 1H), 7.97 (d, 1H),7.86 (d, 1H), 7.84 (dd, 1H), 7.65 (s, 1H), 7.46 (d, 1H), 7.30 (s, 1H),7.20 (d, 1H), 7.18 (d, 1H), 7.08 (dd, 1H), 6.89 (s, 1H), 3.90 (s, 3H),2.47 (s, 3H), 2.31 (s, 3H).

EXAMPLE 121[4-(4-Chloro-phenyl)-5-propyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 25% yield as off-white solid. MS ISP (m/e): 434.3 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.38 (s, 1H), 7.82 (d, 1H), 7.62 (s,1H), 7.53 and 7.46 (2 d, 2×2H), 7.21 (s, 1H), 7.16 (d, 1H), 7.02 (dd,1H), 6.86 (s, 1H), 3.81 (s, 3H), 2.59 (t, 2H), 2.30 (s, 3H), 1.59 (m,2H), 0.86 (t, 3H).

EXAMPLE 122[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(5-methoxy-4-phenyl-pyrimidin-2-yl)-amine

Obtained in 23% yield as light yellow solid. MS ISP (m/e): 388.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.27 (s, 1H), 8.12 (m, 3H),7.86 (d, 1H), 7.62 (s, 1H), 7.48 (m, 3H), 7.17 (d, 1H), 7.15 (s, 1H),7.02 (dd, 1H), 6.87 (s, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 2.30 (s, 3H).

EXAMPLE 123[4-(3,5-Dimethyl-pyrazin-2-yl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 22% yield as light yellow solid. MS ISP (m/e): 388.3[(M+H)⁺].)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.61 (d, 1H), 8.45 (s,1H), 7.63 (m, 2H), 7.34 (d, 1H), 7.15-7.20 (m, 2H), 6.88 (s, 1H), 6.80(dd, 1H), 3.85 (s, 3H), 2.80 (s, 3H), 2.61 (s, 3H), 2.30 (s, 3H).

EXAMPLE 124(4-Isopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 42% yield as yellow oil. MS ISP (m/e): 324.3 [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm)=8.33 (d, 1H), 7.88 (d, 1H), 7.63 (s, 1H),7.18 (s, 1H), 7.16 (d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 6.68 (d, 1H),3.88 (s, 3H), 2.92 (m, 1H), 2.30 (s, 3H), 1.32 (d, 6H).

EXAMPLE 125(4-tert-Butyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 30% yield as light yellow solid. MS ISP (m/e): 338.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.38 (d, 1H), 8.40 (d, 1H),7.63 (s, 1H), 7.18 (s, 1H), 7.17 (d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H),6.82 (d, 1H), 3.89 (s, 3H), 2.30 (s, 3H), 1.37 (s, 9H).

EXAMPLE 126[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxymethyl-pyrimidin-2-yl)-amine

Obtained in 29% yield as light yellow solid. MS ISP (m/e): 326.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (d, 1H), 7.71 (d, 1H),7.63 (s, 1H), 7.21 (s, 1H), 7.17 (d, 1H), 7.07 (dd, 1H), 6.92 (d, 1H),6.87 (s, 1H), 4.46 (s, 2H), 3.87 (s, 3H), 3.51 (s, 3H), 2.30 (s, 3H).

EXAMPLE 127 Acetic acid2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylmethylEster

Obtained in 11% yield as off-white solid. MS ISP (m/e): 354.2 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (d, 1H), 7.66 (d, 1H), 7.63 (s,1H), 7.23 (s, 1H), 7.17 (d, 1H), 7.11 (dd, 1H), 6.88 (s, 1H), 6.80 (d,1H), 5.10 (s, 2H), 3.87 (s, 3H), 2.30 (s, 3H), 2.21 (s, 3H).

EXAMPLE 1281-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-ethanol

Obtained in 22% yield as light yellow solid. MS ISP (m/e): 326.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.43 (d, 1H), 7.64 (m, 2H),7.24 (s, 1H), 7.19 (d, 1H), 7.09 (dd, 1H), 6.88 (s, 1H), 6.80 (d, 1H),4.78 (q, 1H), 3.87 (s, 3H), 2.30 (s, 3H), 1.52 (d, 3H).

EXAMPLE 1292-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Obtained in 23% yield as off-white solid. MS ISP (m/e): 340.2 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.44 (d, 1H), 7.64 (s, 1H), 7.63 (d,1H), 7.22 (s, 1H), 7.19 (d, 1H), 7.07 (dd, 1H), 6.89 (s, 1H), 6.88 (d,1H), 4.01 (s, 1H), 3.88 (s, 3H), 2.31 (s, 3H), 1.55 (s, 6H).

EXAMPLE 130(4-Cyclopentylmethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 15% yield as yellow oil. MS ISP (m/e): 364.2 [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm)=8.32 (d, 1H), 7.80 (d, 1H), 7.63 (s, 1H),7.18 (s, 1H), 7.17 (d, 1H), 7.05 (dd, 1H), 6.87 (s, 1H), 6.65 (d, 1H),3.87 (s, 3H), 2.67 (d, 2H), 2.31 (s, 3H), 2.27-2.33 (m, 1H), 1.50-1.80(m, 8H).

EXAMPLE 131(4-Cyclopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 44% yield as light yellow solid. MS ISP (m/e): 322.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.22 (d, 1H), 7.81 (d, 1H),7.62 (s, 1H), 7.15 (d, 1H), 7.10 (s, 1H), 6.94 (dd, 1H), 6.87 (s, 1H),6.70 (d, 1H), 3.89 (s, 3H), 2.30 (s, 3H), 2.27-2.33 (m, 1H), 1.94 (m,1H), 1.20 (m, 2H), 1.08 (m, 2H).

EXAMPLE 132(4-Cyclopentyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 13% yield as light yellow solid. MS ISP (m/e): 350.4[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.30 (d, 1H), 7.82 (d, 1H),7.63 (s, 1H), 7.17 (d, 1H), 7.15 (s, 1H), 7.03 (dd, 1H), 6.87 (s, 1H),6.68 (d, 1H), 3.87 (s, 3H), 3.08 (m, 1H), 2.30 (s, 3H), 2.00-2.28 (m,2H), 1.65-1.92 (m, 6H).

EXAMPLE 133(4-Cyclohexyl-5-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 38% yield as light yellow solid. MS ISP (m/e): 378.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.13 (s, 1H), 7.93 (d, 1H),7.62 (s, 1H), 7.15 (d, 1H), 7.08 (s, 1H), 6.94 (dd, 1H), 6.87 (s, 1H),3.90 (s, 3H), 2.78 (m, 1H), 2.30 (s, 3H), 2.20 (s, 3H), 1.60-1.95 (m,8H), 1.3-1.5 (m, 2H).

EXAMPLE 134 Ethyl4-benzyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate

Obtained in 10% yield as light yellow solid. MS ISP (m/e): 444.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.99 (s, 1H), 7.63 (s, 1H),7.59 (d, 1H), 7.42 (s, 1H), 7.20-7.35 (m, 5H), 7.13 (d, 1H), 7.06 (dd,1H), 6.87 (s, 1H), 4.52 (s, 2H), 4.36 (q, 2H), 3.79 (s, 3H), 2.30 (s,3H), 1.37 (t, 3H).

EXAMPLE 135 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-methyl-pent-3-enyl)-pyrimidine-5-carboxylate

Obtained in 8% yield as light yellow solid. MS ISP (m/e): 436.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.95 (s, 1H), 7.82 (d, 1H),7.65 (s, 1H), 7.42 (s, 1H), 7.20 (d, 1H), 7.10 (dd, 1H), 6.89 (s, 1H),5.22 (t, 1H), 4.36 (q, 2H), 3.88 (s, 3H), 3.16 (m, 2H), 2.45 (m, 2H),2.30 (s, 3H), 1.68 and 1.59 (2 s, 2×3H).

EXAMPLE 136[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-methyl-pent-3-enyl)-5-phenyl-pyrimidin-2-yl]-amine

Obtained in 17% yield as light yellow solid. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.27 (s, 1H), 7.84 (d, 1H), 7.64 (s, 1H), 7.15-7.50 (m, 6H), 7.20(d, 1H), 7.12 (dd, 1H), 6.87 (s, 1H), 5.06 (t, 1H), 3.88 (s, 3H), 2.72(m, 2H), 2.40 (m, 2H), 2.31 (s, 3H), 1.63 and 1.49 (2 s, 2×3H).

EXAMPLE 1376-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4H-benzo[1,4]oxazin-3-one

Obtained in 20% yield as white solid. MS ISP (m/e): 429.2 [(M+H)⁺]. ¹HNMR (DMSO-D₆, 300 MHz): δ (ppm)=10.96 (s, 1H), 9.84 (s, 1H), 8.55 (d,1H), 7.85 (d, 1H), 7.75 (dd, 1H), 7.74 (d, 1H), 7.68 (s, 1H), 7.33 (dd,1H), 7.31 (s, 1H), 7.28 (d, 1H), 7.10 (d, 1H), 7.07 (s, 1H), 4.68 (s,2H), 3.81 (s, 3H), 2.16 (s, 3H).

EXAMPLE 138Cyclopropyl-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile

2-Cyclopropyl-4-oxo-4-(4-trifluoromethyl-phenyl)-butyronitrile

A solution of potassium cyanide (313 mg, 4.8 mmol) in water (1 mL) wasadded at to a solution of(E)-3-cyclopropyl-1-(4-trifluoromethyl-phenyl)-propenone (961 mg, 4.0mmol) in a ethanol (8 mL) and acetic acid (0.26 mL). The reactionmixture was stirred at for 6 days and then partitioned between ethylacetate and saturated sodium hydrogencarbonate solution. The organiclayer was washed with brine, dried over sodium sulfate, and evaporatedunder reduced pressure. The residual oil was subjected to columnchromatography on silica gel using heptane/0-15% ethyl acetate to givethe title compound as white solid (620 mg, 58%). Mp 91-93° C.

b)Cyclopropyl-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile

Using in analogous manner the procedure described in example 28a),2-cyclopropyl-4-oxo-4-(4-trifluoromethyl-phenyl)-butyronitrile (170 mg,0.5 mmol) was reacted with tert.-butoxy-bis-(dimethylamino)-methane, andthe resulting product was subsequently reacted withN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrateoperating in analogous manner as described in example 39b) to give thetitle compound (46 mg, 24%). MS ISP (m/e): 505.3 [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=8.81 (s, 1H), 7.82 (d, 2H), 7.60-7.75 (m, 4H),7.39 (s, 1H), 7.20 (d, 1H), 7.12 (dd, 1H), 6.87 (s, 1H), 3.82 (s, 3H),3.74 (d, 1H), 2.30 (s, 3H), 1.20 (m, 1H), 0.55-0.90 (m, 4H).

EXAMPLE 139 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate

A mixture of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (298 mg, 0.80 mmol), ethyl 4-dimethylamino-2-oxo-but-3-enoate(171 mg, 1.0 mmol) and potassium carbonate (69 mg, 0.5 mmol) in ethanol(2 mL) was heated in a sealed tube in a microwave oven to 170° C. for0.5 h. The mixture was cooled, diluted with ethyl acetate (30 mL), andthen washed with saturated sodium carbonate solution (10 mL) and withbrine (10 mL). The organic layer was dried over sodium sulfate andevaporated under reduced pressure. The residual material was purified bychromatography on silica gel using dichloromethane/0-20% methanol aseluent to give the title compound (96 mg, 34%) as a pale-yellow solid.MS ISP (m/e): 354.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.67 (d,1H), 7.91 (d, 1H), 7.64 (s, 1H), 7.45 (s, 1H), 7.44 (d, 1H), 7.19 (d,1H), 7.02 (dd, 1H), 6.88 (s, 1H), 4.47 (q, 2H), 3.91 (s, 3H), 2.30 (s,3H), 1.44 (t, 3H).

EXAMPLE 140[4-(2-Chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (149mg, 0.4 mmol) and 1-(2-chloro-phenyl)-3-dimethylamino-propenone (105 mg,0.5 mmol) using in analogous manner the procedure described in example139. Obtained as a white solid (49 mg, 31%). MS ISP (m/e): 392.1[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.53 (d, 1H), 7.85 (d, 1H),7.68 (m, 1H), 7.63 (d, 1H), 7.51 (m, 1H), 7.40 (m, 2H), 7.34 (s, 1H),7.17 (d, 1H), 7.16 (s, 1H), 7.06 (dd, 1H), 6.87 (s, 1H), 3.84 (s, 3H),2.30 (s, 3H).

EXAMPLE 141 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-methyl-pyrimidine-4-carboxylate

The title compound was prepared fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (298mg, 0.8 mmol) and ethyl 4-dimethylamino-3-methyl-2-oxo-but-3-enoate (185mg, 1.0 mmol) using in analogous manner the procedure described inexample 139. Obtained as a white solid (30 mg, 8%). MS ISP (m/e): 368.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (s, 1H), 7.83 (d, 1H),7.63 (s, 1H), 7.31 (s, 1H), 7.17 (d, 1H), 7.02 (dd, 1H), 6.87 (s, 1H),4.46 (q, 2H), 3.89 (s, 3H), 2.41 (s, 3H), 2.30 (s, 3H), 1.44 (t, 3H).

EXAMPLE 142(4,5-Dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (149mg, 0.4 mmol) and 1-(2-chloro-phenyl)-3-dimethylamino-propenone (64 mg,0.5 mmol) using in analogous manner the procedure described in example139. Obtained as a white solid (12 mg, 10%). MS ISP (m/e): 310.2[(M+H)⁺]. NMR (CDCl₃, 300 MHz): δ (ppm)=8.14 (s, 1H), 7.75 (d, 1H), 7.62(s, 1H), 7.15 (d, 1H), 7.05 (m, 2H), 6.86 (s, 1H), 3.88 (s, 3H), 2.41(s, 3H), 2.30 (s, 3H), 2.18 (s, 3H).

EXAMPLE 143(4-Ethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared fromN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (149mg, 0.4 mmol) and 1-dimethylamino-pent-1-en-3-one using (64 mg, 0.5mmol) using in analogous manner the procedure described in example 139.Obtained as awhite solid (18 mg, 16%). MS ISP (m/e): 310.2 [(M+H)⁺]. NMR(CDCl₃, 300 MHz): δ (ppm)=8.33 (d, 1H), 7.81 (d, 1H), 7.63 (s, 1H), 7.25(s, 1H), 7.15 (d, 1H), 7.07 (dd, 1H), 6.87 (s, 1H), 6.67 (d, 1H), 3.87(s, 3H), 2.71 (q, 2H), 2.30 (s, 3H), 1.33 (t, 3H).

EXAMPLE 144(4-tert-Butyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A mixture of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (224 mg, 0.60 mmol), crude3-dimethylamino-1-pyridin-3-yl-propenone (118 mg, 0.60 mmol) andtriethylamine (0.50 mL, 3.60 mmol) in ethanol (1.5 mL) was heated in asealed tube in a microwave oven to 170° C. for 0.5 h. The mixture wascooled, diluted with ethyl acetate (30 mL), and then washed withsaturated sodium carbonate solution (5 mL) and with brine (5 mL). Theorganic layer was dried over sodium sulfate and evaporated under reducedpressure. The residual material was purified by chromatography on silicagel using dichloromethane/0-10% methanol as eluent to give the titlecompound (116 mg, 47%) as a white solid. MS ISP (m/e): 406.3 [(M+H)⁺].NMR (CDCl₃, 300 MHz): δ (ppm)=8.00 (d, 1H), 7.67 (s, 1H), 7.39 (s, 1H),7.18 (d, 1H), 7.11 (s, 1H), 6.97 (dd, 1H), 6.90 (s, 1H), 3.89 (s, 3H),2.30 (s, 3H), 1.39 (s, 9H).

EXAMPLES 145-150

Using in analogous manner the procedure described in example 144,heptane-3,5-dione, 6-methyl-heptane-2,4-dione,1-phenyl-butane-1,3-dione,4,4,4-trifluoro-1-pyrazin-2-yl-butane-1,3-dione,4,4,4-trifluoro-1-furan-2-yl-butane-1,3-dione, and2-benzoyl-cyclohexanone were reacted withN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate,respectively, to afford the following compounds:

EXAMPLE 145(4-Isobutyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 12% yield as light yellow solid. MS ISP (m/e): 352.3[(M+H)⁺]. NMR (CDCl₃, 300 MHz): δ (ppm)=7.96 (d, 1H), 7.62 (s, 1H), 7.14(d, 1H), 7.12 (s, 1H), 6.98 (dd, 1H), 6.87 (s, 1H), 6.51 (s, 1H), 3.87(s, 3H), 2.49 (d, 2H), 2.40 (s, 3H), 2.30 (s, 3H), 1.25 (m, 1H), 0.97(d, 6H).

EXAMPLE 146(4,6-Diethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 18% yield as light yellow solid. MS ISP (m/e): 338.2[(M+H)⁺]. NMR (CDCl₃, 300 MHz): δ (ppm)=8.00 (d, 1H), 7.62 (s, 1H), 7.15(d, 1H), 7.13 (s, 1H), 6.98 (dd, 1H), 6.87 (s, 1H), 6.55 (s, 1H), 3.88(s, 3H), 2.68 (q, 2H), 2.30 (s, 3H), 1.32 (t, 3H).

EXAMPLE 147[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-phenyl-pyrimidin-2-yl)-amine

Obtained in 11% yield as off-white solid. MS ISP (m/e): 372.2 [(M+H)⁺].NMR (CDCl₃, 300 MHz): δ (ppm)=8.09 (m, 2H), 8.02 (d, 1H), 7.64 (s, 1H),7.18 (d, 1H), 7.12 (s, 1H), 7.05 (dd, 1H), 6.89 (s, 1H), 3.90 (s, 3H),2.51 (s, 3H), 2.31 (s, 3H).

EXAMPLE 148[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-pyrazin-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-amine

Obtained in 4% yield as light yellow solid. MS ISP (m/e): 428.2[(M+H)⁺]. NMR (CDCl₃, 300 MHz): δ (ppm)=9.68 (s, 1H), 8.77 and 8.73 (2d, 2×1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.64 (s, 1H), 7.24 (d, 1H), 7.09(dd, 1H), 6.90 (s, 1H), 3.93 (s, 3H), 2.31 (s, 3H).

EXAMPLE 149(4-Furan-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 3% yield as light yellow solid. MS ISP (m/e): 416.3[(M+H)⁺]. NMR (CDCl₃, 300 MHz): δ (ppm)=8.00 (s, 1H), 7.66 (s, 2H), 7.45(s, 1H), 7.41 (s, 1H), 7.31 (d, 1H), 7.20 (d, 1H), 6.99 (dd, 1H), 6.64(m, 1H), 3.91 (s, 3H), 2.31 (s, 3H).

EXAMPLE 150[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-amine

Obtained in 61% yield as light yellow solid. MS ISP (m/e): 412.3[(M+H)⁺]. NMR (CDCl₃, 300 MHz): δ (ppm)=8.04 (d, 1H), 7.62 (s, 1H), 7.61(m, 2H), 7.46 (m, 3H), (s, 1H), 7.20 (s, 1H), 7.12 (d, 1H), 6.94 (dd,1H), 6.86 (s, 1H), 3.81 (s, 3H), 2.88 and 2.70 (2 t, 2×2H), 2.30 (s,3H), 1.91 and 1.76 (2 m, 2×2H).

EXAMPLE 151 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidine-4-carboxylate

A mixture of N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinedinitrate (371 mg, 1.0 mmol), ethyl 2,4-dioxo-pentanoate (158 mg, 1.0mmol) and potassium carbonate (69 mg, 0.5 mmol) in ethanol (2 mL) washeated in a sealed tube in a microwave oven to 170° C. for 0.5 h. Themixture was cooled, diluted with ethyl acetate (50 mL), and then washedwith water (20 mL) and with brine (20 mL). The organic layer was driedover sodium sulfate and evaporated under reduced pressure. The residualmaterial was purified by chromatography on silica gel usingdichloromethane/0-10% methanol as eluent to give the title compound (229mg, 62%) as a yellow solid. MS ISP (m/e): 368.2 [(M+H)⁺]. ¹H NMR (CDCl₃,300 MHz): δ (ppm)=8.04 (d, 1H), 7.64 (s, 1H), 7.40 (s, 1H), 7.34 (s,1H), 7.17 (d, 1H), 6.98 (dd, 1H), 6.87 (s, 1H), 4.46 (q, 2H), 3.91 (s,3H), 2.54 (s, 3H), 2.30 (s, 3H), 1.43 (t, 3H).

EXAMPLES 152-164

Using in analogous manner the procedure described in example 151,pentane-2,4-dione, 1,1,1,5,5,5-hexafluoro-pentane-2,4-dione,2,6-dimethyl-heptane-3,5-dione, 1-(2-chloro-phenyl)-butane-1,3-dione,ethyl 2,4-dioxo-4-thiophen-2-yl-butyrate, ethyl 2,4-dioxo-hexanoate,ethyl 5-methyl-2,4-dioxo-hexanoate, ethyl5,5-dimethyl-2,4-dioxo-hexanoate, ethyl4-cyclopropyl-2,4-dioxo-butyrate, ethyl2,4-dioxo-4-pyridin-2-yl-butyrate, ethyl2,4-dioxo-4-(4-trifluoromethyl-phenyl)-butyrate, and ethyl5-(4-chloro-phenyl)-2,4-dioxo-pentanoate were reacted withN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate,respectively, to afford the following compounds:

EXAMPLE 152(4,6-Dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 20% yield as off-white solid. MS ISP (m/e): 310.2 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.89 (d, 1H), 7.62 (s, 1H), 7.15 (d,1H), 7.12 (s, 1H), 7.03 (dd, 1H), 6.87 (s, 1H), 6.56 (s, 1H), 3.87 (s,3H), 2.40 (s, 6H), 2.30 (s, 3H).

EXAMPLE 153(4,6-Bis-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 46% yield as yellow solid. MS ISP (m/e): 418.2 [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm) 7.93 (d, 1H), 7.77 (s, 1H), 7.67 (s, 1H),7.35 (s, 1H), 7.23 (d, 1H), 6.97 (dd, 1H), 6.90 (s, 1H), 3.89 (s, 3H),2.31 (s, 3H).

EXAMPLE 154(4-Isopropyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 52% yield as light yellow solid. MS ISP (m/e): 392.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.00 (d, 1H), 7.64 (s, 1H),7.40 (s, 1H), 7.18 (d, 1H), 6.97 (s, 1H), 6.94 (dd, 1H), 6.88 (s, 1H),3.89 (s, 3H), 3.01 (m, 1H), 2.30 (s, 3H), 1.34 (d, 6H).

EXAMPLE 155(4,6-Diisopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 12% yield as off-white solid. MS ISP (m/e): 366.2[(M+H)⁺].)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.10 (d, 1H), 7.63 (s,1H), 7.15 (s, 1H), 7.14 (d, 1H), 6.94 (dd, 1H), 6.88 (s, 1H), 6.55 (s,1H), 3.89 (s, 3H), 2.88 (m, 2H), 2.30 (s, 3H), 1.30 (d, 12H).

EXAMPLE 156[4-(2-Chloro-phenyl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Obtained in 8% yield as light yellow solid. MS ISP (m/e): 406.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.99 (d, 1H), 7.64 (m, 1H),7.62 (s, 1H), 7.50 (m, 1H), 7.38 (m, 2H), 7.29 (s, 1H), 7.15 (d, 1H),7.03 (s, 1H), 7.01 (dd, 1H), 6.86 (s, 1H), 3.89 (s, 3H), 2.52 (s, 3H),2.30 (s, 3H).

EXAMPLE 157 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyrimidine-4-carboxylate

Obtained in 15% yield as light yellow solid. MS ISP (m/e): 436.1[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.05 (d, 1H), 7.87 (d, 1H),7.77 (s, 1H), 7.66 (s, 1H), 7.59 (d, 1H), 7.51 (s, 1H), 7.20 (s, 1H),7.20 (d, 1H), 7.15 (d, 1H), 7.03 (s, 1H), 6.98 (dd, 1H), 6.90 (s, 1H),4.51 (q, 2H), 3.99 (s, 3H), 2.31 (s, 3H), 1.47 (t, 3H).

EXAMPLE 158 Ethyl6-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate

Obtained in 38% yield as light yellow solid. MS ISP (m/e): 382.4[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.06 (d, 1H), 7.63 (s, 1H),7.43 (s, 1H), 7.35 (s, 1H), 7.17 (d, 1H), 6.96 (dd, 1H), 6.88 (s, 1H),4.47 (q, 2H), 3.91 (s, 3H), 2.82 (q, 2H), 2.31 (s, 3H), 1.44 (t, 3H),1.37 (t, 3H).

EXAMPLE 159 Ethyl6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate

Obtained in 49% yield as light yellow solid. MS ISP (m/e): 396.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.10 (d, 1H), 7.63 (s, 1H),7.45 (s, 1H), 7.35 (s, 1H), 7.17 (d, 1H), 6.94 (dd, 1H), 6.88 (s, 1H),4.47 (q, 2H), 3.91 (s, 3H), 3.03 (m, 1H), 2.30 (s, 3H), 1.44 (t, 3H),1.35 (d, 6H).

EXAMPLE 160 Ethyl6-tert-butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate

Obtained in 24% yield as light yellow solid. MS ISP (m/e): 410.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.05 (d, 1H), 7.63 (s, 1H),7.49 (s, 1H), 7.47 (s, 1H), 7.17 (d, 1H), 6.95 (dd, 1H), 6.88 (s, 1H),4.48 (q, 2H), 3.91 (s, 3H), 2.30 (s, 3H), 1.44 (t, 3H), 1.40 (s, 9H).

EXAMPLE 161 Ethyl6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate

Obtained in 23% yield as light yellow solid. MS ISP (m/e): 394.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.98 (d, 1H), 7.63 (s, 1H),7.38 (s, 1H), 7.36 (s, 1H), 7.15 (d, 1H), 6.87 (m, 2H), 4.48 (q, 2H),3.91 (s, 3H), 2.30 (s, 3H), 2.05 (m, 1H), 1.44 (t, 3H), 1.40 (s, 9H),1.25 (m, 2H), 1.15 (m, 2H).

EXAMPLE 162 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrimidine-4-carboxylate

Obtained in 14% yield as light yellow solid. MS ISP (m/e): 431.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.78 (dd, 1H), 8.45 (s, 1H),8.44 (d, 1H), 8.01 (d, 1H), 7.88 (td, 1H), 7.66 (s, 1H), 7.60 (s, 1H),7.46 (dd, 1H), 7.22 (d, 1H), 7.08 (dd, 1H), 6.90 (s, 1H), 4.51 (q, 2H),3.94 (s, 3H), 2.31 (s, 3H), 1.47 (t, 3H).

EXAMPLE 163 Ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate

Obtained in 26% yield as light yellow solid. MS ISP (m/e): 498.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.26 (d, 2H), 8.01 (d, 1H),7.92 (s, 1H), 7.79 (d, 2H), 7.66 (s, 1H), 7.59 (s, 1H), 7.22 (d, 1H),7.07 (dd, 1H), 6.90 (s, 1H), 4.52 (q, 2H), 3.93 (s, 3H), 2.31 (s, 3H),1.47 (t, 3H).

EXAMPLE 164 Ethyl6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate

Obtained in 33% yield as light yellow solid. MS ISP (m/e): 478.1[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.90 (s, 1H), 7.63 (s, 1H),7.44 (s, 1H), 7.31 (d, 2H), 7.29 (s, 1H), 7.21 (d, 2H), 7.16 (d, 1H),6.96 (dd, 1H), 6.87 (s, 1H), 4.45 (q, 2H), 3.83 (s, 3H), 2.30 (s, 3H),1.42 (t, 3H).

EXAMPLE 1652-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-propan-2-ol

To a solution of ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidine-4-carboxylate(184 mg, 0.5 mmol) in tetrahydrofurane (10 mL) was added at 0° C. over 2min a 3 M solution of methylmagnesiumchloride in tetrahydrofurane (0.55mL, 1.65 mmol). The reaction mixture was stirred at 0° C. for 15 minfollowed by 1 h at. The mixture was poured on saturated sodium carbonatesolution (20 mL) and the product was extracted with ethyl acetate (40mL). The organic layer was washed with brine (20 mL), dried over sodiumsulfate and evaporated under reduced pressure. The residual material wascrystallized from dichloromethane/heptane to give the title compound togive the title compound (105 mg, 59%) as an off-white solid. MS ISP(m/e): 354.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.76 (d, 1H),7.63 (s, 1H), 7.18 (d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 6.75 (s, 1H),4.04 (s, 1H), 3.88 (s, 3H), 2.47 (s, 3H), 2.30 (s, 3H), 1.53 (s, 6H).

EXAMPLE 166-173

Using in analogous manner the procedure described in example 165, theproducts of examples 158, 159, 161, 160, 157, 141, 162, and 164 werereacted with methylmagnesium-chloride, respectively, to give, afterpurification of the crude products by crystallization fromdichloromethane/heptane or by chromatography on silica gel usingdichloro-methane/0-10% methanol as eluent, the following compounds:

EXAMPLE 1662-{6-Ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Obtained in 35% yield as light yellow solid. MS ISP (m/e): 368.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.84 (d, 1H), 7.63 (s, 1H),7.21 (s, 1H), 7.17 (d, 1H), 7.00 (dd, 1H), 6.88 (s, 1H), 6.74 (s, 1H),4.10 (s, 1H), 3.88 (s, 3H), 2.43 (q, 2H), 2.30 (s, 3H), 1.54 (s, 6H),1.34 (t, 3H).

EXAMPLE 1672-{6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Obtained in 49% yield as light yellow solid. MS ISP (m/e): 382.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.91 (d, 1H), 7.64 (s, 1H),7.19 (s, 1H), 7.17 (d, 1H), 6.98 (dd, 1H), 6.88 (s, 1H), 6.74 (s, 1H),4.18 (s, 1H), 3.89 (s, 3H), 2.94 (m, 1H), 2.30 (s, 3H), 1.54 (s, 6H),1.33 (d, 6H).

EXAMPLE 1682-{6-Cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Obtained in 31% yield as light white solid. MS ISP (m/e): 380.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.84 (d, 1H), 7.65 (s, 1H),7.16 (d, 1H), 7.12 (s, 1H), 6.90 (dd, 1H), 6.88 (s, 1H), 6.78 (s, 1H),4.20 (s, 1H), 3.89 (s, 3H), 2.31 (s, 3H), 1.96 (m, 1H), 1.53 (s, 6H),1.22 (m, 2H), 1.09 (m, 2H).

EXAMPLE 1692-{6-tert-Butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Obtained in 17% yield as light yellow solid. MS ISP (m/e): 396.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.94 (d, 1H), 7.64 (s, 1H),7.19 (s, 1H), 7.17 (d, 1H), 6.98 (dd, 1H), 6.89 (s, 1H), 6.87 (s, 1H),4.17 (s, 1H), 3.89 (s, 3H), 2.30 (s, 3H), 1.54 (s, 6H), 1.38 (s, 9H).

EXAMPLE 1702-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyrimidin-4-yl}-propan-2-ol

Obtained in 62% yield as light yellow solid. MS ISP (m/e): 422.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.90 (d, 1H), 7.78 (d, 1H),7.64 (s, 1H), 7.53 (d, 1H), 7.20 (d, 1H), 7.19 (s, 1H), 7.18 (m, 1H),7.01 (dd, 1H), 6.90 (s, 1H), 4.00 (s, 1H), 3.96 (s, 3H), 2.31 (s, 3H),1.58 (s, 6H).

EXAMPLE 1712-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-methyl-pyrimidin-4-yl}-propan-2-ol

Obtained in 54% yield as light yellow solid. MS ISP (m/e): 354.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.22 (s, 1H), 7.63 (s, 1H),7.53 (d, 1H), 7.18 (d, 1H), 7.13 (s, 1H), 7.03 (dd, 1H), 6.87 (s, 1H),5.30 (s, 1H), 3.87 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H), 1.59 (s, 6H).

EXAMPLE 1722-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrimidin-4-yl}-propan-2-ol

Obtained in 82% yield as light yellow solid. MS ISP (m/e): 417.3[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.75 (dd, 1H), 8.44 (d, 1H),7.94 (s, 1H), 7.87 (td, 1H), 7.77 (d, 1H), 7.66 (s, 1H), 7.43 (dd, 1H),7.24 (d, 1H), 7.13 (dd, 1H), 6.91 (s, 1H), 4.29 (s, 1H), 3.91 (s, 3H),2.31 (s, 3H), 1.63 (s, 6H).

EXAMPLE 1732-{6-(4-Chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Obtained in 47% yield as off-white solid. MS ISP (m/e): 464.2 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.67 (d, 1H), 7.62 (s, 1H), 7.30 (d,2H), 7.22 (d, 2H), 7.15 (d, 1H), 6.99 (dd, 1H), 6.88 (s, 1H), 6.73 (s,1H), 3.99 (s, 2H), 3.94 (br s, 1H), 3.78 (s, 3H), 2.30 (s, 3H), 1.51 (s,6H).

EXAMPLE 1742-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

To a solution of ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate(597 mg, 1.2 mmol) in tetrahydro-furane (25 mL) was added at 0° C. over2 min a 3 M solution of methylmagnesiumchloride in tetrahydrofurane(1.68 mL, 5.04 mmol). The reaction mixture was stirred at 0° C. for 15min followed by 1.5 h at. The mixture was poured on saturated sodiumcarbonate solution (20 mL) and the product was extracted with ethylacetate (80 mL). The organic layer was washed with brine (20 mL), driedover sodium sulfate and evaporated under reduced pressure. The residualmaterial was purified by chromatography on silica gel usingdichloromethane/0-10% methanol as eluent. Following a more liopophilicby-product (54 mg, example 175) the title compound was eluted andcrystallized from dichloromethane/diethyl ether to give a white solid(314 mg, 54%). MS ISP (m/e): 484.4 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.21 (d, 2H), 7.82 (d, 1H), 7.77 (d, 2H), 7.66 (s, 1H), 7.36 (s,2H), 7.22 (d, 1H), 7.10 (dd, 1H), 6.90 (s, 1H), 3.90 (s, 3H), 3.84 (brs, 1H), 2.31 (s, 3H), 1.56 (s, 6H).

EXAMPLE 1751-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-ethanone

Obtained as by-product in the preparation of example 174 in 10% yield aslight yellow solid. MS ISP (m/e): 468.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=8.26 (d, 2H), 7.84 (s, 1H), 7.82 (d, 1H), 7.79 (d, 2H),7.67 (s, 1H), 7.52 (s, 1H), 7.26 (m, 2H), 7.17 (dd, 1H), 6.91 (s, 1H),3.92 (s, 3H), 2.76 (s, 3H), 2.32 (s, 3H).

EXAMPLE 1763-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-pentan-3-ol

To a solution of2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylicacid ethyl ester (46 mg, 0.13 mmol) in tetrahydrofurane (2.5 mL) wasadded at 0° C. over 1 min a 1 M solution of ethylmagnesiumbromide intetrahydrofurane (0.43 mL, 0.43 mmol). The reaction mixture was stirredat 0° C. for 15 min followed by 1 h at. The mixture was poured onsaturated sodium carbonate solution (5 mL) and the mixture was extractedwith ethyl acetate (40 mL). The organic layer was washed with brine (20mL), dried over sodium sulfate and evaporated under reduced pressure.The residual material was purified by chromatography on silica gel usingdichloromethane/0-10% methanol as eluent to give the title compound (4mg, 9%) as yellow oil. MS ISP (m/e): 368.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=8.42 (d, 1H), 7.66 (d, 1H), 7.65 (s, 1H), 7.39 (s, 1H),7.20 (d, 1H), 7.06 (dd, 1H), 6.89 (s, 1H), 6.79 (d, 1H), 4.32 (br s,1H), 3.88 (s, 3H), 2.31 (s, 3H), 2.35 (m, 4H), 0.76 (t, 6H).

EXAMPLE 1771-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl

Obtained as by-product in the preparation of example 177 in 3% yield aswhite solid. MS ISP (m/e): 340.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.41 (d, 1H), 7.66 (s, 2H), 7.20 (s, 1H), 7.17 (d, 1H), 7.09 (dd,1H), 6.88 (s, 1H), 6.78 (d, 1H), 4.60 (brt, 1H), 3.87 (s, 3H), 2.30 (s,3H), 1.6-1.8 (m, 2H), 0.99 (t, 3H).

EXAMPLE 178Dicyclopropyl-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-methanol

To a solution of2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylicacid ethyl ester (46 mg, 0.13 mmol) in tetrahydrofurane (2.5 mL) wasadded at 0° C. over 1 min a 0.5 M solution ofcyclopropylmagnesiumbromide in tetrahydrofurane (1.02 mL, 0.51 mmol).The reaction mixture was stirred at 0° C. for 15 min followed by 1.5 hat. The mixture was poured on saturated sodium carbonate solution (5 mL)and the mixture was extracted with ethyl acetate (40 mL). The organiclayer was washed with brine (20 mL), dried over sodium sulfate andevaporated under reduced pressure. The residual material was purified bychromatography on silica gel using dichloromethane/0-10% methanol aseluent to give the title compound as light yellow foam (44 mg, 88%). MSISP (m/e): 392.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (d,1H), 7.64 (s, 1H), 7.56 (d, 1H), 7.23 (s, 1H), 7.19 (d, 1H), 7.08 (dd,1H), 7.00 (d, 1H), 6.88 (s, 1H), 4.15 (s, 1H), 3.87 (s, 3H), 2.30 (s,3H), 1.14 (m, 2H), 0.70, 0.50, 0.35, 0.25 (4 m, 4×2H).

EXAMPLE 1792-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluoro-phenyl)-pyrimidin-4-yl]-propan-2-ol

a) Ethyl 2,4-dioxo-4-(3,4,5-trifluoro-phenyl)-butyrate

Potassium tert.-butoxide (1.12 g, 10.0 mmol) was added to a solution of1-(3,4,5-trifluoro-phenyl)-ethanone (1.74 g, 10.0 mmol) and diethyloxalate (1.49 mL, 11.0 mmol) in diethyl ether (20 mL) cooled to 0° C.The heterogenous mixture was stirred for 15 min at 0° C. followed by 15h at. The mixture was partitioned between 3 N hydrochloric acid (20 mL)and diethyl ether (50 mL). The organic layer was washed with brine (20mL), dried over sodium sulfate and evaporated under reduced pressure andthe residual oil was crystallized from diethyl ether/heptane to give thetitle compound as a white solid.

2-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluoro-phenyl)-pyrimidin-4-yl]-propan-2-ol

Ethyl 2,4-dioxo-4-(3,4,5-trifluoro-phenyl)-butyrate (274 mg, 1.0 mmol)was reacted withN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate (298mg, 0.80 mmol) in analogous manner as described in example 139, and theresulting product was subjected in analogous manner to the proceduredescribed in example 165 to give the title compound light yellow solid(35 mg, 9%). MS ISP (m/e): 470.4 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.81 (m, 2H), 7.78 (d, 1H), 7.75 (s, 1H), 7.66 (s, 1H), 7.35 (s,1H), 7.22 (d, 1H), 7.04 (dd, 1H), 6.90 (s, 1H), 3.91 (s, 3H), 3.76 (brs, 1H), 2.31 (s, 3H), 1.61 (s, 6H).

EXAMPLE 1802-{6-(2,4-Dichloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Ethyl 3-(2,4-dichloro-phenyl)-3-oxo-propionate (145 mg, 0.5 mmol) wassubjected in analogous manner to the procedure described in example179b) to give the title compound as light yellow foam (42 mg, 22%). MSISP (m/e): 484.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.82 (d,1H), 7.64 (d, 1H), 7.64 (s, 1H), 7.53 (d, 1H), 7.36 (dd, 1H), 7.33 (s,1H), 7.23 (s, 1H), 7.18 (d, 1H), 7.04 (dd, 1H), 6.88 (s, 1H), 3.95 (brs, 1H), 3.84 (s, 3H), 2.30 (s, 3H), 1.59 (s, 6H).

EXAMPLE 1812-{6-(4-Chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Ethyl 3-(4-chloro-phenyl)-3-oxo-propionate (127 mg, 0.5 mmol) wassubjected in analogous manner to the procedure described in example179b) to give the title compound as light yellow foam (42 mg, 13%). MSISP (m/e): 450.2 [(M+H)⁺].)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.05 (d,2H), 7.84 (d, 1H), 7.66 (s, 1H), 7.48 (d, 2H), 7.31 (s, 1H), 7.29 (s,1H), 7.21 (d, 1H), 7.06 (dd, 1H), 6.89 (s, 1H), 3.94 (br s, 1H), 3.89(s, 3H), 2.31 (s, 3H), 1.61 (s, 6H).

EXAMPLE 1822-{6-(2-Chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Ethyl 3-(2-chloro-phenyl)-3-oxo-propionate (127 mg, 0.5 mmol) wassubjected in analogous manner to the procedure described in example179b) to give the title compound as light yellow foam (33 mg, 18%). MSISP (m/e): 450.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.88 (d,1H), 7.66 (m, 1H), 7.64 (s, 1H), 7.52 (m, 1H), 7.41 (m, 2H), 7.34 (s,1H), 7.25 (s, 1H), 7.18 (d, 1H), 7.04 (dd, 1H), 6.88 (s, 1H), 4.08 (brs, 1H), 3.84 (s, 3H), 2.30 (s, 3H), 1.60 (s, 6H).

EXAMPLE 1832-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5,6,7,8-tetrahydro-quinazolin-4-yl}-propan-2-ol

Ethyl oxo-(2-oxo-cyclohexyl)-acetate (198 mg, 1.0 mmol) was subjected inanalogous manner to the procedure described in example 179b) to give thetitle compound as light yellow foam (15 mg, 5%). MS ISP (m/e): 394.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.67 (d, 1H), 7.63 (s, 1H),7.45 (s, 1H), 7.13 (d, 1H), 7.00 (dd, 1H), 6.88 (s, 1H), 3.87 (s, 3H),2.75-2.95 (m, 4H), 2.30 (s, 3H), 1.75-1.95 (m, 4H), 1.58 (s, 6H).

EXAMPLE 184(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

The title compound was prepared from4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) and3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine (88 mg, 0.57 mmol) usingin analogous manner the procedure described in example 43b). Columnchromatography (15 g silica, dichloromethane+3.7% methanol v/v) affordedthe title compound (148 mg, 86%) as a white solid. MS ISP (m/e): 374.4[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.98 (dd, 1H), 7.65 (s, 1H),7.26 (m, 8H), 6.92 (s, 1H), 6.53 (s, 1H), 3.98 (s, 2H), 2.38 8s, 3H),2.31 (s, 3H). Mp 155-158° C.

EXAMPLE 185(6-Ethoxy-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

A solution of(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine(63 mg, 0.2 mmol) and 21% sodium ethanolate solution in ethanol (112 uL,0.3 mmol) was heated to 200° C. for 30 minutes in a microwave oven. Thesame amount of sodium ethanolate solution was added and the reaction wasagain heated to 200° C. for 30 minutes in a microwave oven. Water wasadded and the reaction was extracted twice with ethyl acetate. Thecombined organic layers were washed with brine, dried over sodiumsulfate, filtered and the solvent was evaporated under reduced pressure.The residue was purified by column chromatography on silica gel usingdichloromethane/methanol (19:1 v/v) as eluent to yield the titlecompound as a light brown solid (25 mg, 39%). MS ISP (m/e): 325.2 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.64 (s, 1H), 7.45 (t, 1H),7.34 (s, 1H), 7.15 (d, 1H), 6.92 (d, 1H), 6.87 (s, 1H), 6.50 (s, 1H),6.37 (d, 1H), 6.24 (d, 1H), 4.35 (q, 2H), 3.83 (s, 3H), 2.30 (s, 3H),1.41 (t, 3H).

EXAMPLE 186N-(4-Fluoro-phenyl)-N′-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyridine-2,6-diamine

a)(6-Chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 62 from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2,6-dichloropyridine. The title compound was obtained as a yellow solid(Yield=60%). MS ISP (m/e): 315.1 & 317.1 (100 & 37) [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=7.63 (s, 1H), 7.48 (t, 1H), 7.37 (s, 1H), 7.18(d, 1H), 6.95-6.80 (m, 2H), 6.82 (d, 1H), 6.72 (d, 1H), 6.64 (s, 1H),3.86 (s, 3H), 2.30 (s, 3H).

b)N-(4-Fluoro-phenyl)-N′-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-fluoroaniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a colorless foam (Yield=17%). MS ISP(m/e): 390.4 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.02 (s,1H), 8.83 (s, 1H), 7.64 (d, 1H), 7.60-7.50 (m, 2H), 7.45-7.35 (m, 2H),7.24 (dxd, 1H), 7.15 (d, 1H), 7.07 (t, 1H), 7.02 (s, 1H), 6.24 (qa, 1H),3.59 (s, 3H), 2.15 (s, 3H).

EXAMPLE 187N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-(trifluoromethoxy)aniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish solid (Yield=10%). MS ISP(m/e): 456.3 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.63 (s, 1H), 7.45-7.35 (m, 3H),7.20-7.10 (m, 3H), 6.94 (dxd, 1H), 6.87 (s, 1H), 6.44 (s, 1H), 6.36 (s,1H), 6.34 (dxd, 1H), 3.73 (s, 3H), 2.30 (s, 3H).

EXAMPLE 188N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethoxy-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 3-(trifluoromethoxy)aniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish solid (Yield=3%). MS ISP(m/e): 456.3 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.63 (s, 1H), 7.45-7.35 (m, 3H),7.20-7.10 (m, 2H), 6.96 (dxd, 1H), 6.90-6.80 (m 2H), 6.43 (s, 1H), 6.42(s, 1H), 6.35 (dxd, 1H), 3.74 (s, 3H), 2.30 (s, 3H).

EXAMPLE 189N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-pentafluorosulfanyl-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-aminosulfurpentafluoride and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a colorless solid (Yield=44%). MS ISP(m/e): 498.3 (100) [(M+H)⁺].

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.70-7.60 (m, 3H), 7.55-7.40 (m, 3H),7.20-7.10 (m, 2H), 6.57 (s, 1H), 6.48 (s, 1H), 6.42 (d, 1H), 6.37 (d,1H), 3.72 (s, 3H), 2.30 (s, 3H).

EXAMPLE 190N-[3-Methoxy-4-(4-methyl-imidazole-1-yl)-phenyl)]-N′-(3-sulfurpentafluoride-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 3-aminosulfurpentafluoride and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a slightly orange solid (Yield=30%).MS ISP (m/e): 498.1 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.84 (s, 1H), 7.63 (s, 1H), 7.60-7.50 (m, 1H), 7.44 (t, 1H),7.40-7.30 (m, 2H), 7.20-7.10 (m, 2H), 6.95 (dxd, 1H), 6.87 (s, 1H), 6.45(s, 1H), 6.43 (s, 1H), 6.39 (d, 1H), 6.30 (d, 1H), 3.71 (s, 3H), 3.30(s, 3H).

EXAMPLE 191N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethyl-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 3-trifluoromethylaniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish solid (Yield=48%). MS ISP(m/e): 440.3 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.24 (s,1H), 9.13 (s, 1H), 7.93 (s, 1H), 7.82 (d, 1H), 7.65 (s, 1H), 7.55-7.40(m, 2H), 7.36 (d, 1H), 7.25-7.10 (m, 3H), 7.00 (s, 1H), 6.32 (t, 2H),3.54 (s, 3H), 2.15 (s, 3H).

EXAMPLE 192N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethyl-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-trifluoromethylaniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish solid (Yield=18%). MS ISN(m/e): 438.4 (100) [(M−H)⁻]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.64 (s,1H), 7.60-7.45 (m, 4H), 7.44 (d, 1H), 7.20-7.10 (m, 2H), 6.95 (dxd, 1H),6.88 (s, 1H), 6.52 (s, 1H), 6.46 (s, 1H), 6.39 (t, 2H), 3.73 (s, 3H),2.31 (s, 3H).

EXAMPLE 193N-(3-Fluoro-phenyl)-N′-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyridine-2,6-diamine

Prepared in analogy to example 62 from 3-fluoroaniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish solid (Yield=24%). MS ISP(m/e): 390.3 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.10 (svery broad, 2H), 7.70-7.50 (m, 2H), 7.45 (t, 2H), 7.39 (s, 1H),7.30-7.10 (m, 4H), 7.02 (s, 1H), 6.63 (t broad, 1H), 6.30 (t, 2H), 3.62(s, 3H), 2.14 (s broad, 3H).

EXAMPLE 194N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-methyl-N′-phenyl-pyridine-2,6-diamine

Prepared in analogy to example 62 from N-methylaniline and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish solid (Yield=16%). MS ISP(m/e): 386.2 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.06 (s,1H), 7.68 (d, 1H), 7.61 (s, 1H), 7.50-7.35 (m, 3H), 7.35-7.15 (m, 4H),7.09 (1H), 6.99 (s, 1H), 6.19 (d, 1H), 5.95 (d, 1H), 3.70 (s, 3H), 3.44(s, 3H), 2.14 (s, 3H).

EXAMPLE 195N-Benzyl-N′-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyridine-2,6-diamine

Prepared in analogy to example 62 from benzylamine and(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brown solid (Yield=11%). MS ISP(m/e): 386.2 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=8.88 (s,1H), 7.67 (d, 1H), 7.59 (d, 1H), 7.35-7.25 (m, 3H), 7.35-7.10 (m, 4H),7.06 (d, 1H), 6.97 (d, 1H), 6.90 (t, 1H), 6.00 (d, 1H), 5.95 (d, 1H),4.54 (d, 2H), 3.65 (s, 3H), 2.13 (s, 3H).

EXAMPLE 196N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine

a)(6-Chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 62 from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and2,6-dichloro-4-trifluoromethyl-pyridine. The title compound was obtainedas a yellowish solid (Yield=30%). MS ISP (m/e): 383.1 (39) [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm)=7.67 (d, 1H), 7.39 (d, 1H), 7.23 (d, 1H),7.11 (s, 1H), 6.99 (s, 1H), 6.965-6.85 (m, 3H), 3.87 (s, 3H), 2.31 (s,3H).

b)N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-(trifluoromethoxy)aniline and(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a yellowish solid (Yield=33%). MS ISP(m/e): 524.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.65 (d,1H), 7.42 (d, 2H), 7.19 (d, 2H), 7.13 (d, 1H), 6.97 (dxd, 1H), 6.89 (s,1H), 6.65 (s, 1H), 6.58 (s, 1H), 6.48 (s, 1H), 6.42 (s, 1H), 3.74 (s,3H), 2.31 (s, 3H).

EXAMPLE 197N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine

Prepared in analogy to example 62 from 3-(trifluoromethoxy)aniline and(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a yellowish solid (Yield=63%). MS ISP(m/e): 524.3 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.65 (d,1H), 7.42 (s broad, 1H), 7.35-7.25 (m, 2H), 7.19 (d, 1H), 7.12 (d, 1H),7.00 (dxd, 1H), 6.95-6.85 (m, 2H), 6.77 (d, 1H), 6.50 (s, 1H), 6.46 (s,1H), 3.73 (s, 3H), 2.30 (s, 3H).

EXAMPLE 198N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N′-(4-trifluoromethyl-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-trifluoromethylaniline and(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a yellowish solid (Yield=61%). MS ISP(m/e): 508.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.65 (d,1H), 7.65-7.45 (AA′BB′-System, 4H), 7.21 (d, 1H), 7.13 (d, 1H), 6.98(dxd, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 6.75 (s, 1H), 6.54 (s, 1H), 6.50(s, 1H), 3.72 (s, 3H), 2.31 (s, 3H).

EXAMPLE 199N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N′-(3-trifluoromethyl-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 3-trifluoromethylaniline and(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a yellowish solid (Yield=60%). MS ISP(m/e): 508.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.74 (s,1H), 7.65 (d, 1H), 7.60 (d, 1H), 7.43 (t, 1H), 7.30 (d, 1H), 7.18 (d,1H), 7.11 (d, 1H), 7.00 (dxd, 1H), 6.89 (s, 1H), 6.87 (s, 1H), 6.82 (s,1H), 6.51 (s, 1H), 6.44 (s, 1H9, 3.70 (s, 3H), 3.31 (s, 3H).

EXAMPLE 200N-(4-Sulfurpentafluoride-phenyl)-N′-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-aminosulfurpentafluoride and(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a yellowish solid (Yield=43%). MS ISP(m/e): 566.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.69 (s,1H), 7.66 (s, 2H), 7.52 (d, 2H), 7.20 (d, 1H), 7.13 (d, 1H), 7.10 (s,1H), 6.97 (dxd, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 6.56 (s, 1H), 6.51 (s,1H), 3.71 (s, 3H), 2.31 (s, 3H).

EXAMPLE 201N,N′-Bis-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-pyridine-2,6-diamine

Prepared in analogy to example 62 from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a yellowish solid (Yield=18%). MS ISP(m/e): 550.4 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.63 (d,2H), 7.24 (d, 2H), 7.15 (d, 2H), 6.88 (s, 2H), 6.66 (s, 2H), 6.50 (s,2H), 3.73 (s, 6H), 2.30 (, 6H).

EXAMPLE 202[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethoxy-phenylamino)-pyridin-4-yl]-methanol

a) 4-(tert-Butyl-dimethyl-silanyloxymethyl)-2,6-dichloro-pyridine

A solution of 2,6-dichloropyridine-4-methanol (150 mg, 0.84 mmol),tert-butyl-chloro-dimethyl-silane (152 mg, 1.01 mmol) and imidazol (143mg, 2.01 mmol) in 1 mL of N,N-dimethylformamide was stirred overnightat. The reaction mixture was concentrated in the rotatory evaporator,water was added and the slurry extracted with ethyl acetate.Chromatography on amino-modified silica gel (Merck HPTLC Silica Gel 60NH2F254S) using heptane/ethylacetate (gradient 0 to 50% ethyl acetate)gave the pure title compound as a colorless solid (160 mg, 65%). MS ISP(m/e): 292.1 & 294.0 (100 & 97) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.21 (s, 2H), 4.70 (s, 2H), 0.95 (s, 9H), 0.12 (6H).

b)[4-(tert-Butyl-dimethyl-silanyloxymethyl)-6-chloro-pyridin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine

Prepared in analogy to example 62 from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and4-(tert-butyl-dimethyl-silanyloxymethyl)-2,6-dichloro-pyridine. Thetitle compound was obtained as a yellowish solid (Yield=31%). ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=7.64 (s, 1H), 7.36 (d, 1H), 7.17 (d, 1H),6.95-6.85 (m, 2H), 6.75 (s, 1H), 6.73 (s, 1H), 6.68 (s broad, 1H), 4.65(s, 2H), 3.86 (s, 3H), 2.30 (s, 3H), 0.94 (s, 9H), 0.11 (s, 6H).

c)4-(tert-Butyl-dimethyl-silanyloxymethyl)-N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine

Prepared in analogy to example 62 from 4-(trifluoromethoxy)aniline and[4-(tert-butyl-dimethyl-silanyloxymethyl)-6-chloro-pyridin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.The title compound was obtained as a brownish gum (Yield=56%).

¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.63 (s, 1H), 7.38 (d, 2H), 7.20-7.10(m, 4H), 6.96 (dxd, 1H), 6.87 (s, 1H), 6.42 (s, 1H), 6.35-6.25 (m, 3H),4.62 (s, 2H), 3.74 (s, 3H), 2.30 (s, 3H), 0.93 (s, 9H), 0.10 (s, 6H).

d)[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethoxy-phenylamino)-pyridin-4-yl]-methanol

4-(tert-Butyl-dimethyl-silanyloxymethyl)-N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine(50 mg, 0.083 mmol) was dissolved in 1 mL of tetrahydrofurane andtetrabutyl ammonium fluoride (44 mg, 0.17 mmol) were added. The mixturewas stirred at for 2 hours, concentrated in the rotatory evaporator anddiluted with water. Extraction with ethyl acetate and purification bychromatography on amino-modified silica gel (Merck HPTLC Silica Gel 60NH2F254S) using ethyl acetate/methanol (gradient 0 to 2% methanol) gavethe pure title compound as a yellowish solid (5 mg, 10%). MS ISP (m/e):486.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.58 (s, 1H),7.41 (d, 2H), 7.19 (d, 1H), 7.20-7.05 (m, 3H), 6.97 (dxd, 1H), 6.83 (s,1H), 6.78 (s broad, 1H), 6.67 (s broad, 1H), 6.40 (s, 1H), 6.33 (s, 1H),4.59 (s, 2H), 3.67 (s, 3H), 2.28 (s, 3H).

EXAMPLE 203{1-[4-(4-Benzyl-6-methyl-pyrimidin-2-ylamino)-phenyl]-1H-imidazol-4-yl}-methanol

A mixture of 4-benzyl-2-chloro-6-methyl-pyrimidine (86 mg, 0.39 mmol),1-(4-amino-phenyl)-1H-imidazol-4-yl]-methanol (75 mg, 0.39 mmol, Europ.J. Med. Chem. 19 (3), 285-7 (1984), CAS 94128-93-5) and potassiumcarbonate (1.10 g, 7.86 mmol) in dioxane (4 mL) andN,N-dimethylacetamide (1 mL) was degassed with nitrogen. Palladium(II)acetate (3.6 mg, 0.016 mmol) and 2-(dicyclohexylphosphino)biphenyl (12mg, 0.031 mmol) were added and the reaction mixture was irradiated in amicrowave oven at 200° C. for 25 minutes.[1-(4-Amino-phenyl)-1H-imidazol-4-yl]-methanol (43 mg, 0.19 mmol) wasadded and the reaction mixture was irradiated in a microwave oven at200° C. for another 25 minutes. The reaction mixture was filtered; thefiltrate was diluted with ethyl acetate, washed with water and brine,dried with magnesium sulfate and concentrated in vacuo. Purification bycolumn chromatography on silica eluting with dichloromethane/methanol(14:1 v/v) afforded the title compound as a light yellow viscous oil (19mg, 13%). MS ISP (m/e): 372.2 [(M+H)⁺].

EXAMPLE 204{1-[4-(4-Benzyl-6-methyl-pyrimidin-2-ylamino)-phenyl]-1H-imidazol-2-yl}-methanol

A mixture of 4-benzyl-2-chloro-6-methyl-pyrimidine (104 mg, 0.48 mmol),1-(4-amino-phenyl)-1H-imidazol-2-yl]-methanol (90 mg, 0.48 mmol) andpotassium carbonate (1.33 g, 9.5 mmol) in dioxane (4 mL) andN,N-dimethylacetamide (1 mL) was degassed with nitrogen. Palladium(II)acetate (4.3 mg, 0.019 mmol) and 2-dicyclohexylphosphino)bi-phenyl (13.6mg, 0.038 mmol) were added and the reaction mixture was irradiated in amicrowave oven at 200° C. for 30 minutes.[1-(4-Amino-phenyl)-1H-imidazol-4-yl]-methanol (43 mg, 0.19 mmol) wasadded and the reaction mixture was irradiated in a microwave oven at200° C. for another 25 minutes. The reaction mixture was filtered; thefiltrate was diluted with ethyl acetate, washed with water and brine,dried with magnesium sulfate and concentrated in vacuo. Purification bycolumn chromatography on silica eluting with dichloromethane/methanol(14:1 v/v) afforded the title compound as a light yellow solid (93 mg,52%). MS ISP (m/e): 372.2 [(M+H)⁺]. Mp 95-98° C.

EXAMPLE 205(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine

a) 1-(2-Methoxy-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole

A solution of 2-chloro-5-nitroanisole (1.0 g, 5.2 mmol),3-methyl-1H-1,2,4-triazole (1.74 g, 20.9 mmol) and potassium hydroxide(0.44 g, 7.8 mmol) in dimethyl sulfoxide (5 ML) was heated to 80° C.under an atmosphere of nitrogen for two days. Water and 1M aqueoushydrogen chloride solution was added and the reaction was stirred for 45minutes. The precipitate was filtered off, washed with water, dissolvedin dichloromethane. The aqueous layer was extracted twice withdichloromethane. The combined organic layers were washed with water,dried over sodium sulfate, filtered and the solvent was evaporated. Theresidue was purified by reversed preparative HPLC usingacetonitril/water (0.1% formic acid) to yield the title compound as ayellow solid (77 mg, 6%). MS ISP (m/e): 235.2 (100) [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=8.88 (s, 1H), 8.10 (d, 1H), 7.96-8.02 (m, 2H),4.10 (s, 3H), 2.51 (s, 3H).

b) 3-Methoxy-4-(3-methyl-[1,2,4]-triazol-1-yl)-phenylamine

1-(2-Methoxy-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole (77 mg, 0.33mmol) was dissolved in methanol (5 mL). The flask was evacuated andflushed with nitrogen. This procedure was repeated two times. 10%Palladium on charcoal (8 mg) was added. The reaction was stirred atunder an atmosphere of hydrogen over night, filtered and the filtratewas evaporated under reduced pressure to yield the title compound as abrown solid (67 mg, ca. 100%). MS ISP (m/e): 205.2 (100) [(M+H)⁺]. ¹HNMR (CDCl₃, 300 MHz): δ (ppm)=8.35 (s, 1H), 7.37 (d, 1H), 6.32-6.35 (m,2H), 3.82 (s, 3H), 2.47 (s, 3H).

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine

Palladium(II) acetate (5.9 mg, 0.026 mmol) and2-(dicyclohexylphosphino)biphenyl (19 mg, 0.052 mmol) were dissolvedunder an atmosphere of nitrogen in dioxane (2 mL). The reaction wasstirred for 25 minutes at. Sodium tert.-butylate (48 mg, 0.49 mmol),3-methoxy-4-(3-methyl-[1,2,4]triazol-1-yl)-phenylamine (67 mg, 0.33mmol) dissolved in dioxane (1.5 mL) and4-benzyl-2-chloro-6-methyl-pyrimidine (79 mg, 0.36 mmol) were added. Thereaction was heated three times for 30 minutes to 200° C. in a microwaveoven. Water was added and the reaction was extracted twice with ethylacetate. The combined organic layers were dried over sodium sulfate,filtered and the solvent was evaporated under reduced pressure. Theresidue was purified by column chromatography on silica gel usingmethylenechloride/methanol (19:1 v/v) as eluent to yield the titlecompound as a yellow gum (38 mg, 30%). MS ISP (m/e): 387.3 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.49 (s, 1H), 7.97 (s, 1H),7.56 (d, 1H), 7.26-7.33 (m, 5H), 6.98 (d, 1H), 6.51 (s, 1H), 3.97 (s,2H), 3.83 (s, 3H), 2.48 (s, 3H), 2.37 (s, 3H).

EXAMPLE 206(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(3-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine

a) 1-(2-Fluoro-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole

3,4-Difluoronitrobenzene (514 mg, 3.23 mmol), 3-methyl-1H-1,2,4-triazole(325 mg, 3.72 mmol) and di-potassium hydrogen phosphate trihydrate (1.49g, 6.46 mmol) in 1 dimethyl sulfoxide (5 mL) were stirred for 6 hours at70° C. The mixture was concentrated in vacuo; the residue was dilutedwith water and extracted three times with ethyl acetate. The combinedorganic layers were washed four times with water, twice with brine,dried over magnesium sulfate and evaporated. Column chromatography (30 gsilica, heptane/ethyl acetate 1:1 v/v) afforded the title compound (261mg, 36%) as white crystals MS ISP (m/e): 223.3[(M+H)⁺]. ¹H NMR (CDCl₃,300 MHz): δ (ppm)=8.72 (d, 1H), 8.20 (m, 3H), 2.52 (s, 3H). Mp 105-107°C.

b) 3-Fluoro-4-(3-methyl-[1,2,4]triazol-1-yl)-phenylamine

1-(2-Fluoro-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole (250 mg, 1.13mmol) was dissolved in tetrahydrofurane (6 mL) and triethylamine (5 mL)and stirred for 2 hours with 10% palladium on carbon (55 mg) under 1.5bar of hydrogen. The reaction mixture was filtered and the solvent wasremoved under reduced pressure to yield the title compound (159 mg, 73%)as a yellow solid MS ISP (m/e): 193.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz):δ (ppm)=8.31 (d, 1H), 7.45 (dd, 1H), 6.51 (m, 2H), 3.94 (s broad, 2H),2.48 (s, 3H). Mp 122-125° C.

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(3-methyl-[1,2,4]-triazol-1-yl)-phenyl]-amine

Palladium(II) acetate (5 mg, 0.022 mmol) and2-(dicyclohexylphosphino)biphenyl (16 mg, 0.08 mmol) were stirred indioxane (1.5 mL) while nitrogene was bubbled through the solution. Amixture of 4-benzyl-2-chloro-6-methyl-pyrimidine (120 mg, 0.55 mmol),3-fluoro-4-(3-methyl-[1,2,4]triazol-1-yl)-phenylamine (105 mg, 0.55mmol) and potassium carbonate (1.53 g, 10.9 mmol) in dioxane (5 mL) andN,N-dimethylacetamide (1.5 mL) was degassed with nitrogen, the aboveprepared catalyst solution was added and the reaction mixture wasirradiated in a microwave oven at 200° C. for 20 minutes. The reactionmixture was partitioned between ethyl acetate and water; the water layerwas extracted twice with ethyl acetate and the combined organic phaseswashed three times with water, once with brine, dried with magnesiumsulfate and the solvent was removed in vacuo. The light brown solid waspurified by trituration in heptane/ethyl acetate (9:1 v/v, 6 mL) toafford the title compound as a beige solid (140 mg, 68%). MS ISP (m/e):375.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.43 (d, 1H), 8.98 (dd,1H), 8.66 (dd, 1H), 7.30 (m, 5H), 7.18 (m, 2H), 6.54 (s, 1H), 3.98 (s,2H), 2.50 (s, 3H), 2.38 (s, 3H). Mp 183-185° C.

EXAMPLE 207(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(5-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine

a) 1-(2-Fluoro-4-nitro-phenyl)-5-methyl-1H-[1,2,4]triazole

3,4-Difluoronitrobenzene (514 mg, 3.23 mmol), 3-methyl-1H-1,2,4-triazole(325 mg, 3.72 mmol) and di-potassium hydrogen phosphate trihydrate (1.49g, 6.46 mmol) in dimethyl sulfoxide (1.5 mL) were stirred for 6 hours at70° C. The mixture was concentrated in vacuo; the residue was diluted inwater and extracted three times with ethyl acetate. The combined organiclayers were washed four times with water, twice with brine, dried withmagnesium sulfate and evaporated. Column chromatography (30 g silica,heptane/ethyl acetate 1:1 v/v) afforded the title compound (160 mg, 22%)as white crystals MS ISP (m/e): 223.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz):δ (ppm)=8.22 (m, 2H), 8.04 (s, 1H), 7.74 (dd, 1H), 2.48 (d, 3H). Mp56-58° C.

b) 3-Fluoro-4-(5-methyl-[1,2,4]triazol-1-yl)-phenylamine

1-(2-Fluoro-4-nitro-phenyl)-5-methyl-1H-[1,2,4]triazole (120 mg, 0.54mmol) was dissolved in tetrahydrofurane (6 mL) and triethylamine (10 mL)and stirred for 4 hours with 10% palladium on carbon (50 mg) under 3 barof hydrogen. The reaction mixture was filtered and the solvent wasremoved in vacuo to yield the title compound (78 mg, 75%) as a yellowsolid. MS ISP (m/e): 193.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.93 (s, 1H), 7.16 (dd, 1H), 6.51 (m, 2H), 4.03 (s broad, 2H),2.38 (s, 3H). Mp 106-108° C.

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(5-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine

The title compound was prepared from4-benzyl-2-chloro-6-methyl-pyrimidine (86 mg, 0.54 mmol) and3-fluoro-4-(5-methyl-[1,2,4]triazol-1-yl)-phenylamine (75 mg, 0.39 mmol)using in analogous manner the procedure described in example 206c).Column chromatography (15 g silica, dichloromethane+3.5% methanol v/v)afforded the title compound as a light yellow waxy solid (100 mg, 68%).¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.07 (dd, 1H), 7.97 (s, 1H), 7.27 (m,7H), 6.56 (s, 1H), 4.00 (s, 2H), 2.42 (d, 3H), 2.39 (s, 3H). MS ISP(m/e): 375.2 [(M+H)⁺]

EXAMPLE 208(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-oxazol-5-yl)-phenyl]-amine

Palladium(II) acetate (9.3 mg, 0.041 mmol) and2-(dicyclohexylphosphino)biphenyl (30 mg, 0.083 mmol) were stirred indioxane (1.5 mL) for 15 minutes at under an atmosphere of nitrogen.Sodium tert.-butylate (76 mg, 0.78 mmol),4-(2-methyl-oxazol-5-yl)phenylamine (90 mg, 0.52 mmol, CAS 89260-50-4)dissolved in dioxane (0.7 mL) and 4-benzyl-2-chloro-6-methyl-pyrimidine(124 mg, 0.57 mmol) were added. The reaction was heated for 30 minutesto 200° C. in a microwave oven. Water was added and the reaction wasextracted twice with ethyl acetate. The combined organic layers weredried over sodium sulfate, filtered and the solvent was evaporated underreduced pressure. The residue was purified by column chromatography onsilica gel using dichloromethane and then methylenechloride/methanol(19:1 v/v) as eluent to yield the title compound as a yellow solid (112mg, 61%). MS ISP (m/e): 357.2 (100) [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.69 (d, 2H), 7.53 (d, 2H), 7.26-7.35 (m, 4H), 7.11-7.12 (m, 2H),6.45 (s, 1H), 3.97 (s, 2H), 2.52 (s, 3H), 2.36 (s, 3H).

EXAMPLE 209(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenyl]-amine

a) 5-(2-Methoxy-4-nitro-phenyl)-2-methyl-thiazole

In a microwave vial a mixture of 2-bromo-5-nitroanisole (800 mg, 3.38mmol), potassium acetate (503 mg, 5.07 mmol) andtetrakis(triphenylphosphine)-palladium(0) (197 mg, 0.17 mmol) inN,N-dimethylacetamide (12 mL) were flushed with argon while2-methylthiazole (1.71 g, 16.9 mmol) was added. The tube was sealed andthe mixture irradiated two times for 30 minutes at 160° C. The red-brownmixture was partitioned between ethyl acetate and water. The water layerwas re-extracted with ethyl acetate. The combined organic phases werewashed three times with water, once with brine, dried with magnesiumsulfate and evaporated to dryness. Column chromatography (70 g silica,heptane/ethyl acetate 7:3 v/v) afforded the title compound (360 mg, 42%)as a yellow solid. MS ISP (m/e): 251.1 [(M+H)⁺]. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=8.15 (s, 1H), 7.90 (dd, 1H), 7.84 (s, 1H), 7.72 (d, 1H),4.05 (s, 3H), 2.76 (s, 3H). Mp 114-117° C.

b) 3-Methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine

A suspension of 5-(2-methoxy-4-nitro-phenyl)-2-methyl-thiazole (330 mg,1.32 mmol) and anhydrous stannous chloride (1.28 g, 6.6 mmol) in ethanol(21 mL) was stirred at reflux for one hour. The yellow solution wasevaporated and the residue dissolved in ethyl acetate. This solution waswashed twice with 2N aqueous sodium hydroxide solution, with brine,dried with magnesium sulfate and evaporated to dryness to afford thetitle compound (266 mg, 91%) as an orange solid. MS ISP (m/e): 221.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.81 (s, 1H), 7.33 (d, 1H),6.31 (m, 2H), 3.87 (s, 3H), 3.83 (m, 2H), 2.69 (s, 3H). Mp 125-129° C.

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenyl]-amine

The title compound was prepared from4-benzyl-2-chloro-6-methyl-pyrimidine (130 mg, 0.59 mmol) and3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (131 mg, 0.59 mmol)using in analogous manner the procedure described in example 206c).Column chromatography (20 g silica, heptane/ethyl acetate 1:1 v/v)afforded the title compound as an off-white solid (165 mg, 69%). MS ISP(m/e): 403.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.90 (s, 1H),7.82 (s, 1H), 7.45 (d, 1H), 7.29 (m, 5H), 7.14 (s, 1H), 6.98 (dd, 1H),6.48 (s, 1H), 3.97 (s, 2H), 3.87 (s, 3H), 2.71 (s, 3H), 2.37 (s, 3H). Mp138-141° C.

EXAMPLE 210(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2,4-dimethyl-thiazol-5-yl)-3-methoxy-phenyl]-amine

5-(2-Methoxy-4-nitro-phenyl)-2,4-dimethyl-thiazole

In a microwave vial a mixture of 2-bromo-5-nitroanisole (600 mg, 2.53mmol), potassium acetate (377 mg, 3.80 mmol) andtetrakis(triphenylphosphine)-palladium(0) (148 mg, 0.13 mmol) inN,N-dimethylacetamide (8 mL) was flushed with nitrogen while2,4-dimethylthiazole (1.47 g, 12.6 mmol) was added. The tube was sealedand the mixture irradiated for 30 minutes at 170° C. The red-brownmixture was partitioned between ethyl acetate and water. The aqueouslayer was re-extracted with ethyl acetate. The combined organic phaseswere washed with water, with brine, dried with magnesium sulfate and thesolvent was evaporated to dryness. Column chromatography (40 g silica,heptane/ethyl acetate 7/3) afforded the title compound (415 mg, 62%) asa yellow solid. MS ISP (m/e): 265.1 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.90 (dd, 1H), 7.81 (d, 1H), 7.45 (d, 1H), 3.95 (s, 3H), 2.71 (s,3H), 2.35 (s, 3H). Mp 123-125° C.

b) 4-(2,4-Dimethyl-thiazol-5-yl)-3-methoxy-phenylamine

A suspension of 5-(2-methoxy-4-nitro-phenyl)-2,4-dimethyl-thiazole (415mg, 1.57 mmol) and anhydrous stannous chloride (1.52 g, 7.85 mmol) inethanol (25 mL) was stirred at reflux for 3 hours. The yellow solutionwas evaporated and the residue dissolved in ethyl acetate. This solutionwas washed with 1N aqueous sodium hydroxide solution, twice with water,with brine, dried with magnesium sulfate and the solvent was evaporatedto dryness. Column chromatography (50 g silica, heptane/ethyl acetate30-60% v/v) afforded the title compound (276 mg, 75%) as a pale yellowsolid. MS ISP (m/e): 235.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.04 (d, 1H), 6.31 (m, 2H), 3.80 (s broad, 2H), 3.78 (s, 3H), 2.66(s, 3H), 2.29 (s, 3H). Mp 112-115° C.

c)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2,4-dimethyl-thiazol-5-yl)-3-methoxy-phenyl]-amine

The title compound was prepared from4-benzyl-2-chloro-6-methyl-pyrimidine (130 mg, 0.59 mmol) and4-(2,4-dimethyl-thiazol-5-yl)-3-methoxy-phenylamine (139 mg, 0.49 mmol)using in analogous manner the procedure described in example 206c).Column chromatography (20 g silica, dichloromethane/ethyl acetate 1/1v/v) afforded the title compound (193 mg, 78%) as a light yellow waxysolid. MS ISP (m/e): 417.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=7.78 (d, 1H), 7.29 (m, 5H), 7.17 (d, 1H), 7.14 (s, 1H), 6.99 (dd,1H), 6.48 (s, 1H), 3.97 (s, 2H), 3.78 (s, 3H), 2.67 (s, 3H), 2.37 (s,3H), 2.32 (s, 3H).

EXAMPLE 211(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-amine

2-(2-Methoxy-4-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane

A mixture of 4-bromo-5-nitroanisole (5.0 g, 21.2 mmol),bis(pinacolato)diboron (8.21 g, 31.7 mmol) and potassium acetate (6.28g, 63.3 mmol, dried on high vacuum at 100° C.) in dioxane (75 mL) waspurged for 5 minutes with nitrogen. Bis(triphenylphosphine)palladium(II)chloride (1.48 g, 2.11 mmol) was added and the mixture was heated for 18hours to 100° C. under nitrogen atmosphere. The mixture was diluted withethyl acetate, washed with water and brine, dried over magnesium sulfateand the solvent was evaporated. Column chromatography (330 g silica,heptane/ethyl acetate 5-60%) afforded the title compound (3.46 g, 58%)as a light brown solid.

MS EI (m/e): 279 [(M⁺)]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.78 (s, 2H),7.39 (s, 1H), 3.92 (s, 3H), 1.37 (s, 12H). Mp 75-78° C.

b) 4-(2-Methoxy-4-nitro-phenyl)-1-methyl-1H-pyrazole

A solution of2-(2-methoxy-4-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(635 mg, 1.79 mmol) and 1-methyl-4-iodo-1H-pyrazole (745 mg, 3.58 mmol)in ethanol (11 mL) and toluene (26 mL) was purged with argon for 5minutes. 1,1′-bis(diphenylphosphino)ferrocene palladium (II) chloride(73.0 mg, 0.89 mmol) was added and the mixture was heated to 80° C.,then 2M aqueous sodium carbonate solution (14 mL) was added and stirringat 80° C. was continued for further 24 hours. The mixture was dilutedwith ethyl acetate, washed with water and brine, dried over magnesiumsulfate and the solvent was evaporated. Column chromatography (20 gsilica, dichloromethane) afforded the title compound (245 mg, 58%) as ayellow solid. MS ISP (m/e): 234.0 [(M+H)⁺]. ¹H NMR (DMSO, 300 MHz): δ(ppm)=8.35 (s, 1H), 8.08 (s, 1H), 7.85 (m, 3H), 4.03 (s, 3H), 3.90 (s,3H). Mp 132-134° C.

c) 3-Methoxy-4-(1-methyl-1H-pyrazol-4-yl)-phenylamine

A mixture of 4-(2-methoxy-4-nitro-phenyl)-1-methyl-1H-pyrazole (240 mg,1.03 mmol) and palladium on carbon 10% (55 mg, 0.052 mmol) in methanol(15 mL) was stirred for 2 hours at under hydrogen atmosphere. Themixture was filtrated and the solvent evaporated to afford the titlecompound (210 mg, 100%) as a white solid. MS ISP (m/e): 204.3.0[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.76 (s, 1H), 7.70 (s, 1H),7.28 (d, 1H), 6.32 (d, 2H), 3.91 (s, 3H), 3.85 (s, 3H), 3.68 (s broad,2H). Mp 129-131° C.

d)(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-amine

The title compound was prepared from4-benzyl-2-chloro-6-methyl-pyrimidine (119 mg, 0.54 mmol) and3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-phenylamine (100 mg, 0.49 mmol)using in analogous manner the procedure described in example 206c).Column chromatography (25 g silica, dichloromethane/ethyl acetate 0-25%v/v) afforded the title compound (42 mg, 22%) as a light yellow viscousoil. MS ISP (m/e): 386.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.82(s, 1H), 7.76 (m, 2H), 7.39 (d, 1H), 7.29 (m, 5H), 7.08 (s, 1H), 6.98(dd, 1H), 6.44 (s, 1H), 3.96 (s, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 2.35(s, 3H).

EXAMPLE 212(4-Benzyl-6-methyl-pyrimidin-2-yl)-(4-pyridin-4-yl-phenyl)-amine

Prepared in analogy to example 62 from 4-(pyridin-4-yl)aniline and4-benzyl-2-chloro-6-methyl-pyrimidine (example 43a). The title compoundwas obtained as a brownish oil (Yield=31%). MS ISP (m/e): 353.1 (100)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=9.80 (s, 1H), 8.57 (d, 2H),7.95 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.40-7.15 (m, 5H), 6.68 (s,1H), 3.95 (s, 2H), 2.34 (s, 3H).

EXAMPLE 213[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(6-methyl-2-pyrrolidin-1-yl-pyrimidin-4-yl)-amine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol) and4-chloro-6-methyl-2-pyrrolidin-1-yl-pyrimidine (65 mg, 0.33 mmol,example 95a) in analogous manner as described in example 90. The crudeproduct was purified by stirring with diethyl ether. It was obtained in58% yield as a light brown solid.

MS ISP (m/e): 365.3 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ(ppm)=9.30 (s, 1H), 8.06 (s, 1H), 7.65 (s, 1H), 7.21 (d, 1H), 7.15 (d,1H), 7.02 (s, 1H), 5.91 (s, 1H), 3.81 (s, 3H), 3.50 (br m, 4H), 2.15 (s,3H), 2.14 (s, 3H), 1.90 (br m, 4H).

EXAMPLE 214[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(6-methyl-2-piperidin-1-yl-pyrimidin-4-yl)-amine

The title compound was prepared from3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol) and4-chloro-6-methyl-2-piperidin-1-yl-pyrimidine (70 mg, 0.33 mmol, example97a) in analogous manner as described in example 90. The crude productwas purified by stirring with diethyl ether. It was obtained in 79%yield as a grey solid. MS ISP (m/e): 379.3 (100) [(M+H)⁺]. ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.29 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H),7.22 (d, 1H), 7.04 (d, 1H), 7.03 (s, 1H), 5.89 (s, 1H), 3.80 (s, 3H),3.74 (m, 4H), 2.15 (s, 3H), 2.14 (s, 3H), 1.60 (m, 2H), 1.50 (m, 4H).

EXAMPLE 2152-{5-Ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

A solution of ethyl 2-oxo-pentanoate (144 mg, 1.0 mmol) inN,N-dimethylformamide diethyl acetal (0.68 mL) was heated to 100° C. for2 h. The mixture was evaporated under reduced pressure and the remainingcrude ethyl 3-[1-dimethylamino-methylidene]-2-oxo-hexanoate was reactedwith N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate(298 mg, 0.80 mmol) in analogous manner as described in example 139. Theresulting ethyl5-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylatewas subjected in analogous manner to the procedure described in example165 to give the title compound as a light yellow solid (12 mg, 3%). MSISP (m/e): 368.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.31 (s,1H), 7.63 (s, 1H), 7.53 (d, 1H), 7.23 (s, 1H), 7.18 (d, 1H), 7.04 (dd,1H), 6.87 (s, 1H), 5.44 (br s, 1H), 3.87 (s, 3H), 2.73 (q, 2H), 2.30 (s,3H), 1.60 (s, 6H), 1.30 (t, 3H).

EXAMPLE 2162-{5-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Ethyl 3-[1-dimethylamino-methylidene]-4-methyl-2-oxo-pentanoate (170 mg,0.80 mmol) was reacted withN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate inanalogous manner as described in example 139 and the resulting ethyl5-isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylatewas subjected in analogous manner to the procedure described in example165 to give the title compound as a light yellow solid (10 mg, 4%). MSISP (m/e): 382.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.45 (s,1H), 7.64 (s, 1H), 7.53 (d, 1H), 7.25 (s, 1H), 7.18 (d, 1H), 7.04 (dd,1H), 6.87 (s, 1H), 5.65 (br s, 1H), 3.87 (s, 3H), 3.31 (m, 1H), 2.30 (s,3H), 1.61 (s, 6H), 1.28 (d, 6H).

EXAMPLE 217 Ethyl2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimidine-4-carboxylate

A mixture of N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidinenitrate (719 mg, 2.0 mmol), ethyl 5-methyl-2,4-dioxo-hexanoate (372 mg,2.0 mmol) and potassium carbonate (138 mg, 1.0 mmol) in ethanol (5 mL)was heated in a sealed tube in a microwave oven to 170° C. for 0.5 h.The mixture was cooled, diluted with ethyl acetate (50 mL), and thenwashed with water (20 mL) and with brine (20 mL). The organic layer wasdried over sodium sulfate and evaporated under reduced pressure. Theresidual material was purified by chromatography on silica gel usingdichloromethane/0-10% methanol as eluent to give the title compound (153mg, 20%) as a light yellow solid. MS ISP (m/e): 384.3 [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=8.11 (dd, 1H), 7.68 (s, 1H), 7.47 (s, 1H),7.38 (s, 1H), 7.25-7.30 (2H), 6.94 (s, 1H), 4.48 (q, 2H), 3.05 (m, 1H),2.31 (s, 3H), 1.46 (t, 3H), 1.36 (d, 6H).

EXAMPLE 2182-{2-[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 165, ethyl2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate(115 mg, 0.3 mmol) was reacted with methylmagnesiumchloride to give thetitle compound (66 mg, 59%) as a light yellow solid. MS ISP (m/e): 370.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.99 (dd, 1H), 7.64 (s, 1H),7.25-7.35 (2H), 7.22 (s, 1H), 6.94 (s, 1H), 6.79 (s, 1H), 3.92 (br s,1H), 2.95 (m, 1H), 2.31 (s, 3H), 1.54 (s, 6H), 1.33 (d, 6H).

EXAMPLE 219 Ethyl2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate

Using in analogous manner the procedure described in example 217, butreplacing ethyl 5-methyl-2,4-dioxo-hexanoate by2,4-dioxo-4-(4-trifluoromethyl-phenyl)-butyric acid ethyl ester (576 mg,2.0 mmol), the title compound was obtained as light yellow solid (128mg, 13%). MS ISP (m/e): 486.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.25 (d, 2H), 8.08 (dd, 1H), 7.95 (s, 1H), 7.82 (d, 2H), 7.71 (s,1H), 7.64 (s, 1H), 7.30-7.35 (2H), 6.96 (s, 1H), 4.54 (q, 2H), 2.31 (s,3H), 1.50 (t, 3H).

EXAMPLE 2202-[2-[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Using in analogous manner the procedure described in example 165, ethyl2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate(87 mg, 0.18 mmol) was reacted with methylmagnesiumchloride to give thetitle compound (47 mg, 55%) as a light yellow solid. MS ISP (m/e): 472.2[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.19 (d, 2H), 7.97 (dd, 1H),7.80 (d, 2H), 7.72 (br s, 1H), 7.42 (s, 2H), 7.28-7.32 (2H), 6.98 (s,1H), 3.68 (br s, 1H), 2.32 (s, 3H), 1.63 (s, 6H).

EXAMPLE 2212-{6-Dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

a) 2-(2-Chloro-6-dimethylamino-pyrimidin-4-yl)-propan-2-ol

Using in analogous manner the procedure described in example 88b), butreplacing ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl2-chloro-6-dimethylamino-pyrimidine-4-carboxylate (645 mg, 3.0 mmol),the title compound was obtained as light yellow solid (504 mg, 78%). MSISP (m/e): 216.2 [(M+H)⁺].

b)2-{6-Dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-(2-chloro-6-dimethylamino-pyrimidin-4-yl)-propan-2-ol (65 mg, 0.3mmol) was reacted with 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine(61 mg, 0.3 mmol) to give the title compound was obtained as lightyellow foam (24 mg, 21%). MS ISP (m/e): 383.3 [(M+H)⁺]. ¹H NMR (CDCl₃,300 MHz): δ (ppm)=7.75 (d, 1H), 7.63 (s, 1H), 7.26 (s, 1H), 7.15 (d,1H), 6.99 (dd, 1H), 6.87 (s, 1H), 6.01 (s, 1H), 4.38 (br s, 1H), 3.86(s, 3H), 3.16 (s, 6H), 2.30 (s, 3H), 1.51 (s, 6H).

EXAMPLE 2222-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-morpholin-4-yl-pyrimidin-4-yl}-propan-2-ol

a) 2-(2-Chloro-6-moMholin-4-yl-pyrimidin-4-yl)-propan-2-ol

Using in analogous manner the procedure described in example 88b), butreplacing ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl2-chloro-6-morpholin-4-yl-pyrimidine-4-carboxylate (900 mg, 3.5 mmol),the title compound was obtained as light yellow solid (769 mg, 85%). MSISP (m/e): 258.1 [(M+H)⁺].

b)2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-morpholin-4-yl-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-(2-chloro-6-morpholin-4-yl-pyrimidin-4-yl)-propan-2-ol (77 mg, 0.3mmol) was reacted with 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine(61 mg, 0.3 mmol) to give the title compound was obtained as lightyellow foam (62 mg, 49%). MS ISP (m/e): 425.2 [(M+H)⁺].)⁺]. ¹H NMR(CDCl₃, 300 MHz): □ (ppm)=7.82 (s, 2H), 7.16 (d, 1H), 6.98 (dd, 1H),6.95 (s, 1H), 6.87 (s, 1H), 6.12 (s, 1H), 4.15 (br s, 1H), 3.81 (s, 3H),3.78 and 3.65 (2 m, 2×4H), 3.16 (s, 6H), 2.30 (s, 3H), 1.51 (s, 6H).

EXAMPLE 2231-{6-(1-Hydroxy-1-methyl-ethyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyamino]-pyrimidin-4-yl}-4-methyl-piperidin-4-ol

a) Methyl2-chloro-6-(4-hydroxy-4-methyl-piperidin-1-yl)-pyrimidine-4-carboxylate

A mixture of methyl 2,4-dichloropyrimidine-6-carboxylate (1.66 g, 8.0mmol), 4-methyl-piperidin-4-ol (1.21 g, 8 mmol) and sodium carbonate(1.74 g, 16.0 mmol) in methanol (8 mL) was stirred for 1 h at. Themixture was partitioned between ethyl acetate and water, and the organiclayer was subsequently washed with brine, dried over sodium sulfate andevaporated under reduced pressure to give crude title compound (1.70 g,72%) as light yellow solid. MS ISP (m/e): 286.1 [(M+H)⁺].

b)1-[2-Chloro-6-(1-hydroxy-1-methyl-ethyl)-pyrimidin-4-yl]-4-methyl-piperidin-4-ol

Using in analogous manner the procedure described in example 88b), butreplacing ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl2-chloro-6-(4-hydroxy-4-methyl-piperidin-1-yl)-pyrimidine-4-carboxylate(1.71 g, 6.0 mmol), the title compound was obtained as light yellowsolid (0.38 g, 22%). MS ISP (m/e): 286.1 [(M+H)⁺].

c)2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-(2-chloro-6-morpholin-4-yl-pyrimidin-4-yl)-propan-2-ol (77 mg, 0.3mmol) was reacted with 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine(61 mg, 0.3 mmol) to give the title compound was obtained as off-whitefoam (70 mg, 52%). MS ISP (m/e): 453.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300MHz): δ (ppm)=7.73 (d, 1H), 7.62 (s, 1H), 7.14 (d, 1H), 6.97 (s, 1),6.92 (dd, 1H), 6.87 (s, 1H), 6.14 (s, 1H), 4.28 (br s, 1H), 4.10 (m,3H), 3.85 (s, 3H), 3.47 (m, 2H), 2.30 (s, 3H), 1.55-1.70 (m, 4H), 1.51(s, 6H), 1.32 (s, 3H).

EXAMPLE 2242-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylicacid dimethylamide

a) 2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic Acid

Pd(dppf)Cl₂ (0.214 g, 0.02 mmol) was added to a mixture of methyl2,4-dichloropyrimidine-6-carboxylate (2.07 g, 10 mmol) and4-(trifluoromethyl)phenyl-boronic acid (1.90 g, 10 mmol) in DME (100 mL)and sat. aq. NaHCO3 (20 mL), and the mixture was stirred in anatmosphere of argon at 80° C. for 3 h. The reaction mixture was cooledto and added to ice water (100 mL). The mixture was extracted with ethylacetate (2×100 mL) and the organic phase was extracted with saturatedsodium carbonate solution (50 mL). The combined aqueous layers wereacidified by the addition of 25% HCl (100 mL) and subsequently extractedwith ethyl acetate (2×100 mL). The organic phase was washed with brine,dried over sodium sulfate, and the solvents were removed under reducedpressure. The residual solid was recrystallized from ethylacetate/heptane to give the title compound (1.82 g, 60%) as light redsolid. MS ISN (m/e): 301.2 [(M−H)⁻]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.51 (s, 1H), 8.33 and 7.84 (2 d, 2×2H).

b) 2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic AcidDimethylamide

Oxalyl chloride (0.38 mL, 4.5 mmol) and N,N-dimethylformamide (0.03 mL)were added to a suspension of2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid (303mg, 1.0 mmol) in dichloromethane (20 mL). The mixture was stirred at for3 h and then evaporated under reduced pressure. The residue wasdissolved in dichloro-methane (25 mL) and the solution was stirredtogether with 60% aqueous dimethylamine (1.2 mL, 13.3 mmol) andsaturated aqueous sodium hydrogencarbonate solution (8 mL) for 1 h at.The mixture was diluted with dichloromethane (25 mL), and the organiclayer was washed with water and brine, dried over sodium sulfate, andevaporated under reduced pressure. The residual material was purified bychromatography on silica gel using heptane/0-40% ethyl acetate as eluentto give the title compound (215 mg, 65%) as a white solid. MS ISP (m/e):330.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.24 (d, 2H), 7.99 (s,1H), 7.80 d, 2H), 3.17 (s, 6H).

c)2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethylphenyl)-pyrimidine-4-carboxylicAcid Dimethylamide

Using in analogous manner the procedure described in example 1e),2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic aciddimethylamide (99 mg, 0.3 mmol) was reacted with3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol) togive the title compound as yellow solid (76 mg, 51%). MS ISP (m/e):497.4 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.21 (d, 2H), 7.77 (d,2H), 7.74 (d, 1H), 7.66 (s, 1H), 7.45 (s, 1H), 7.41 (s, 1H), 7.23 (d,1H), 7.18 (dd, 1H), 6.90 (s, 1H), 3.89 (s, 3H), 3.18 and 3.15 (2 s,2×3H), 2.31 (s, 3H).

EXAMPLE 225[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone

a)[2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone

Oxalyl chloride (0.38 mL, 4.5 mmol) and N,N-dimethylformamide (0.03 mL)were added to a suspension of2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid (303mg, 1.0 mmol) in dichloromethane (20 mL). The mixture was stirred at for3 h and then evaporated under reduced pressure. The residue wasdissolved in dichloro-methane (25 mL) and the solution was stirredtogether morpholine (0.174 mL, 2.0 mmol) and saturated aqueous sodiumhydrogencarbonate solution (8 mL) for 1 h at. The mixture was dilutedwith dichloromethane (25 mL), and the organic layer was washed withwater and brine, dried over sodium sulfate, and evaporated under reducedpressure. The residual material was purified by chromatography on silicagel using heptane/0-40% ethyl acetate as eluent to give the titlecompound (260 mg, 66%) as a white solid. MS ISP (m/e): 372.2 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.25 (d, 2H), 8.04 (s, 1H), 7.80 d,2H), 3.83 (br s, 4H), 3.74 (m, 4H).

b)2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone

Using in analogous manner the procedure described in example 1e),2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic aciddimethylamide (112 mg, 0.3 mmol) was reacted with3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol) togive the title compound as yellow solid (42 mg, 27%). MS ISP (m/e):539.3 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.21 (d, 2H), 7.77 (d,2H), 7.69 (d, 1H), 7.67 (s, 1H), 7.57 (s, 1H), 7.48 (s, 1H), 7.2-7.3(2H), 6.91 (s, 1H), 3.88 (s, 3H), 3.83 and 3.69 (2 m, 2×4H), 2.31 (s,3H).

EXAMPLE 2261-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-cyclopentanol

A solution of ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate(99 mg, 0.2 mmol) in tetrahydrofurane (2 mL) was added at 0° C. over 1min to a 0.3 M solution of butane-1,4-bis(magnesiumbromide) intetrahydrofurane (1.6 mL, 0.49 mmol). The reaction mixture was stirredat 0° C. for 10 min followed by 2 h at. The mixture was poured onsaturated ammonium chloride solution (5 mL) and the mixture wasextracted with ethyl acetate (40 mL). The organic layer was washed withbrine (20 mL), dried over sodium sulfate and evaporated under reducedpressure. The residual material was purified by chromatography on silicagel using ethyl acetate as eluent to give the title compound (10 mg,10%) as light yellow foam. MS ISP (m/e): 510.4 [(M+H)⁺]. ¹H NMR (CDCl₃,300 MHz): δ (ppm)=8.20 (d, 2H), 7.82 (d, 1H), 7.76 (d, 2H), 7.66 (s,1H), 7.39 (s, 1H), 7.37 (s, 1H), 7.22 (d, 1H), 7.10 (dd, 1H), 6.90 (s,1H), 3.89 (s, 3H), 2.31 (s, 3H), 1.85-2.25 (m, 4H).

EXAMPLE 2272-[2-[4-(3-Methyl-[1,2,4]thiadiazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

a) 4-(3-Methyl-[1,2,4]thiadiazol-5-yl)-phenylamine

To a suspension of 3-methyl-5-(4-nitro-phenyl)-[1,2,4]thiadiazole (422mg, 1.9 mmol, CAS 800408-77-9, Wilkins, D. J.; Bradley, P. A. Science ofSynthesis (2004), 13, 277-295.) in ethanol (19 mL) was added understirring tin(II)chloride (1.86 g, 9.54 mmol) and heated to 70° C. for 4hours. The mixture was poured on cold aqueous saturated sodium hydrogencarbonate solution. The suspension was stirred for 30 minutes and thesolid was filtered off, washed with water. The residue was heated two tothree times with tetrahydrofurane and filtered. The aqueous layer wasextracted twice with ethyl acetate. The combined organic layers weredried over sodium sulfate and the solvent was evaporated under reducedpressure. The residue was stirred with diethyl ether and the solid wasfiltered off and washed with diethyl ether/heptane to yield the titlecompound as a yellow solid (355 mg, 97%). MS ISP (m/e): 192.2 (100)[(M+H)⁺]. ¹H NMR (DMSO-D₆, 300 MHz): δ (ppm)=7.64 (d, 2H), 6.63 (d, 3H),6.01 (BR s, 2H, NH2), 2.54 (s, 3H).

2-[2-[4-(3-Methyl-[1,2,4]thiadiazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Palladium(II) acetate (3.6 mg, 0.016 mmol) and2-(dicyclohexylphosphino)biphenyl (11 mg, 0.032 mmol) were stirred indioxane (1 mL) for 10 minutes at under an atmosphere of nitrogen. Sodiumtert.-butylate (29 mg, 0.3 mmol),4-(3-methyl-[1,2,4-]thiadiazol-5-yl)-phenylamine (38 mg, 0.20 mmol) and)2-[2-chloro-6-(4-trifluoromethyl-phenyl)pyrimidine-4-yl]-propan-2-ol (70mg, 0.22 mmol) dissolved in dioxane (1 mL) were added. The reaction washeated for 30 minutes to 130° C. in a microwave oven. Water was addedand the reaction was extracted twice with ethyl acetate. The combinedorganic layers were washed with brine, dried over sodium sulfate,filtered and the solvent was evaporated under reduced pressure. Theresidue was purified by column chromatography on silica gel usingheptane/ethyl acetate (1:1 v/v) as eluent to yield the title compound asa yellow solid (26 mg, 28%). MS ISP (m/e): 472.2 (100) [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=8.21 (d, 2H), 7.97 (d, 2H), 7.85 (d, 2H), 7.79(d, 2H), 7.45 (br s, 1H, NH), 7.39 (s, 1H), 3.72 (s, 1H, OH), 2.73 (s,3H), 1.62 (s, 6H).

EXAMPLE 228(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-oxazol-5-yl)-phenyl]-amine

Palladium(II) acetate (5.4 mg, 0.024 mmol) and2-(dicyclohexylphosphino)biphenyl (17 mg, 0.048 mmol) were stirred indioxane (3 mL) for 20 minutes at under an atmosphere of nitrogen. Sodiumtert.-butylate (44 mg, 0.45 mmol),3-methoxy-4-(2-methyl-oxazol-5-yl)-phenylamine (61 mg, 0.30 mmol, CAS568556-28-5; E. J. Jwanowicz et. al. Bioorganic & Medicinal ChemistryLetters, 13(12), 2059-2063; 2003) and4-benzyl-2-chloro-6-methyl-pyrimidine (72 mg, 0.33 mmol) were added. Thereaction was heated for 30 minutes to 130° C. in a microwave oven. Waterwas added and the reaction was extracted three times with ethyl acetate.The combined organic layers were dried over sodium sulfate, filtered andthe solvent was evaporated under reduced pressure. The residue waspurified by column chromatography on silica gel using dichloromethaneand then methylenechloride/methanol (19:1 v/v) as eluent to yield thetitle compound as a yellow solid (31 mg, 27%). MS ISP (m/e): 387.2 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=7.86 (s, 1H), 7.61 (d, 2H),7.26-7.33 (m, 5H), 7.15 (br s, 1H), 6.98 (d, 1H), 6.48 (s, 1H), 3.97 (s,2H), 3.90 (s, 3H), 2.51 (s, 3H), 2.37 (s, 3H).

EXAMPLE 2292-{6-(4-Chloro-phenyl)-2-[4-(2-methyl-oxazol-5-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

a) 2-Chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid

Using in analogous manner the procedure described in example 224a), butreplacing 4-(trifluoromethyl)phenylboronic acid by 4-chlorophenylboronicacid (1.04 g, 5 mmol), the title compound was obtained as light yellowsolid (0.78 g, 58%). MS ISN (m/e): 267.2 [(M−H)⁻].

b) Ethyl 2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylate

To a solution of 2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylicacid (1.35 g, 5.0 mmol) in ethanol (50 mL) was added diethyl ether (10mL) which had been saturated previously with hydrochloric acid gas at.The reaction mixture was stirred for 24 h at. The solution wasevaporated under reduced pressure and the residual oil was dissolved inethyl acetate. The solution was washed with saturated sodiumhydrogencarbonate solution and with brine, dried over sodium sulfate,and evaporated under reduced pressure. The residual material wascrystallized from ethyl acetate/heptane to give the title compound (1.17g, 78%) as light yellow solid. MS ISN (m/e): 297.1 [(M+H)⁺]. ¹H NMR(CDCl₃, 300 MHz): δ (ppm)=8.31 (s, 1H), 8.13 and 7.53 (2 d, 2×2H), 4.53(q, 2H), 1.47 (t, 3H).

c) 2-[2-Chloro-6-(4-chloro-phenyl)-pyrimidin-4-yl]-propan-2-ol

To a solution of ethyl2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylate (297 mg, 1.0 mmol)in tetrahydrofurane (6 mL) was added at—over 2 min a 3 M solution ofmethylmagnesiumchloride in tetrahydrofurane (0.80 mL, 2.4 mmol). Thereaction mixture was stirred at—for 30 min followed by 2 h at. Themixture was poured on saturated ammonium chloride solution (20 mL) andthe product was extracted with ethyl acetate (40 mL). The organic layerwas washed with brine (20 mL), dried over sodium sulfate and evaporatedunder reduced pressure. The residual material was purified bychromatography on silica gel using heptane/0-50% ethyl acetate as eluentto give after crystallization from ethyl acetate/heptane the titlecompound (185 mg, 65%) as as white solid. MS ISP (m/e): 283.1 [(M+H)⁺].¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.07 (d, 2H), 7.80 (s, 1H), 7.49 (d,2H), 3.16 (s, 1H), 1.62 (s, 6H).

d)2-6{-(4-Chloro-phenyl)-2-[4-(2-methyl-oxazol-5-yl)-phenalamino]-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-[2-chloro-6-(4-chloro-phenyl)-pyrimidin-4-yl]-propan-2-ol (112 mg, 0.3mmol) was reacted with 4-(2-methyl-oxazol-5-yl)-phenylamine (61 mg, 0.3mmol) to give the title compound as light yellow solid (28 mg, 22%). MSISP (m/e): 421.1 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.04, 7.74,7.63 and 7.50 (4 d, 4×2H), 7.20 (s, 1H), 7.23 (s, 1H), 7.15 (s, 1H),4.01 (s, 1H), 2.53 (s, 3H), 1.61 (s, 6H).

EXAMPLE 2302-{6-(4-Chloro-phenyl)-2-[4-(2-ethyl-oxazol-5-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol

Using in analogous manner the procedure described in example 229d), butreplacing 4-(2-methyl-oxazol-5-yl)-phenylamine by4-(2-ethyl-oxazol-5-yl)-phenylamine (57 mg, 0.2 mmol), the titlecompound was obtained as light yellow solid (12 mg, 14%). MS ISP (m/e):435.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.04, 7.74, 7.64 and7.50 (4 d, 4×2H), 7.17 (s, 1H), 4.01 (s, 1H), 2.86 (q, 2H), 1.60 (s,6H), 1.40 (t, 3H).

EXAMPLE 2312-[2-[4-(2-Methyl-oxazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

a) Ethyl 2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate

Using in analogous manner the procedure described in example 229b), butreplacing 2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid by2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid (1.89g, 6.0 mmol), the title compound was obtained as light yellow solid(1.83 g, 87%). MS ISP (m/e): 331.0 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.34 (s, 1H), 8.30 and 7.82 (2 d, 2×2H), 4.55 (q, 2H), 1.48 (t,3H).

b) 2-[2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Using in analogous manner the procedure described in example 229c), butreplacing ethyl 2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylate byethyl 2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate(661 mg, 2.0 mmol), the title compound was obtained as light yellowsolid (486 mg, 77%). ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.23 (d, 2H), 7.89(s, 1H), 7.78 (d, 2H), 3.12 (s, 1H), 1.64 (s, 6H).

c)2-[2-[4-(2-Methyl-oxazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol (95mg, 0.3 mmol) was reacted with 4-(2-methyl-oxazol-5-yl)-phenylamine (52mg, 0.3 mmol) to give the title compound as light yellow solid (29 mg,21%). MS ISP (m/e): 455.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.20, 7.78, 7.75 and 7.63 (4 d, 4×2H), 7.31 (s, 2H), 7.16 (s, 1H),3.93 (s, 1H), 2.53 (s, 3H), 1.61 (s, 6H).

EXAMPLE 2322-[2-[4-(2,4-Dimethyl-oxazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol (95mg, 0.3 mmol) was reacted with 4-(2,4-dimethyl-oxazol-5-yl)-phenylamine(56 mg, 0.3 mmol) to give the title compound as light yellow solid (72mg, 51%). MS ISP (m/e): 469.2 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ(ppm)=8.20, 7.78, 7.75 and 7.63 (4 d, 4×2H), 7.31 (s, 2H), 3.93 (s, 1H),2.53 (s, 3H), 1.61 (s, 6H).

EXAMPLE 2332-[2-[3-Methoxy-4-(2-methyl-thiazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol (95mg, 0.3 mmol) was reacted with3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (66 mg, 0.3 mmol) togive the title compound as light yellow solid (36 mg, 24%). MS ISP(m/e): 501.1 [(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.21 (d, 2H),7.98 (s, 1H), 7.77 (m, 3H), 7.54 (d, 1H), 7.34 (2 s, 2×1H), 7.10 (dd,1H), 3.98 (s, 3H), 3.87 (s, 1H), 2.73 (s, 3H), 1.62 (s, 6H).

EXAMPLE 2345-[4-(1-Hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile

a) 2-(4-Methyl-imidazol-1-yl)-5-nitro-benzonitrile

A suspension of 831 mg (5 mmol) of 3-cyano-4-fluoronitrobenzene, of 0.82g (10 mmol) 4-methylimidazol and of 1.38 g (10 mmol) potassium carbonatein acetonitrile (10 mL) was stirred for 60 h at 20° C. The solvent wasevaporated and the residue was partitioned between ethyl acetate and 1Naqueous sodium hydroxide solution. The aqueous layer was extracted withethyl acetate. The combined organic layers were washed with brine, driedover sodium sulphate, and the solvent was evaporated under reducedpressure. The crude product was crystallized from ethanol/water yieldingthe title compound (0.65 g, 57%) as an off-white solid. ¹H NMR (DMSO-D₆,250 MHz): δ (ppm)=8.95 (s, 1H), 8.62 (d, 1H), 8.16 (s, 1H), 7.93 (d,1H), 7.49 (s, 1H), 2.21 (s, 3H).

b) 5-Amino-2-(4-methyl-imidazol-1-yl)-benzonitrile

0.65 g (2.84 mmol) 2-(4-methyl-imidazol-1-yl)-5-nitro-benzonitriledissolved in ethyl acetate (10 mL) were hydrogenated under an atmosphereof hydrogen at 20° C. for 5 h in the presence of 150 mg of 10% palladiumon charcoal. The catalyst was filtered off and washed with ethylacetate. The solvent of the filtrate was evaporated under reducedpressure and dried to yield the title compound (0.45 g, 80%) as yellowsolid. MS ISP (m/e): 199.1 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 250 MHz): δ(ppm)=7.72 (s, 1H), 7.23 (d, 1H), 7.10 (s, 1H), 6.96 (s, 1H), 6.91 (d,1H), 2.15 (s, 3H).

c)5-[4-(1-Hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile

Using in analogous manner the procedure described in example 1e),2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol (95mg, 0.3 mmol) was reacted with3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (59 mg, 0.3 mmol) togive the title compound as light yellow solid (91 mg, 63%). MS ISP(m/e): 479.1 [(M+H)⁺]. ¹H NMR (DMSO-d₆, 300 MHz): δ (ppm)=10.31 (s, 1H),8.53 (d, 1H), 8.35 (d, 2H), 8.17 (dd, 1H), 7.94 (d, 2H), 7.92 (s, 1H),7.78 (s, 1H), 7.61 (d, 1H), 7.28 (s, 1H), 5.52 (s, 1H), 2.19 (s, 3H),1.54 (s, 6H).

EXAMPLE 2352-[2-[3-Methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

a) 4-Methyl-1-(2-methyl-4-nitro-phenyl)-1H-imidazole

A mixture of 2-chloro-5-nitro-toluene (2.0 g, 12 mmol), of4-methylimidazole (1.0 g, 12 mmol) and of cesium carbonate (5.7 g, 17.5mmol) in acetonitrile (20 mL) was refluxed for 15 h. The reactionmixture was cooled, quenched by addition of water and extracted withethyl acetate. The organic layer was dried over sodium sulfate andevaporated under reduced pressure and the crude material was purified bycolumn chromatography on silica gel using ethyl acetate as eluent toyield the title compound (1.27 g, 50%) as a slightly brownish solid. MSISP (m/e): 218.3 (100) [(M+H)⁺].

b) 3-Methyl-4-(4-methyl-imidazol-1-yl)-phenylamine

A mixture of 4-methyl-1-(2-methyl-4-nitro-phenyl)-1H-imidazole (1.26 g,5.8 mmol) and of stannous chloride dihydrate (6.81 g, 30.2 mmol) inethyl acetate (40 mL) and ethanol (20 mL) was stirred for 1 hour at 70°C. The reaction mixture was quenched by addition of water, neutralizedwith sodium hydrogen carbonate and extracted with ethyl acetate. Theorganic layer was dried over sodium sulfate and evaporated under reducedpressure to give the crude title compound (1.08 g, 99%) as a yellowishgum. MS ISP (m/e): 188.4 (100) [(M+H)⁺].

c)2-[2-[3-Methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol

Using in analogous manner the procedure described in example 1e),2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol (95mg, 0.3 mmol) was reacted with3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (56 mg, 0.3 mmol) togive the title compound as light yellow solid (38 mg, 27%). MS ISP(m/e): 468.2 [(M+H)⁺]. ¹H NMR (DMSO-d₆, 300 MHz): δ (ppm)=9.88 (s, 1H),8.35 (d, 2H), 7.96 (s, 1H), 7.95 (d, 2H), 7.74 (dd, 1H), 7.71 (s, 1H),7.63 (s, 1H), 7.20 (d, 1H), 7.04 (s, 1H), 5.45 (s, 1H), 2.17 (s, 3H),2.15 (s, 3H), 1.52 (s, 6H).

EXAMPLE 236(4,6-Dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine

a) 4-(2-Methyl-pyridin-4-yl)-phenylamine

The title compound was prepared from 4-bromo-2-methylpyridine and4-(4,4,5,5-tetramethyl-1,2,3-dioxaborolan-2-yl)aniline by the methoddescribed in Organic Letters 8, 3421 (2006). Obtained as a brownishsolid (Yield=18%). MS ISP (m/e): 185.1 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆,300 MHz): δ (ppm)=9.80 (s, 1H), 8.57 (d, 2H), 7.95 (d, 2H), 7.74 8.34(d, 1H), 7.51 (dxd, 2H), 7.43 (s, 1H), 7.35 (dxd, 1H), 6.65 (dxd, 2H),5.48 (s, 2H), 2.46 (s, 3H).

b)(4,6-Dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine

The title compound was prepared in analogy to example 62 from4-(2-methyl-pyridin-4-yl)-phenylamine and2-chloro-4,6-dimethylpyrimidine. Obtained as a yellowish solid(Yield=33%). MS ISP (m/e): 291.1 (100) [(M+H)⁺]. ¹H NMR (DMSO-D₆, 300MHz): δ (ppm)=9.73 (s, 1H), 8.43 (d, 1H), 7.97 (d, 2H), 7.73 (d, 2H),7.55 (s, 1H); 7.47 (d, 1H), 6.67 (s, 1H), 2.50 (s, 3H hidden inDMSO-peak), 2.34 (s, 6H).

EXAMPLE 237(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine

The title compound was prepared in analogy to example 62 from4-(2-methyl-pyridin-4-yl)-phenylamine and4-benzyl-2-chloro-6-methyl-pyrimidine (example 43a). Obtained as ayellowish solid (Yield=48%). MS ISP (m/e): 367.1 (100) [(M+H)⁺]. ¹H NMR(DMSO-D₆, 300 MHz): δ (ppm)=9.77 (s, 1H), 8.45 (d, 1H), 7.93 (d, 2H),7.71 (d, 2H), 7.55 (s, 1H), 7.47 (d, 1H), 7.35-7.20 (m, 5H), 6.67 (s,1H), 3.95 (s, 2H), 2.51 (s, 3H), 2.33 (s, 3H).

EXAMPLE 238N4-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-5-fluoro-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyrimidine-2,4-diamine

Palladium(II) acetate (5.4 mg, 0.024 mmol) and2-(dicyclohexylphosphino)biphenyl (17 mg, 0.048 mmol) were stirred indioxane (2.7 mL) for 10 minutes at 20° C. under an atmosphere ofnitrogen. Sodium tert.-butoxide (44 mg, 0.45 mmol),3-methoxy-4-(4-methyl-imidazole-1-yl)-phenylamine (61 mg, 0.30 mmol) and(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-(2-chloro-5-fluoro-pyrimidin-4-yl)-amine(94 mg, 0.33 mmol, WO2008099210) were added. The reaction was heated for30 minutes to 200° C. in a microwave oven. Palladium(II) acetate (5.4mg, 0.024 mmol), 2-(dicyclohexylphosphino)-biphenyl (17 mg, 0.048 mmol),sodium carbonate (48 mg, 0.45 mmol),(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-(2-chloro-5-fluoro-pyrimidin-4-yl)-amine(85 mg, 0.3 mmol) and dioxane (1 mL) were added. The reaction was heatedagain for 30 minutes to 200° C. in a microwave oven. Water was added tothe cooled reaction mixture and the mixture was extracted with ethylacetate. The organic layer was dried over sodium sulfate and evaporatedunder reduced pressure. The residue was purified by columnchromatography on silica gel using dichloromethane and thendichloromethane/methanol (19:1 v/v) as eluent to yield the titlecompound as a yellow solid (41 mg, 30%). MS ISP (m/e): 451.2 (100)[(M+H)⁺]. ¹H NMR (CDCl₃, 300 MHz): δ (ppm)=8.02 (s, 1H), 7.60 (s, 1H),7.30 (s, 1H), 7.09 (d, 1H), 7.03 (m, 2H), 6.82 (s, 1H), 6.45 (br s, 1H,NH), 6.11 (s, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 2.29 (s, 3H), 1.32 (s,9H).

1. A compound of general formula I

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings in the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings in the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂ or when L isNR⁸, the rings in the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl for L being NR⁸, or when L is C(O), therings in the heteroaryl group are optionally substituted by one or morelower alkoxy, hydroxy or NR⁸ ₂ for L being C(O); R′ is halogen, loweralkyl, lower alkoxy, cyano, lower alkyl substituted by fluoro, loweralkoxy substituted by fluoro, SF₅, or is a five-membered heteroarylgroup, which is optionally substituted by lower alkyl; Ar is afive-membered heteroaryl group or is pyridinyl; Z is CH or N; X-Y isN—CR⁴═CR⁵, CH—CR⁴═N, CH—CR⁴═CR⁵ or N—NH; and wherein R⁴ and R⁵ formtogether with the corresponding carbon atoms to which they are attachedoptionally form an additional ring with —(CH₂)_(n), with the provisothat if X-Y is CH—CR⁴═CR⁵ or CH—CR⁴═N, then Z is N; or R⁴ and R⁵ areeach independently hydrogen, halogen, lower alkyl, lower alkoxy,C(O)O-lower alkyl, lower alkyl substituted by one or more groupsselected from fluoro, hydroxy, cyano and cycloalkyl, or are cyano,phenyl, benzyl or a five- or six-membered heteroaryl group wherein therings of the heteroaryl group are optionally substituted by one or moreR′, or are cycloalkyl or heterocycloalkyl, each of which optionallysubstituted by lower alkyl and hydroxy, with the proviso that R⁴ alsooptionally is hydroxy or NR⁸ ₂; L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or—C(O)—; R⁶ and R⁷ are each independently hydrogen, lower alkyl,cycloalkyl, phenyl or R⁶ and R⁷ together with the carbon atom to whichthey are attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶also optionally is hydroxy or lower alkoxy; R⁸ is hydrogen or loweralkyl; m is 0 or 1; and n is 3 or 4; or a pharmaceutically active acidaddition salt thereof.
 2. The compound of claim 1 having formula I-A,

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings of the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings of the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings of theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂ or when L isNR⁸, the rings of the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl for L being NR⁸, or when L is C(O), therings of the heteroaryl group are optionally substituted by one or morelower alkoxy, hydroxy or NR⁸ ₂ for L being C(O); R′ is halogen, loweralkyl, lower alkoxy, cyano, lower alkyl substituted by fluoro, loweralkoxy substituted by fluoro, SF₅, or is a five-membered heteroarylgroup, which is optionally substituted by lower alkyl; Ar is afive-membered heteroaryl group or is pyridinyl; R⁴ and R⁵ are eachindependently hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-loweralkyl, lower alkyl substituted by one or more groups selected fromfluoro, hydroxy, cyano and cycloalkyl, or are cyano, phenyl, benzyl or afive- or six membered heteroaryl group, wherein the rings in theheteroaryl group are optionally substituted by one or more R′, or arecycloalkyl or heterocycloalkyl, each of which is optionally substitutedby lower alkyl and hydroxy, with the proviso that R⁴ also optionally ishydroxy or NR⁸ ₂, or wherein R⁴ and R⁵ together with the correspondingcarbon atoms to which they are attached optionally form an additionalring with —(CH₂)_(n); L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—; R⁶ andR⁷ are each independently hydrogen, lower alkyl, cycloalkyl, phenyl orR⁶ and R⁷ together with the carbon atom to which they are attached forma C₃₋₆-cycloalkyl group, with the proviso that R⁶ also optionally ishydroxy or lower alkoxy; R⁸ is hydrogen or lower alkyl; m is 0 or 1; andn is 3 or 4; or a pharmaceutically active acid addition salt thereof. 3.The compound of claim 2 having formula I-A-1

wherein R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings in the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings in the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂ or when L isNR⁸, the rings in the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl, or when L is C(O), the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy or NR⁸ ₂; R′ is halogen, lower alkyl, lower alkoxy, cyano, loweralkyl substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, oris a five-membered heteroaryl group, which is optionally substituted bylower alkyl; R⁴ and R⁵ are each independently hydrogen, halogen, loweralkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by oneor more groups selected from fluoro, hydroxy, cyano and cycloalkyl, orare cyano, phenyl, benzyl or a five- or six-membered heteroaryl group,wherein the rings of the heteroaryl group are optionally substituted byone or more R′, or are cycloalkyl or heterocycloalkyl, each of which isoptionally substituted by lower alkyl and hydroxy, with the proviso thatR⁴ also optionally is hydroxy or NR⁸ ₂, or wherein R⁴ and R⁵ togetherwith the corresponding carbon atoms to which they are attached form anadditional ring with —(CH₂)_(n); L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or—C(O)—; R⁶ and R⁷ are each independently hydrogen, lower alkyl,cycloalkyl, phenyl or R⁶ and R⁷ together with the carbon atom to whichthey are attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶also optionally is hydroxy or lower alkoxy; R⁸ is hydrogen or loweralkyl; m is 0 or 1; and n is 3 or 4; or a pharmaceutically active acidaddition salt thereof.
 4. The compound of claim 3, selected from thegroup consisting of(4-benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzyl)-pyrimidin-2-yl]-amine;[4-(3-chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl)-pyrimidin-2-yl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,4,5-trifluoro-phenoxy)-pyrimidin-2-yl]-amine;[4-(3,4-difluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(4-chloro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(2,6-dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(2-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine;and[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromethoxy-phenoxy)-pyrimidin-2-yl]-amine.5. The compound of claim 3, selected from the group consisting of[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromethyl-phenoxy)-pyrimidin-2-yl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,3,4,4,4-pentafluoro-butoxy)-pyrimidin-2-yl]-amine;{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;ethyl4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-amine;(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;(4-ethoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;andN4-(2,2,3,3,4,4,4-heptafluoro-butyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine.6. The compound of claim 3, selected from the group consisting of[4-(4-chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxy-6-methyl-pyrimidin-2-yl)-amine;(4-isopropoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(4-tert-butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;2-{6-ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;N4-(3-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;N4-(4-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;N4,N4-diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine;and1-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-piperidin-4-ol.7. The compound of claim 3, selected from the group consisting of[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl-pyrimidin-2-yl)-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl-pyrimidin-2-yl)-amine;2-({2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-methyl-amino)-ethanol;2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl-pyrimidin-4-yl}-propan-2-ol;2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-pyrimidin-4-yl}-propan-2-ol;[4-butyl-6-(4-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-pyrimidin-2-yl)-amine;5-(4,6-dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile;5-[4-(4-chloro-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile;and[5-ethyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.8. The compound of claim 3, selected from the group consisting of[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-phenyl)-pyrimidin-2-yl]-amine;[4-(2,5-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(3,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(2,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(4-chloro-3-methyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(4-chloro-phenyl)-5-propyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(5-methoxy-4-phenyl-pyrimidin-2-yl)-amine;(4-cyclopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;ethyl4-benzyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-5-carboxylate;and[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-methyl-pent-3-enyl)-5-phenyl-pyrimidin-2-yl]-amine.9. The compound of claim 3, selected from the group consisting of6-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4H-benzo[1,4]oxazin-3-one;[4-(2-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;(4-isobutyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;(4,6-diethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-phenyl-pyrimidin-2-yl)-amine;(4-furan-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-amine;(4,6-dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;(4,6-bis-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;and(4-isopropyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.10. The compound of claim 3, selected from the group consisting of(4,6-diisopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;[4-(2-chloro-phenyl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyrimidine-4-carboxylate;ethyl6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate;ethyl6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate;ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrimidine-4-carboxylate;ethyl2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate;ethyl6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxylate;2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-yl}-propan-2-ol;and2-{6-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol.11. The compound of claim 3, selected from the group consisting of2-{6-isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-{6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-{6-tert-butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyrimidin-4-yl}-propan-2-ol;2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrimidin-4-yl}-propan-2-ol;2-{6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-ethanone;3-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-pentan-3-ol;and2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluoro-phenyl)-pyrimidin-4-yl]-propan-2-ol.12. The compound of claim 3, selected from the group consisting of2-{6-(2,4-dichloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-{6-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-{6-(2-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5,6,7,8-tetrahydro-quinazolin-4-yl}-propan-2-ol;2-{2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimidin-4-yl}-propan-2-ol;2-[2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;2-{6-dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-propan-2-ol;1-{6-(1-hydroxy-1-methyl-ethyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4-methyl-piperidin-4-ol;1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-cyclopentanol;5-[4-(1-hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile;and2-[2-[3-methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol.13. The compound of claim 2, wherein R¹—Ar is 2-methyl-imidazol-1-yl,3-methyl-[1,2,4]triazol-1-yl, thiazol-5-yl, 2-methyl-thiazol-5-yl,2-methyl-oxazol-5-yl, 2-methyl-pyridin-4-yl, 1-methyl-1H-pyrazol-4-yl,3-methyl-[1,2,4]triazol-1-yl, [1,2,4]triazol-1-yl,5-methyl-[1,2,4]triazol-1-yl, 1,3,4]oxadiazol-2-yl, 4-pyridin-4-yl,2-methyl-pyridin-4-yl, 3-methyl-[1,2,4]thiadiazol-5-yl, or oxazol-5-yl.14. The compound of claim 13, selected from the group consisting of(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol-1-yl)-phenyl]-amine;(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenyl]-amine;(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-oxazol-5-yl)-phenyl]-amine;2-[2-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;(4,6-dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine;and(4-benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine.15. The compound of claim 1 having formula I-B

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings of the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings of the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings of theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or when L isNR³, the rings of the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl, or when L is C(O), the rings of theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy or NR⁸ ₂; R′ is halogen, lower alkyl, lower alkoxy, cyano, loweralkyl substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, oris a five-membered heteroaryl group, which is optionally substituted bylower alkyl; Ar is a five-membered heteroaryl group or is pyridinyl; R⁴is hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower alkyl,lower alkyl substituted by one or more groups selected from fluoro,hydroxy, cyano and cycloalkyl, or is cyano, phenyl, benzyl or a five- orsix-membered heteroaryl group, wherein the rings of the heteroaryl groupare optionally substituted by one or more R′, or is cycloalkyl orheterocycloalkyl, each of which is optionally substituted by lower alkyland hydroxy, or is hydroxy or NR⁸ ₂; L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or—C(O)—; R⁶ and R⁷ are each independently hydrogen, lower alkyl,cycloalkyl, or phenyl or R⁶ and R⁷ together with the carbon atom towhich they are attached form a C₃₋₆-cycloalkyl group, with the provisothat R⁶ also optionally is hydroxy or lower alkoxy; R⁸ is hydrogen orlower alkyl; and m is 0 or 1; or a pharmaceutically active acid additionsalt thereof.
 16. The compound of claim 15, selected from the groupconsisting of(6-benzyl-2-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amineand{6-[1-(4-chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.17. The compound of claim 1 having formula I-C

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings in the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings in the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings in theheteroaryl group are optionally substituted by one or moreis loweralkoxy, hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, orwhen L is NR³, the rings in the heteroaryl group are optionallysubstituted by one or more CH₂—C(O)O-lower alkyl, or when L is C(O), therings in the heteroaryl group are optionally substituted by one or morelower alkoxy, hydroxy or NR⁸ ₂; R′ is halogen, lower alkyl, loweralkoxy, cyano, lower alkyl substituted by fluoro, lower alkoxysubstituted by fluoro, SF₅, or is a five-membered heteroaryl group,which is optionally substituted by lower alkyl; Ar is a five-memberedheteroaryl group or is pyridinyl; R⁴ is hydrogen, halogen, lower alkyl,lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or moregroups selected from fluoro, hydroxy, cyano and cycloalkyl, or arecyano, phenyl, benzyl or a five- or six membered heteroaryl group,wherein the rings of the heteroaryl group are optionally substituted byone or more R′, or are cycloalkyl or heterocycloalkyl, each of which isoptionally substituted by lower alkyl and hydroxy or is hydroxy or NR₁₂;L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—; R⁶ and R⁷ are eachindependently hydrogen, lower alkyl, cycloalkyl, or phenyl or R⁶ and R⁷together with the carbon atom to which they are attached form aC₃₋₆-cycloalkyl group, with the proviso that R⁶ also optionally ishydroxy or lower alkoxy; R⁸ is hydrogen or lower alkyl; and m is 0 or 1;or a pharmaceutically active acid addition salt thereof.
 18. Thecompound of claim 17, which is(2-benzyl-6-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.19. The compound of claim 1 having formula I-D

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings in the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings in the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or when L isNR³, the rings in the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl, or when L is C(O), the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy or NR⁸ ₂; R′ is halogen, lower alkyl, lower alkoxy, cyano, loweralkyl substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, oris a five-membered heteroaryl group, which is optionally substituted bylower alkyl; Ar is a five-membered heteroaryl group or is pyridinyl; R⁴and R⁵ are each independently hydrogen, halogen, lower alkyl, loweralkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or more groupsselected from fluoro, hydroxy, cyano and cycloalkyl, or are cyano,phenyl, benzyl or a five- or six-membered heteroaryl group, wherein therings in the heteroaryl group are optionally substituted by one or moreR′, or are cycloalkyl or heterocycloalkyl, each of which is optionallysubstituted by lower alkyl and hydroxy′, with the proviso that R⁴ alsooptionally is hydroxy or NR⁸ ₂, or wherein R⁴ and R⁵ together with thecorresponding carbon atoms to which they are attached form an additionalring with —(CH₂)_(n); L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—; R⁶ andR⁷ are each independently hydrogen, lower alkyl, cycloalkyl, or phenylor R⁶ and R⁷ together with the carbon atom to which they are attachedform a C₃₋₆-cycloalkyl group, with the proviso that R⁶ also optionallyis hydroxy or lower alkoxy; R⁸ is hydrogen or lower alkyl; m is 0 or 1;and n is 3 or 4; or a pharmaceutically active acid addition saltthereof.
 20. The compound of claim 19, selected from the groupconsisting ofN-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-phenyl-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethoxy-phenyl)-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-pentafluorosulfanyl-phenyl)-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethyl-phenyl)-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(4-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N′-(3-trifluoromethoxy-phenyl)-4-trifluoromethyl-pyridine-2,6-diamine;N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N′-(4-trifluoromethyl-phenyl)-pyridine-2,6-diamine;and[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethoxy-phenylamino)-pyridin-4-yl]-methanol.21. The compound of claim 1 having formula I-E

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings in the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings in the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂, or when L isNR⁸, the rings in the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl, or when L is C(O), the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy or NR⁸ ₂; R′ is halogen, lower alkyl, lower alkoxy, cyano, loweralkyl substituted by fluoro, lower alkoxy substituted by fluoro, SF₅, oris a five-membered heteroaryl group, which is optionally substituted bylower alkyl; Ar is a five-membered heteroaryl group or is pyridinyl; Lis a bond, —CR⁶R⁷—, —O—, —NR⁸— or —C(O)—; R⁶ and R⁷ are eachindependently from each other hydrogen, lower alkyl, cycloalkyl, orphenyl or R⁶ and R⁷ together with the carbon atom to which they areattached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶ alsooptionally is hydroxy or lower alkoxy; R⁸ is hydrogen or lower alkyl;and m is 0 or 1; or a pharmaceutically active acid addition saltthereof.
 22. The compound of claim 21, selected from the groupconsisting of[5-(4-chloro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amineand[5-(4-fluoro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine.23. A pharmaceutical composition comprising a therapeutically effectiveamount of a compound of formula I

wherein R¹ is hydrogen, lower alkyl or lower alkyl substituted byhydroxy; R² is hydrogen, lower alkoxy, lower alkyl, cyano or halogen; R³is lower alkyl, lower alkenyl, lower alkyl substituted by fluoro,(CH₂)₂O-lower alkyl, (CH₂)₂NR⁸ ₂, or is 4H-benzo[1,4]oxazin-3-one,cycloalkyl optionally substituted by hydroxy, or is heterocycloalkyl,which heterocycloalkyl is optionally substituted by hydroxy orS(O)₂-lower alkyl, or is (CH₂)_(m)-aryl or is a five- or six-memberedheteroaryl group, wherein the rings in the heteroaryl group areoptionally substituted by one or more R′ for any definition of L, orwhen L is a bond, the rings in the heteroaryl group are optionallysubstituted by one or more halogen, hydroxy, —C(O)O-lower alkyl,OC(O)-lower alkyl or C(O)NH₂, or when L is —CR⁶R⁷—, the rings in theheteroaryl group are optionally substituted by one or more lower alkoxy,hydroxy, —C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH₂ or when L isNR⁸, the rings in the heteroaryl group are optionally substituted by oneor more CH₂—C(O)O-lower alkyl for L being NR⁸, or when L is C(O), therings in the heteroaryl group are optionally substituted by one or morelower alkoxy, hydroxy or NR⁸ ₂ for L being C(O); R′ is halogen, loweralkyl, lower alkoxy, cyano, lower alkyl substituted by fluoro, loweralkoxy substituted by fluoro, SF₅, or is a five-membered heteroarylgroup, which is optionally substituted by lower alkyl; Ar is afive-membered heteroaryl group or is pyridinyl; Z is CH or N; X-Y isN—CR⁴═CR⁵CH—CR⁴═N, CH—CR⁴═CR⁵ or N—NH; and wherein R⁴ and R⁵ formtogether with the corresponding carbon atoms to which they are attachedoptionally form an additional ring with —(CH₂)_(n), with the provisothat if X-Y is CH—CR⁴═CR⁵ or CH—CR⁴═N, then Z is N; or R⁴ and R⁵ areeach independently hydrogen, halogen, lower alkyl, lower alkoxy,C(O)O-lower alkyl, lower alkyl substituted by one or more groupsselected from fluoro, hydroxy, cyano and cycloalkyl, or are cyano,phenyl, benzyl or a five- or six-membered heteroaryl group wherein therings of the heteroaryl group are optionally substituted by one or moreR′, or are cycloalkyl or heterocycloalkyl, each of which optionallysubstituted by lower alkyl and hydroxy, with the proviso that R⁴ alsooptionally is hydroxy or NR⁸ ₂; L is a bond, —CR⁶R⁷—, —O—, —NR⁸— or—C(O)—; R⁶ and R⁷ are each independently hydrogen, lower alkyl,cycloalkyl, phenyl or R⁶ and R⁷ together with the carbon atom to whichthey are attached form a C₃₋₆-cycloalkyl group, with the proviso that R⁶also optionally is hydroxy or lower alkoxy; R⁸ is hydrogen or loweralkyl; m is 0 or 1; and n is 3 or 4; or a pharmaceutically active acidaddition salt thereof and a pharmaceutically acceptable carrier.